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Abstract
The riboflavin analog roseoflavin – an antibiotic produced by the bacteria
Streptomyces davawensis and Streptomyces cinnabarinus, and the key intermedi-
ate of the roseoflavin biosynthesis, 8-demthyl-8-amino riboflavin which is an
antibiotic as well, are both known to have a growth inhibiting effect on the
human pathogen Listeria monocytogens. The adverse effect of roseoflavin on
L. monocytogenes has been proposed to be a result of its interaction with the
FMN riboswitch Rli96, regulating expression of the riboflavin transporter gene
lmo1945. Whether flavin analogs, such as roseoflavin and 8-demethyl-8-amino
riboflavin, are assimilated by L. monocytogenes through the riboflavin trans-
porter protein Lmo1945 has not yet been known. In addition, the conversion of
flavin analogs into cofactor analogs by flavokinase/FAD synthetase enzymes
from L. monocytogenes has not been investigated. The functional analysis of
the effect of the cofactor analogs on the FMN riboswitch Rli96 could help to
elucidate how flavin analogs affect riboflavin auxotrophic bacteria, including
L. monocytogenes.
Through heterologous expression of Lmo1945 in a riboflavin transporter de-
ficient Bacillus subtilis strain, the role of Lmo1945 in the uptake of riboflavin
and roseoflavin was confirmed. Two enzymes, catalyzing the conversion of
riboflavin into the cofactors flavin mononucleotide (FMN) and flavin adenine
dinucleotide (FAD) have been identified by sequence analysis. The bifunctional
flavokinase/FAD synthetase Lmo1329 and the unique monofunctional FAD
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synthetase Lmo0728 were purified and kinetically characterized. Addition-
ally, their involvement in the generation of the cofactor analogs roseoflavin
mononucleotide (RoFMN), 8-demethyl-8-amino riboflavin mononucleotide
(AFMN), roseoflavin adenine dinucleotide (RoFAD) and 8-demethyl-8-amino
riboflavin adenine dinucleotide (AFAD) were shown in vitro. Notably, the
bifunctional enzyme Lmo1329 did not convert the roseoflavin derived cofactor
RoFMN into RoFAD.
In vivo reporter gene assays and in vitro transcription/translation experiments
showed that the FMN riboswitch Rli96, and consequently the expression of
the riboflavin transporter gene lmo1945, is negatively affected by FMN and
RoFMN but not by AFMN.
With the FMN riboswitch Rli96, the riboflavin transporter Lmo1945, the bi-
functional flavokinase/FAD synthetase Lmo1329 and the monofunctional FAD
synthetase Lmo0728, the key mechanisms of riboflavin uptake and metabolism
in L. monocytogenes were identified and characterized. Particularly, the FAD
synthetase Lmo0728 is the first monofunctional FAD synthetase that has been
described in bacteria.
As a second part of this thesis a novel reporter system for in vivo studies of
translational riboswitches in Streptomyces species was evaluated. However,
the system proved to not be suitable for the desired application, i.e. the con-
firmation of previously obtained in vitro data. Several attempts to adapt and
optimize the system failed which turned out to be due to the complexity of the
natural expression platform in streptomycetes.
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Zusammenfassung
Von dem Riboflavinanalogon Roseoflavin – einem Antibiotikum das von den
Bakterien Streptomyces davawensis und Streptomyces cinnabarinus produziert
wird sowie von 8-Demethyl-8-Amino-Riboflavin, einem wichtigen Zwischen-
produkt der Roseoflavinbiosynthese, ist bekannt, dass sie auf das humanpatho-
gene Bakterium Listeria monocytogenes eine wachstumshemmende Wirkung
haben. Die hemmende Wirkung von Roseoflavin auf L. monocytogeneswurde
seinem Einfluss auf den FMN Riboswitch Rli96, der die Expression des Ribflav-
intransportergens lmo1945 reguliert, zugeschrieben. Ob auch Flavinanaloga,
wie Roseoflavin und 8-Demethyl-8-Amino-Riboflavin, von L. monocytogenes
mittels des Riboflavintransporters Lmo1945 aufgenommen werden, war bis-
lang nicht bekannt. Auch die Umsetzung von Flavinanaloga zu Cofaktoranaloga
durch Flavokinasen/FAD synthetasen in L. monocytogeneswurde bisher noch
nicht untersucht. Die funktionelle Charakterisiereng der Interaktion zwischen
Cofaktoranaloga und dem FMN Riboswitch Rli96 könnte dazu beitragen, den
Einfluss von Flavinanaloga auf riboflavinauxotrophe Bakterien wie L. monocy-
togenes besser zu verstehen.
Durch die heterologe Expression von Lmo1945 in einem spezialisierten Bacillus
subtilis Stamm konnte die Rolle von Lmo1945 als funktioneller Transporter
für Riboflavin und Roseoflavin bestätigt werden. Zwei Enzyme, die die
Umsetzung von Riboflavin in die Cofaktoren Flavinmononukleotid (FMN)
und Flavin-Adenin-Dinukleotid (FAD) katalysieren, konnten durch Sequen-
zvergleiche identifiziert werden. Die bifunktionelle Flavokinase/FAD syn-
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thetase Lmo1329 und die monofunktionelle FAD synthetase Lmo0728 wurden
aufgereiningt und anschließend bezüglich ihrer kinetischen Eigenschaften
charakterisiert. Weiterhin konnte ihre Rolle in der Biosynthese der Cofak-
toranaloga Roseoflavinmononukleotid (RoFMN), 8-Demethyl-8-Amino-Ribo-
flavinmononukleotid (AFMN), Roseoflavin-Adenin-Dinkleotid (RoFAD) und
8-Demethyl-8-Amino-Riboflavin-Adenin-Dinukleotid (AFAD) durch in vitro
Experimente aufgezeigt werden. Bemerkenswert war, dass die bifunktionelle
Flavokinase/FAD synthetase Lmo1329 RoFMN nicht in RoFAD umsetzt. Mit-
tels eines in vivo Reportersystems und gekoppelten in vitro Transkriptions-
/Translationsexperimenten konnte gezeigt werden, dass der FMN Riboswitch
Rli96, und infolgedessen auch die Expression des Riboflavintransportergens
lmo1945 von FMNundRoFMN, jedoch nicht vonAFMNbeeinträchtigt wurde.
Somit konnten mit dem FMN Riboswitch Rli96, dem Riboflavintransporter
Lmo1945, der bifunktionellen Flavokinase/FAD synthetase Lmo1329 und der
monofunktionellen FAD synthetase Lmo0728 die zentralen Mechanismen im
Riboflavinstoffwechsel von L. monocytogenes aufgezeigt und charakterisiert
werden. Besonderes Augenmerk fällt dabei auf die FAD synthetase Lm0728, die
als erste bakterielle monofunktionelle FAD synthetase beschrieben wurde.
In einem zweiten Teil dieser Arbeit wurde ein neuartiges Reportersystem
für die in vivo Charakterisierung von translationalen Riboswitches in Strepto-
myceten evaluiert. Jedoch stellte sich das System für die gewünschte Anwen-
dung, der Verifizierung von vorherigen in vitro Experimenten, als ungeeignet
heraus. Mehrere Optimierungs- und Anpassungsversuche blieben aufgrund
der natürlichen Komplexität der Expressionsplattform in Streptomyceten erfol-
glos.
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Introduction
1.1 Flavins and Flavoenzymes
Riboflavin (vitamin B2; RF) (figure 1.3 on page 9) is the universal precursor for
the phosphorylated cofactors riboflavin 50-phosphate (flavin mononucleotide,
FMN) and flavin adenine dinucleotide (FAD) that are essential metabolites
in all types of organisms. Riboflavin is synthesized de novo by plants and
many microorganisms. Animals and also some species of bacteria, however,
rely solely on the uptake of riboflavin (Gerdes et al., 2002). FMN and FAD
serve as cofactors for so-called flavoenzymes that are involved in a wide range
of biochemical reactions, such as dehydrogenations, one- and two-electron
transfer from and to redox centers, light emission, the activation of oxygen for
oxidation and hydroxylation (Massey, 1995; Fraaije and Mattevi, 2000). The
biochemical utility of riboflavin derived cofactors in flavoenzymes relies on
the redox activity of the isoalloxazine ring system, which is able to assume
three different redox states: the oxidized or quinone state, the one-electron
reduced or semiquinone (radical) state, and the two-electron reduced (fully
reduced) or hydroquinone state (Massey, 1994; Abbas and Sibirny, 2011). In a
study that included 374 flavoenzymes from 22 species throughout all domains
of life, Macheroux et al. reported more than 90% of flavoenzymes being
oxidoreductases, while less than 10% of flavoenzymes catalyzed non-redox
reactions. They also found that the majority of flavoenzymes used FAD as
cofactor (75%), while 25% utilized FMN (Macheroux et al., 2011).
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1.2 Biosynthesis and Transport of Riboflavin
Riboflavin is synthesized in bacteria, fungi and plants from guanosine-50-
triphosphate (GTP) and two molecules of ribulose-5-phosphate. The biosyn-
thetic pathway has been described in detail by Fischer and Bacher. It in-
volves a set of enzymes consisting of GTP cyclohydrolase II (EC 3.5.4.25),
3,4-dihydroxy-2-butanone-4-phosphate synthase (EC 4.1.99.12), diaminohy-
droxyphosphoribosylaminopyrimidine deaminase (EC 3.5.4.26), 5-amino-6-(5-
phosphoribosylamino)uracil reductase (EC 1.1.1.193), lumazine synthase (EC
2.5.1.78) and riboflavin synthase (EC 2.5.1.9) (Bacher et al., 2000; Fischer and
Bacher, 2005).
In procaryotes functionally related genes are often located in close proximity
to each other on the chromosome (Demerec and Hartman, 1959; Overbeek
et al., 1999). If expression of such clusters is controlled by the same promoter
and regulated by an operator (i.e. repressor or activator), they are referred
to as operons (Jacob and Monod, 1961). Genes involved in the biosynthesis
of riboflavin have been found to form operons (rib-operon) in many bacterial
species, e.g. Bacillus subtilis (Perkins and Pero, 2001), Fusobacterium nucleatum
(Serganov et al., 2009) and S. davawensis (Grill et al., 2007). The expression
of genes from rib-operons is typically modulated by the interaction of FMN
with the aptamer portion of an FMN riboswitch, located directly upstream of
the operon (Gelfand et al., 1999; Vitreschak et al., 2002). FMN riboswitches
re described in more detail in section 1.4. However, in other species, such
as Escherichia coli, the genes involved in riboflavin biosynthesis are scattered
throughout the chromosome (Neidhardt, 1994), while some bacterial species
do not possess riboflavin biosynthetic genes at all, and thus are unable to
synthesize riboflavin de novo, including the pathogenic species L. monocytogenes
and Enterococcus faecalis (Fischer and Bacher, 2005).
Riboflavin uptake in bacteria is mediated by a surprisingly high number of
different types of riboflavin transport systems. The membrane-embedded
substrate-binding subunit (EcfS) RibU of an energy-coupling factor (ECF)
transporter system has been described for Lactococcus lactis (Burgess et al.,
2006) and for B. subtilis (Vogl et al., 2007). A RibU orthologue was predicted in
L. monocytogenes downstream of an FMN riboswitch (Mansjö and Johansson,
2
2011). The structure of RibU from L. monocytogeneswas resolved recently, al-
though no functional characterization was performed (Karpowich et al., 2015).
A different class of energy independent riboflavin transporter proteins, such
as RibM from S. davawensis (Grill et al., 2007; Hemberger et al., 2011) and C.
glutamicum (Vogl et al., 2007) that are homologues of the nicotinamide riboside
permease protein PnuC fromHaemophilus influenzae have been described (Sauer
et al., 2004). Deka et al. have identified another riboflavin transport mechanism
present in riboflavin auxotrophic pathogenic spirochetes such as Treponema
pallidum. They have identified the ATP-binding casette (ABC) type riboflavin
transport system RfuABCDwith the riboflavin binding component RfuA (Deka
et al., 2013). The genes impX in Fusobacterium nucleatum and rfnT inMesorhizo-
bium loti, Sinorhizobium meliloti and Agrobacterium tumefacienswere predicted
to be putative riboflavin transporters due to their location downstream of
the conserved FMN riboswitch motif and the prediction of transmembrane
domains (Vitreschak et al., 2002). It was speculated that only Gram-positve
bacteria feature riboflavin transport systems, while Gram-negative bacteria rely
solely on the endogenous de novo synthesis of riboflavin (Abbas and Sibirny,
2011). However, García Angulo et al. were able to identify and characterize the
riboflavin transporter RibN in the Gram-negative soil bacterium Rhizobium legu-
minosarum. Furthermore RibN orthologues were found in the Gram-negative
species Ochrobactrum anthropi and Vibrio cholerae (García Angulo et al., 2013).
With the increasing number of available complete genome sequences from
bacteria, Gutiérrez-Preciado et al. recently were able to identify the two new
putative riboflavin transporter genes ribZ in Clostridium difficile and ribV in
Mesoplasma florum. They were able to confirm the riboflavin transporter activity
of RibZ from C. difficile as well as of the previously uncharacterized putative
transporters RibXY from Chloroflexus aurantiacus, ImpX from F. nucleatum and
RfnT from O. anthropi (Gutiérrez-Preciado et al., 2015).
Eukaryotic riboflavin transporter proteins have been identified in yeast (Reihl
and Stolz, 2005) and also in mammals, namely in humans and rats (Yonezawa
et al., 2008; Yao et al., 2010). However, none of those proteins is similar to any
known bacterial riboflavin transporter.
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1.3 Synthesis of the Flavin Cofactors FMN and FAD
After riboflavin has been either de novo synthesized, or taken up by transporters,
all organisms are faced with the necessity to convert it into its metabolic active
forms, the cofactors FMN and FAD. The irreversible conversion of riboflavin
and ATP to FMN and ADP is catalyzed by flavokinases (FK, EC 2.7.1.26). In a
second, reversible reaction, FMN is further metabolized under the consumption
of ATP to FAD and pyrophosphate by FAD synthetases (FADS, EC 2.7.7.2)
(Fischer and Bacher, 2005). Efimov et al. proposed a steady-state kinetic
mechanism for the bifunctional flavokinase/FAD synthetase (FK/FADS) from
Corynebacterium ammoniagenes, and they suggested that FMN has to be released
after its synthesis in order to rebind to a different domain of the enzyme where
it is then adenylylated (Efimov et al., 1998). A reaction scheme of the two
reactions is given in figure 1.1.
!
Figure 1.1: Riboflavin is converted into the cofactors FMN and FAD. Reaction
scheme for the conversion of riboflavin and ATP to FMN and ADP, cat-
alyzed by flavokinase (EC 2.7.1.26) and the formation of FAD and py-
rophosphate from FMN and ATP, catalyzed by FAD synthetase (EC 2.7.7.2).
In bacteria both reactions are typically catalyzed by bifunctional enzymes,
first described by Manstein and Pai for the bifunctional flavokinase/FAD syn-
thetase from Brevibacterium ammoniagenes, while in eukaryotes like in the yeast
Saccharomyces cerevisiae, and also in humans, the two reactions are catalyzed
by two independent enzymes (Manstein and Pai, 1986; Wu et al., 1995; Santos
et al., 2000; Karthikeyan et al., 2003; Brizio et al., 2006). The monofunctional
flavokinase RibR from B. subtilis, first described by Solovieva et al., was found
recently to interact with both FMN riboswitches to synchronize the sulfur and
riboflavin metabolism in in B. subtilis (Solovieva et al., 1999; Pedrolli et al.,
2015a). In the archaeonMethanocaldococcus jannaschii a monofunctional FAD
synthetase (RibL) was identified and characterized by Mashhadi et al.. RibL, in
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contrast to bacterial FAD synthetases, does not catalyze the reverse reaction
of FAD and pyrophosphate to FMN and ATP. Furthermore, RibL activity is
inhibited by pyrophosphate (Mashhadi et al., 2010). To this date, however, no
monofunctional bacterial FAD synthetase has been characterized.
1.4 FMN Riboswitches
Riboswitches are protein independent regulatory elements, residing in the
50-untranslated region (50-UTR) of messenger RNAs (mRNA) and can be found
throughout all three domains of life (Barrick and Breaker, 2007). Riboswitches
typically consist of two elements, an aptamer that binds a specific ligand
molecule (e.g. a metabolite) and an expression platform, which controls ex-
pression of the downstream gene(s) by conformational changes upon binding
of the ligand to the aptamer (Wickiser et al., 2005). The two most important
mechanisms for the riboswitch mediated control of gene expression are the ter-
mination of transcription and the prevention of translation initiation (Winkler
et al., 2002; Vitreschak et al., 2002). Binding of the ligand to the aptamer leads to
the formation of a secondary structure in the expression platform that prevents
expression of the downstream gene(s) (figure 1.2). However, other mechanisms
of riboswitch mediated regulation of gene expression have been described and
were reviewed by Breaker as well as by Serganov and Nudler (Breaker, 2012;
Serganov and Nudler, 2013). Also an FMN riboswitch featuring a combination
of transcription termination and sequestration of the ribosomal binding site
(RBS), regulating the expression of the 3,4-dihydroxy-2-butanone-4-phosphate
synthase gene ribB in E. coli was described recently (Pedrolli et al., 2015b).
Although most riboswitches sense only a single metabolite, more intricate
riboswitch conformations, so called tandem riboswitches have been identified.
Tandem riboswitch arrangements feature two independent aptamers, each
binding a distinct ligand, and expression platforms, so that the binding of only
one of the ligands is sufficient to repress the expression of the downstream
gene(s) (Sudarsan et al., 2006; Coppins et al., 2007).
FMN riboswitches, also referred to as RFN-elements, are riboswitches featuring
an FMN binding aptamer. They are typically found upstream of genes involved
in riboflavin biosynthesis or riboflavin transport. The presence of a regulatory
region, formerly designated as “ribO”, between the Prib promoter and the
first gene of the cluster ribDG, coding for the bifunctional enzyme RibDG
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(EC 3.5.4.26 and EC 1.1.1.193) of B. subtilis has first been reported by Kil et al.
(1992). However, Kil et al. speculated that the regulatory mechanism relied
on binding of the protein RibC to the ribO region. Mack et al. were able show
that RibC was not involved in the regulation of the rib-operon in B. subtilis.
They speculated that the regulation of riboflavin biosynthesis genes occurred
in the absence of a protein factor (Mack et al., 1998). Through comparative
sequence analysis Gelfand et al. (1999) were able to identify this regulatory
region to be highly conserved throughout several branches of bacteria. Gelfand
et al. identified the association of the regulatory properties of the conserved
region with RNA folding, as they stated that it could fold into a conserved
structure with five hairpins and referred to it as “RFN-element”. They also
described the association of the RFN-element with genes involved in riboflavin
biosynthesis and genes similar to ypaA of B. subtilis that has later been reported
to encode the riboflavin transporter protein RibU (Kreneva et al., 2000; Vogl
et al., 2007).
The term “riboswitch” was first introduced by Nahvi et al. and readily ac-
cepted by others (Nahvi et al., 2002; Winkler et al., 2002; Mironov et al., 2002).
From a more extensive alignment of in total 58 RFN-elements found upstream
of riboflavin operons, single riboflavin biosynthesis genes and putative ri-
boflavin transporters respectively, Vitreschak et al. were able to derive two
FMN-mediated regulatory mechanisms of the RFN-elements. Downstream of
the FMN binding aptamer they identified hairpin structures, that either were
followed by runs of uracil bases and thus were considered transcription termi-
nators (figure 1.2–B) or hairpins that include the RBS of the downstream gene
and like so interfere with the translation initiation (figure 1.2–C). In addition,
all RFN-elements of the alignment were found capable of forming alternative
structures where the base stem of the aptamer could pair with parts of the
regulatory hairpin and in this way form either an anti-terminator or an anti-
sequestor secondary structure respectively (figure 1.2–A) (Vitreschak et al.,
2002).
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Figure 1.2: Mechanisms of FMN riboswitch mediated gene regulation. FMN ri-
boswitch mediated regulation mechanisms, as proposed by Vitreschak
et al. (2002) and confirmed by Serganov et al. (2009). Figure adapted from
Pedrolli and Mack (2014).
A: At low FMN concentrations (or in the absence of FMN) the aptamer
does not bind the regulating metabolite and adopts the anti-termination
or anti-sequestor secondary structure. Transcription is able to proceed,
translation may initiate and protein synthesis occurs.
B: At high FMN concentrations the aptamer binds the metabolite which
leads to the formation of the terminator hairpin downstream of the aptamer,
causing transcription termination and dissociation of RNA-polymerase
from the DNA-template.
C: Alternatively at high FMN concentrations the aptamer binds the metabo-
lite and allows the RBS sequestor hairpin to form. Although transcription
still proceeds, protein synthesis does not occur since the ribosome cannot
access the ribosomal binding site (RBS).
It has been predicted by Vitreschak et al. (2002) that expression of riboflavin
biosynthesis genes and transporters in Gram-positive bacteria (including Strep-
tomyces spp., Bacillus spp., Listeria spp.) were regulated by transcription attenua-
tion, while expression of the corresponding genes in Gram-negative bacteria
(e.g. E. coli) would be regulated by prevention of translation initiation. How-
ever, this general statement does not hold true regarding the FMN riboswitches
of the bacterial species that were in the focus of this work. In B. subtilis, one
FMN riboswitch regulates expression of the riboflavin biosynthesis operon
through transcription termination and a second FMN riboswitch controls ex-
pression of ribU coding for the riboflavin transporter RibU by sequestration
of the RBS (Winkler et al., 2002; Sklyarova and Mironov, 2014). In S. coelicolor,
S. davawensis and also other Strepotmyces species an FMN riboswitch controls
expression of the riboflavin synthase gene ribB through translation inhibition
(Grill et al., 2007; Pedrolli et al., 2012). The FMN riboswitch Rli96 upstream of
the riboflavin transporter gene lmo1945 of L. monocytogenes has been reported
to terminate transcription in the presence of FMN (Mansjö and Johansson,
2011).
1.5 Flavin Analogs and Their Potential as Novel
Antimicrobial Drugs
The riboflavin analog roseoflavin is the only known naturally occurring flavin
analog with antibiotic properties (Otani et al., 1974). Roseoflavin is produced
by the two closely related Streptomyces species, S. davawensis and S. cinnabar-
inus (Jankowitsch et al., 2011, 2012). Jankowitsch et al. demonstrated that
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roseoflavin is synthesized in S. davawensis from riboflavin via the intermediate
flavin analog 8-amino riboflavin (figure 1.3). A recombinant S. davawensis strain,
lacking the gene rosA, coding for the N,N-8-amino-8-demethyl-D-riboflavin
dimethyltransferase RosA was shown to be roseoflavin deficient and accu-
mulated 8-amino riboflavin instead (Jankowitsch et al., 2011). Schwarz et al.
recently were able to the key enzyme of roseoflavin biosynthesis in S. davawen-
sis. They describe the enzyme RosB, catalyzing the first steps in the biosynthesis
of roseoflavin, starting from FMN (Schwarz et al., 2016).
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Figure 1.3: Structures of ribofalvin, roseoflavin and 8-amino riboflavin. The struc-
tures of 7,8-dimethyl-10-(D-10-ribityl)isoalloxazine (riboflavin, RF; vita-
min B2), 8-dimethylamino-8-demethyl-riboflavin (roseoflavin, RoF) and
8-amino-8-demethyl-riboflavin (8-amino riboflavin, AF).
The antibiotic effect of both, roseoflavin and 8-amino riboflavin, was
attributed to their phosphorylated forms as cofactor analogs rose-
oflavin mononucleotide/8-demethyl-8-amino riboflavin mononucleotide
(RoFMN/AFMN) and their adenylylated forms roseoflavin adenine
dinucleotide/8-demethyl-8-amino riboflavin adenine dinucleotide (Ro-
FAD/AFAD) (Grill et al., 2008; Pedrolli et al., 2011). The conversion of rose-
oflavin and 8-amino riboflavin to the respective cofactor analogs is catalyzed
by flavokinase and FAD synthetase enzymes respectively, analog to the con-
version of riboflavin to FMN and FAD (figure 1.4). The bifunctional flavok-
inase/flaviFAD synthetase RibC from B. subtilis (unpublished experimental
data) and the monofunctional human FAD synthetase (Pedrolli et al., 2011),
however, did not accept AFMN as a substrate and consequently did not syn-
thesize the cofactor analog AFAD.
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Figure 1.4: Flavin analogs are converted into cofactor analogs. The biosynthesis of
the cofactor analogs roseoflavin mononucleotide (RoFMN), roseoflavin
adenine dinucleotide (RoFAD), 8-demethyl-8-amino riboflavin mononu-
cleotide (AFMN) and 8-demethyl-8-amino riboflavin adenine dinucleotide
(AFAD).
Although the cofactor analogs derived from roseoflavin and 8-amino riboflavin
exhibit considerably different physicochemical properties to FMN an FAD,
including redox potential or hydrophobicity, they are thought to still form
holoenzymes with most of the flavo-apoenzymes present in the cell (Walsh
et al., 1978; Otani et al., 1997; Langer et al., 2013a). However, cofactor analog
bound holoenzymes were reported to be less or not active at all (Grill et al.,
2008; Langer et al., 2013b). Which of the altered properties of the cofactor
analogs is responsible for the reduced activity of flavoenzymes remains un-
clear and might also be different for individual enzymes. Binding of cofactor
analogs to flavoenzymes might not only affect the catalyzed reaction directly
but could also interfere with multimerization or change the overall structure in
a nonbeneficial way (Pedrolli et al., 2014).
In addition to the above described effects of cofactor analogs on the activity
of flavoenzymes, FMN riboswitches have been identified as secondary, non-
protein targets for the flavin analog roseoflavin (Blount and Breaker, 2006; Ott
et al., 2009; Lee et al., 2009). Mansjö and Johansson were able to demonstrate
that roseoflavin in the growth medium affected the FMN riboswitch mediated
gene expression of the gene lmo1945 in L. monocytogenes. However, roseoflavin
was found to also stimulate the expression of genes connected to virulence
and infection abilities in L. monocytogenes (Mansjö and Johansson, 2011). With
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a coupled in vitro transcription/translation assay Pedrolli et al. were able to
show that the cofactor analog RoFMN, and not roseoflavin, interacts with the
FMN riboswitch aptamer in roseoflavin sensitive Streptomyces species.
1.6 Streptomycetes
Streptomycetes are Gram-positive, aerobic soil bacteria. They comprise all
members of the genus Streptomyces within the phylum of actinobacteria (Waks-
man and Henrici, 1943). Known Streptomyces species feature a single, linear
chromosome of approximately 8 – 10 Mbp in length, with a notably high G+C
content of typically > 70% (Kieser et al., 2000). The morphology of strepto-
mycetes is similar to that of eucaryotic filamentous fungi. Streptomycetes in
their natural habitat grow as a vegetative mycelium consisting of branching hy-
phae. They spread through spores that form on aerial hyphae, as a response to
diminishing nutrient supply of the substrate. The similarities of streptomycetes
to fungi are hypothesized to originate from the independent adaptation to
the same ecological niches and lifestyle, i.e. the involvement of both in the
degradation of unsoluble biomass, like lignocellulose or chitin (Hodgson, 2000;
Hopwood, 2006; Flärdh and Buttner, 2009).
In contrast to most other bacteria, streptomycetes differentiate into complex,
multicellular mycelia. The developmental life cycle and differentiation is
shown exemplary for S. coelicolor in figure 1.5. After germination of spores in
favorable environmental conditions, germ tubes are formed that develop into
vegetative hypha. Unlike in rod-shaped bacteria, as e.g. E. coli and B. subtilis,
the hyphal growth of streptomycetes occurs through tip extension and is not
associated with the bacterial actin homologueMreB. The individual cells do not
separate completely but merely form hyphal cross-walls between each other.
When streptomycetes are faced with limitation of nutrients, they initiate the
development of aerial hyphae. To enable the aerial hyphae to break the surface
tension of the aqueous environment of the mycelium and to grow into the
air, their surface is coated with the hydrophobic surfactant peptide SapB. The
aerial hyphae later differentiate from apically growing cells into spores. Other
than endospores formed by Bacillus species, the spores of streptomycetes are
less resistant to harsh environmental conditions. They can, however, survive
extended periods of desiccation (Flärdh and Buttner, 2009).
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to the conversion of aerial hyphae into mature spores 
and what we know about the regulation of these proc-
esses. Finally, recent advances in the study of cell type-
specific gene expression are discussed, and new tools 
and systems are outlined that will greatly facilitate the 
investigation of Streptomyces developmental biology.
Hyphal growth and branching
A defining feature of streptomycetes is that they grow as 
branching hyphae and form a mycelium (FIG. 1). Growth 
occurs through tip extension and the initiation of new 
branches, and consequently new cell-wall material is 
synthesized only at the hyphal tips2. This pronounced 
apical growth can be visualized using fluorescent conju-
gates of vancomycin (FIG. 1) that stain the sites where the 
peptidoglycan precursor lipid II is exported and exposed 
on the cell surface3,4. This pattern is strikingly different 
from that of most other bacteria. In Escherichia coli, 
Bacillus subtilis and many other rod-shaped organisms, 
cell elongation is orchestrated by a helical cytoskeleton 
that is formed by the bacterial actin homologue MreB5,6. 
This cytoskeletal element directs the insertion of new 
peptidoglycan into the lateral wall, resulting in cell exten-
sion and acquisition of the rod shape, whereas the hemi-
spherical cell poles remain inert once they have formed 
as a result of cell division. By contrast, Streptomyces tip 
extension is not dependent on mreB, and cell-wall syn-
thesis occurs at the hyphal tip rather than along the lat-
eral wall. Although all streptomycete genomes that have 
been sequenced so far contain two mreB genes, studies 
of S. coelicolor show that these genes have little impact 
on tip extension in the vegetative mycelium and are 
primarily involved in sporulation in the aerial hyphae7 
(G. Muth, personal communication). Furthermore, 
many other actinobacteria, such as the rod-shaped 
corynebacteria and mycobacteria, have no mreB genes 
and yet, like the streptomycetes, they grow apically by 
building their envelopes at the cell poles4,7–10.
The mreB-independent apical mode of growth in 
actinobacteria depends on the coiled-coil protein DivIVA 
and seems to represent a new way to direct the peptidog-
lycan biosynthetic machinery, in a manner that is distinct 
from those observed during growth and cell division of 
other bacteria. In S. coelicolor, DivIVA is essential and 
has a strong impact on tip extension, branching and cell 
shape. It forms a large focus at each growing hyphal tip, 
and no germ tubes emerge from spores without an asso-
ciated DivIVA focus3 (FIG. 1). Corynebacterial and myco-
bacterial orthologues have similar apical localization 
and morphogenetic activity, and depletion of DivIVA in 
Corynebacterium glutamicum leads to loss of polar cell-
wall assembly and conversion to a spherical cell shape, 
showing that DivIVA is required for the mreB-independ-
ent extension of the cell wall in this organism9. Similar 
data have also been reported for Mycobacterium smeg-
matis8,11. Heterologous DivIVA from both S. coelicolor 
and Mycobacterium tuberculosis, but not from Bacillus 
or Streptococcus species, can restore growth polarity and 
rod shape to the DivIVA-depleted strains of C. glutami-
cum. Thus, DivIVAs from highly diverged actinobacteria 
can fulfil this function in apical cell-wall assembly9.
In Streptomyces, initiation of tip extension during 
hyphal branching requires selection and marking of 
a site where growth will be established, thus defining a 
new axis of cell polarity. Enzymes that are involved in 
export and assembly of peptidoglycan must then be 
recruited to this site to initiate growth and create a new 
hyphal tip. Time-lapse imaging of growing S. coelicolor 
shows that DivIVA assembles into a focus on the lateral 
wall before any outgrowth is visible, and that the new 
branch then emerges from this focus12. Furthermore, 
overexpression of DivIVA leads to the assembly of mul-
tiple foci along the lateral wall, and cell-wall growth is 
established at such foci, leading to multiple aberrantly 
shaped branches12. These data suggest that Streptomyces 
DivIVA may act as a landmark protein that, directly or 
indirectly, recruits the cell-wall biosynthetic machinery 
to new sites. In contrast to the rod-shaped C. glutami-
cum, in which DivIVA assembles at septation sites at a 
Figure 1 | Developmental life cycle of Streptomyces 
coelicolor. Germination of a spore involves swelling, 
polarization of growth and emergence of a germ tube that 
develops into a hypha. This characteristic mode of 
polarized growth is shown in the micrographs, which show 
the apical zones of active cell-wall assembly stained with a 
fluorescent vancomycin conjugate (red) and the 
localization of the polarity determinant protein DivIVA 
tagged with enhanced green fluorescent protein (EGFP; 
green) in two hyphae emerging from a spore. Hyphae grow 
by tip extension and branch into a vegetative mycelium 
that grows across and deep down into the substrate, giving 
rise to the vegetative colony. In response to nutrient 
depletion and other signals, aerial hyphae break surface 
tension, escaping the aqueous environment, and grow into 
the air. The aerial hyphae differentiate into a long chain of 
prespore compartments, which then develop thick spore 
walls, synthesize a grey polyketide spore pigment and 
develop the other characteristics of mature spores. The 
largely dormant spores are the means for dispersal of this 
organism in the environment, and can eventually 
germinate when they encounter suitable conditions. The 
scale bar represents 6 ?m.
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Figure 1.5: The developmental life cycle of S. coelicolor. After germination, a germ
tube emerges from a spore and develops into a vegetative hypha. Hyphae
grow by tip extension and branch into a vegetative mycelium that spreads
into the substrate. Aerial hypha break the surface tension of the aqueous
environment of the substrate and grow into the air. The aerial hyphae dif-
ferentiate into a long cha n of prespore compartments, which then develop
thick sp e walls. Figure adapted from Flärdh and Buttner (2009).
Throughout the past, s reptomycetes hav been s udied in-depth, especially
due to their capability to produce a great variety of secondary metabolites,
including several compounds of pharmaceutical relevance like antifungals,
antivirals, antitumorals, antihypertensives, immunosuppressants and most im-
portant antibiotics. Th production of antibiotic substances by streptomycetes
is assumed to be part of a defense mechanism, possibly triggered by nutri-
ent limitation, in the phase of a rial myc lium for ation. Most antibiotics in
streptomycetes are species specific, and also affect other members of the genus
(Procópio et al., 2012).
S. coelicolor is the genetically best characterized representative of streptomycetes
and i widely used in genetic studies. The analysis of its genome sequence,
presented over one decade ago by Bentley et al., revealed that the chromosome
of streptomycetes features a central “core” region, comprising approximately
half of the genome’s size, containing the origin of replication (oriC) and nearly
all essential genes coding for enzymes involved in cell division, DNA replica-
tion, transcription, translation and amino-acid biosynthesis. The more variabel
outer regions of the chromosome are referred to as “arms” and carry genes with
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non-essential functions, from the secondary metabolism including antibiotic
production (Bentley et al., 2002).
The genes involved in riboflavin biosynthesis have been found to be clustered
in streptomycetes and form an operon controlled by an FMN riboswitch (Vit-
reschak et al., 2002). The arrangement of the riboflavin biosynthesis genes in the
rib-operon in streptomycetes, however, is different from other Gram-positive
bacteria like B. subtilis. The rib-operon in streptomycetes interestingly includes
the gene ribM, coding for the energy independent riboflavin transporter RibM,
while the gene ribG, coding for the bifunctional riboflavin specific deami-
nase/reductase RibG (EC 3.5.4.26 and EC 1.1.1.193), was found in a secondary
location on the chromosomes of S. coelicolor, S. avermitilis and S. davawensis
(Grill et al., 2007).
The FMN riboswitch upstream of the rib-operon in the streptomycetes
S. davawensis and S. coelicolor was shown to regulate the expression of the
riboflavin synthase gene ribB by prevention of translation initiation through se-
questration of the ribB-RBS (see figure 1.6-A). This mechanism is different from
other FMN riboswitches, e.g. the ribG FMN riboswitch of B. subtilis, which reg-
ulate the expression of the rib-operon through transcription termination. The
FMN riboswitch of S. davawensis, in contrast to the one of S. coelicolor, respec-
tively, is able to discriminate between FMN and its roseoflavin derived analog
RoFMN. Opposite to what was observed for S. coelicolor, the FMN riboswitch
of S. davawensis showed upregulation of the expression of its downstream gene
when confronted with RoFMN. Pedrolli et al. were able to interchange this
property by the exchange of a single nucleotide in the sequence coding for the
aptamer of the FMN riboswitch. Exchange of the nucleotide on position 61
in the alignment shown in figure 1.6-B from A to G in S. davawensis confers
sensitivity to RoFMN, while the exchange from G to A in S. coelicolor renders
the FMN riboswitch RoFMN insensitive. The single nucleotide A61 in the
FMN riboswitch provides resistance to the antibiotic flavin analog roseoflavin
to S. davawensis (Pedrolli et al., 2012).
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Figure 1.6: The translational ribB FMN riboswitch in Streptomyces spp. A: Sec-
ondary structure of the ribB FMN riboswitch from S. davawensis. Stem
loops of the aptamer are labeled P1 – P6; nucleotides different to S. coeli-
color highlighted in yellow; nucleotide 61 marked by black box; nucleotides
highlighted in brown are paired in the absence of FMN and form the anti-
sequestor structure; RBS highlighted in red; ribB-start codon underlined.
B: Alignment of the DNA sequence coding for the aptamer portion of the
ribB FMN riboswitch of S. davawensis and S. coelicolor. Identical nucleotides
are shown as points; nucleotide 61 marked by black box. Figure adapted
from Pedrolli et al. (2012).
1.7 Listeria monocytogenes
Listeria monocytogenes is an opportunistic foodborne pathogen causing liste-
riosis, a potentially fatal infection causing meningitis, meningoencephalitis,
sepsis, abortion, perinatal infections, and gastroenteritis. It is one of ten species
in the Gram-positive genus Listeria. L. monocytogenes is an aerobic, facultative
anaerobic, rod-shaped and non-sporulating bacterium. It contains a circular
chromosome of 2.9 Mbp in length with a relatively low G+C content of 39%.
Listeria species are close relatives to species of the genera Bacillus, Clostridium,
Enterococcus, Streptococcus, and Staphylococcus. Comparison of the complete
genome sequences of two Listeria species (L. monocytogenes and L. innocua) with
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the genome of B. subtilis revealed a close relationship that suggests a common
ancestor of the three species (Vázquez-Boland et al., 2001; Glaser et al., 2001;
Liu, 2008). Listeria species can be found in a variety of natural environments,
such as soil, vegetation and fresh water. Silage, sewage as well as human
and animal feces have also been shown to contain L. monocytogenes (Farber
and Peterkin, 1991). A continuous fecal-oral enrichment of L. monocytogenes
in domesticated ruminants (e.g. sheep and cattle) and the consumption of
spoiled silage can result in herd outbreaks (Vázquez-Boland et al., 2001). In
most animals, including humans, infection with L. monocytogenes occurs almost
exclusively through the ingestion of contaminated food. The bacteria have
developed to withstand acidic conditions in the stomach and elevated salt
concentrations found in the small intestine.
Figure 1.7: The intracellular life cycle of L. monocytogenes. (I) invasion factor (InlA,
InlB) mediated internalization of L. monocytogenes by an intestinal epithelial
cell; (II) lysis of the phagocytic vacuole through hemolysin, listeriolysin
(LLO) and phospholipases; (III) replication and ActA induced nucleation
of host actin filaments; (IV) formation of a polar actin tail; (V) formation
of pseudopod, invading neighboring cell; (VI) release of L. monocytogenes
into the cytoplasm after lysis of double membrane vacuole by LLO and
phospholipases. Color legend - yellow: cytoplasm of the epithelial cell;
green: phagocytic vacuole; blue: L. monocytogenes cell; red: polar actin tail.
Figure adapted from Tilney and Portnoy (1989).
In the gastrointestinal tract L. monocytogenes adheres to the epithelial cells of
the mucosa before crossing the intestinal barrier by invasion of enterocytes
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(Schuppler and Loessner, 2010). The different stages of the invasion and the
intracellular life cycle of L. monocytogenes are shown in figure 1.7.
The bacterium enters the host cell with the help of the two surface associ-
ated invasion factors InlA and InlB. Inside the host cell, it escapes from the
phagolysosome by lysis of the phagocytic vacuole. After being released into
the cytoplasm, L. monocytogenes starts replication and recruits host cell actin
using the actin assembly-inducing protein ActA. Polar localization of ActA
and continuos actin polymerization results in a directional movement of the
bacterium. A pseudopod with the bacterium at the tip is formed when it
reaches the plasma membrane. Inside this pseudopod L. monocytogenes enters
neighboring cells. A double membrane vacuole is formed after penetration of
the membrane of the neighboring cell, which is lysed similar to the phagocytic
vacuole subsequent to primary invasion. This mechanism of cell-to-cell inva-
sion allows L. monocytogenes to spread without leaving the host cells’ cytoplasm
(Liu, 2008; Schuppler and Loessner, 2010).
From the gastrointestinal tract L. monocytogenes spreads via the mesenteric
lymph nodes to its primary target organs, the liver and the spleen where, in
immunocompetent, healthy adults, the infection typically is contained and
resolved by the host’s immune system in a subclinical course. In immunocom-
promised hosts (e.g. through HIV infection, in cancer patients, after organ
transplantation or liver cirrhosis), newborns or pregnant women the infection
cannot be contained effectively in the primary target organs and the bacteria
are released into the bloodstream which can lead to localized infections in the
brain or the fetoplacental unit causing a clinical form of listeriosis (Liu, 2008).
Additionally to its adaptation to the adverse conditions in the stomach and
the small intestine, L. monocytogenes is not only capable to tolerate a pH range
from 3.0 to 9.5 and salt concentrations as high as 10%, it is also able to survive
in a temperature range from 0 to 45  C. Especially the growth at refrigeration
temperatures (growth rate ~ 0.5 – 1 d 1 at 4  C) poses enormous problems to
the food industry. L. monocytogenes can survive on foods that were processed to
extend shelf-life (e.g. smoked fish and raw meat saussages) but also on other
foods that are consumed without being cooked before consumption (e.g. dairy
products, vegetables and fruits) (Liu, 2008).
L. monocytogenes is one of the deadliest food-borne pathogens with a death-rate
of approximately 30% in the clinical stage. However, the incidence of clinical
listeriosis is relatively low with only about 3 – 5 cases per million persons
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per year in the United States and Europe (Liu, 2008). Listeria species were
shown to be naturally sensitive to tetracyclines, aminoglycosides, penicillins
(except for oxacillin), frst- and second-generation cephalosporins (cefaclor,
cefazolin, loracarbef) and chloramphenicol while they showed resistance to
most ’modern’ cephalosporins (cefetamet, cefixime, ceftibutene, ceftazidime,
cefdinir, cefpodoxime, cefotaxime, ceftriaxone, cefuroxime) (Troxler et al., 2000).
Hansen et al. found that the the antibiotic susceptibility of L. monocytogenes
has not changed throughout the second half of the 20th century in a study of
L. monocytogenes strains from human isolates, collected during the period 1958
to 2001 in Denmark (Hansen et al., 2005). However, multi-resitant isolates of
L. monocytogenes have been reported elsewhere and pose the risk of a potential
spread of multi-resistant L. monocytogenes (Poyart-Salmeron et al., 1990; Tsakris
et al., 1997; Haubert et al., 2016).
Under laboratory conditions Listeria spp. require the addition of three vitamins
(riboflavin, biotin and thiamin), the cofactor lipoate as well as six amino acids
(leucine, isoleucine, arginine, methionine, valine and cysteine) into chemically
defined growth media to enable growth (Premaratne et al., 1991). Since the
biosynthetic pathways for all amino acids could be identified in the genome
of L. monocytogenes, the amino acid auxotrophy was attributed to possible
repression under laboratory conditions. The biosynthetic pathways for the
biosynthesis of all four vitamins, however, were found to bemissing completely
or partially in L. monocytogenes (Glaser et al., 2001).
From theRfam database collection of RNA families one FMN riboswitch (Rli96) was
identified upstream the gene lmo1945. Since the putative gene product Lmo1945
shows high similarity to the riboflavin transporter RibU from B. subtilis, lmo1945
was assumed to encode a riboflavin transport protein as well (Griffiths-Jones
et al., 2003, 2005; Toledo-Arana et al., 2009; Mansjö and Johansson, 2011).
The secondary structure of Rli96, suggested in figure 1.8, is based on the
Rfam alignment to the covariance model of the FMN riboswitch family (Rfam-
Accession: RF00050) and thermodynamic data obtained through the Mfold
webserver for nucleic acid folding and hybridization prediction (Zuker, 2003).
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Figure 1.8: The transcriptional FMN riboswitch Rli96 from L. monocytogenes. Sug-
gested secondary structure of Rli96 featuring the FMN binding aptamer
and the transcription terminator loop. The bases highlighted in blue are
predicted to pair in the absence of FMN to form an anti-terminator loop, en-
abling transcription to proceed. The suggested secondary structure is based
on the alignment of Rli96 to the FMN riboswitch family (Rfam-Accession:
RF00050) and thermodynamic data obtained through theMfold webserver
(Griffiths-Jones et al., 2003; Zuker, 2003).
1.8 Objectives of the Work
The main objective of this work was to gain insight into the flavin metabolism
of L. monocytogenes. Particularly, the focus was on how toxic flavin analogs
are metabolized and their possible use as antimicrobials against the human
pathogen. This included answering the question if the riboflavin transport pro-
tein Lmo1945 was also responsible for the uptake of riboflavin analogs into the
cells and to which extent the intracellular concentrations of riboflavin derived
cofactors are related to the response of the FMN riboswitch Rli96, controlling
the expression of Lmo1945, to cofactor analogs. In addition, the identification
and characterization of enzymes producing cofactors from riboflavin and its
analogs in L. monocytogeneswere approached.
Furthermore, an in vivo reporter system for the characterization of translation-
ally controlled riboswitches from Streptomyces species was evaluated.
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Materials
2.1 Buﬀers and Solutions
For the preparation of all buffers and solutions ultrapure water, prepared with
Millipore Milli-Q R  Gradient A10was used. All buffers and solution that were
used for HPLC-MS or FPLC applications were filtered through 0.2µm after
preparation and degassed for 20min in an ultrasonic bath prior to use.
If not stated differently, the pH was adjusted to the given values with
concentrated (i.e. > 1M) hydrochloric acid or sodium hydroxide respectively.
2.1.1 Stock Solutions for Buﬀer Preparation
Table 2.1: 0.5M EDTA stock solution; pH 8.0.
Compound Amount Final Conc.
Na2EDTA 93.05 g 0.5M
NaOH (solid) approx. 10.14 ga
H2O ad 500ml
aPre-calculated amount for pH 8.0
Table 2.2: 5M NaCl stock solution; pH not adjusted.
Compound Amount Final Conc.
NaCl 292.2 g 5M
H2O ad 1000ml
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Table 2.3: 0.5M monobasic sodium phosphate stock solution; pH not adjusted
Compound Amount Final Conc.
NaH2PO4 · H2O 69.0 g 0.5M
H2O ad 1000ml
Table 2.4: 0.5M dibasic sodium phosphate stock solution; pH not adjusted
Compound Amount Final Conc.
Na2HPO4 · 2H2O 89.0 g 0.5M
H2O ad 1000ml
Table 2.5: 0.5M sodium phosphate buffer; various pH.
pH monobasic stock (0.5M) dibasic stock (0.5M)
6.0 877ml 123ml
6.5 685ml 315ml
7.0 390ml 610ml
7.5 160ml 840ml
8.0 53ml 947ml
Table 2.6: 1M Tris-HCl stock solution; pH 7.5.
Compound Amount Final Conc.
Tris base 121.1 g 1M
H2O ad 1000mla
aWater added to approx. 800ml, pH adjusted with conc. HCl, volume adjusted with water to
1000ml after the solution has cooled off to room temperature.
Table 2.7: 10x Tris-glycine buffer for SDS-PAGE; pH 8.6 ± 0.2 not adjusted.
Compound Amount Final Conc.
Glycine 144 g 1.92M
Tris base 30.3 g 250mM
SDS 10 g 1%m/v
H2O ad 1000ml
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Table 2.8: Towbin buffera; pH 8.6 ± 0.2 not adjusted.
Compound Amount Final Conc.
Glycine 14.41 g 192mM
Tris base 3.03 g 25mM
Methanol 200ml 20%v/v
H2O ad 1000ml
anot autoclavable, stored af 4  C
Table 2.9: GES lysis buffer; pH 8
Compound Amount Final Conc.
Guanidinium thiocyanate 5.91 g 5M
EDTA 0.5M 2ml 0.1M
N-Lauroylsarcosine 0.05 g 0.5%m/v
H2O ad 10mla
aGuanidinium thiocyanate and EDTA were mixed with approx. 8ml H2O at 65  C. Laurylsar-
cosine was added and the volume was adjusted to 10ml after the solution has cooled off to
room temperature.
Table 2.10: GusA extraction buffer; pH 7
Compound Amount Final Conc.
Sodium phosphate 0.5M; pH 7a 100ml 50mM
DTT 0.771 g 5mM
Triton-X 100 1ml 0.1%v/v
H2O ad 1000ml
asee table 2.5
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2.1.2 Buﬀers for FPLC and HPLC-MS
Table 2.11: Buffer A for IMAC; pH 7.5.
Compound Amount Final Conc.
Sodium phosphate 0.5M; pH 7.5a 100ml 50mM
NaCl 5M 60ml 300mM
Imidazole 2M 10ml 20mM
H2O ad 1000ml
asee table 2.5
Table 2.12: Buffer B for IMAC; pH 7.5.
Compound Amount Final Conc.
Sodium phosphate 0.5M; pH 7.5a 100ml 50mM
NaCl 5M 60ml 300mM
Imidazole 2M 100ml 200mM
H2O ad 1000ml
asee table 2.5
Table 2.13: Buffer A for AEX; pH 8.0.
Compound Amount Final Conc.
Tris-HCl 1M 20ml 20mM
NaCl 5M 5ml 25mM
H2O ad 1000ml
Table 2.14: Buffer B for AEX; pH 8.0.
Compound Amount Final Conc.
Tris-HCl 1M 20ml 20mM
NaCl 5M 100ml 500mM
H2O ad 1000ml
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Table 2.15: Buffer A for MBPTrap; pH 7.4.
Compound Amount Final Conc.
Tris-HCl 1M 20ml 20mM
NaCl 5M 40ml 200mM
EDTA 0.5M 2ml 1mM
H2O ad 1000ml
Table 2.16: Buffer B for MBPTrap; pH 7.4.
Compound Amount Final Conc.
Tris-HCl 1M 20ml 20mM
NaCl 5M 40ml 200mM
EDTA 0.5M 2ml 1mM
Maltose 3.42 g 10mM
H2O ad 1000ml
Table 2.17: Ammonium formate buffer for HPLC-MS; pH 3.7.
Compound Amount Final Conc.
Ammonium formate 2.53 g 20mM
Formic acid 1.84ml 20mM
H2O ad 2000ml
2.1.3 Antibiotics and Inducer
Stock solutions of antibiotics that were prepared with ultrapure water were
sterilized by passing through a syringe filter (RC, 0.2µm). The stocks were
stored in aliquots of 1ml at  20  C in sterilized MCTs. To reach the working
concentration in the culture media, appropriate volumes of the stock solution
were added to the media directly before inoculation.
For solid media containing agar-agar, the antibiotic stock solution was added
after the temperature of the media was below 55  C.
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Table 2.18: Antibiotics used for selection of E. coli.
Antibiotic Stock conc. (mg/ml) Working conc. (µg/ml)
Apramycin 50 50
Ampicillin 100 100
Carbenicillin 100 100
Chloramphenicola 34 34
Kanamycin 100 50
Nalidixic acidb 25 25
aStock in 96% EtOH
bStock in 0.15 M NaOH
Table 2.19: Antibiotics used for selection of B. subtilis.
Antibiotic Stock conc. (mg/ml) Working conc. (µg/ml)
Chloramphenicola 30 5
Erythromycin 10 1
Kanamycin 100 5 - 10
aStock in 96% EtOH
Table 2.20: Antibiotics used for selection of Streptomyces spp.
Antibiotic Stock conc. (mg/ml) Working conc. (µg/ml)
Apramycin 50 50
Hygromycin 50 25
Thiostreptonea 50 50
aStock in DMSO
Table 2.21: Compunds used for induction of protein production.
Compund Stock conc. Working conc.
IPTG 1M 0.1 - 1mM
Thiostreptonea 50mg/ml 10 µg/ml
aStock in DMSO
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2.2 Media
For the preparation of growth media ultrapure water was used by default.
The media were heat sterilized for 20min at 121  C (Varioklav R  75S, H+P
Labortechnik, Habermoos). If not stated differently, the pH was adjusted to
the given values with concentrated (i.e. > 1M) hydrochloric acid or sodium
hydroxide respectively.
Table 2.22: Lysogeny Broth (LB); pH 7.2 (Sambrook and Russell, 2001).
Compound Amount Final Conc.
Tryptone 10 g 10 g/l
Yeast extract 5 g 5 g/l
NaCl 10 g 10 g/l
H2O ad 1000ml
Table 2.23: Lysogeny Agar (LA); pH 7.2 (Sambrook and Russell, 2001).
Compound Amount Final Conc.
Tryptone 10 g 10 g/l
Yeast extract 5 g 5 g/l
NaCl 10 g 10 g/l
Agar-agar 15 g 15 g/l
H2O ad 1000ml
Table 2.24: SOC Medium; pH 6.8 - 7.0 (Hanahan, 1983).
Compound Amount Final Conc.
Tryptone 2 g 20 g/l
Yeast extract 0.5 g 5 g/l
NaCl 1 g 10mM
KCla 1M 0.25ml 2.5mM
MgCl2a 1M 1ml 10mM
Glucoseb 2M 1ml 20mM
H2O ad 100ml
afilter sterilized (0.2µm cellulose acetate) and added after autoclaving
bglucose stock solution was autoclaved separately
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Table 2.25: GYT Medium; pH 7.2 (Tung and Chow, 1995).
Compound Amount Final Conc.
Tryptone 2.5 g 2.5 g/l
Yeast extract 1.25 g 1.25 g/l
Glycerola 50% (v/v) 200ml 10% (v/v)
H2O ad 1000ml
aautoclaved separately
Table 2.26: 2 xYT Medium; pH 7.0.
Compound Amount Final Conc.
Tryptone 16 g 16 g/l
Casamino acids 10 g 10 g/l
NaCl 5 g 5 g/l
H2O ad 1000ml
Table 2.27: Tryptic Soy Broth (TSB); pH 7.3.
Compound Amount Final Conc.
Casein peptone (pancreatic) 17 g 17 g/l
Soya peptone (papain) 3 g 20 g/l
Glucose 2.5 g 2.5 g/l
NaCl 5 g 5 g/l
KH2PO4 2.5 g 2.5 g/l
H2O ad 1000ml
Table 2.28: Yeast Starch Nutrient Broth (YS); pH 7.2 (Kieser et al., 2000).
Compound Amount Final Conc.
Yeast extract 2 g 2 g/l
Soluble potato strach 10 g 10 g/l
H2O ad 1000ml
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Table 2.29:Mannitol Soy Sporulation Medium (MS); pH 7.2 (Kieser et al., 2000).
Compound Amount Final Conc.
Mannitol 20 g 20 g/l
Soybean floura 20 g 20 g/l
Agar-agar 15 g 15 g/l
H2O ad 1000ml
adissolved in hot tap water
Table 2.30: 10 x Spizizen Minimal Salts (SMS); pH 7.2 (Spizizen, 1958).
Compound Amount Final Conc.
Ammonium sulfate 20 g 20 g/l
K2HPO4 140 g 140 g/l
KH2PO4 60 g 60 g/l
Sodium citrate (dihydrate) 10ml 10 g/l
Magnesium sulfate (heptahydrate) 2 g 2 g/l
H2O ad 1000ml
Table 2.31: Spizizen Minimal Medium (SMM); pH 7.2 (Spizizen, 1958).
Compound Amount Final Conc.
10 x Spizizen Minimal Salts 100ml 10% (v/v)
Glucose 50% (w/v) 10ml 0.5 g/l
L-Tryptohan 5mg/ml 10ml 50mg/l
100 xTrace elementsa 10ml 1 x
H2O ad 1000ml
aTrace elements are not included in the original recipe by Spizizen (1958). 100 xTrace elements
solution according to Cutting (1990).
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2.3 Kits and Enzymes
Table 2.32: Kits, Enzymes, Ladders and Dyes
Product Supplier
GeneJetTM Plasmid Miniprep Kit Thermo Scientific
GeneJetTM Genomic DNA Purification Kit Thermo Scientific
GeneJetTM Gel Extraction Kit Thermo Scientific
Mini-PROTEAN R  TGXTM Any kDTM BioRad
His·Tag R  APWestern Reagents Merck Millipore
E. coli T7 S30 Extract System for Circular DNA Promega
T4 DNA Ligase Thermo Scientific
FastAPTM Alkaline Phosphatase Thermo Scientific
KAPAHiFiTM DNA Polymerase KAPA Biosystems
DreamTaq DNA Polymerase Thermo Scientific
Fast DigestTM Restriction Enzymes Thermo Scientific
Type IIs Restriction Enzymes Thermo Scientific
GeneRuler 1 kb Plus DNA Ladder Thermo Scientific
PageRulerTM Plus Prestained Protein Ladder Thermo Scientific
PageBlueTM Protein Staining Solution Thermo Scientific
2.4 Oligonucleotides and Plasmids
A comprehensive list of all oligonucleotides and plasmids used in this work,
including their relevant genetic features and resistance markers is given in
tables 2.33 and 2.34, respectively. A selection of plasmids that were constructed
and used throughout this work is described in more detail, including a graphi-
cal representation of the relevant genetic features in the following sections.
2.4.1 Plasmids for the xylE Reporter System
The plasmids pAM01, pAM023, pAM673, pAM893 and pAM893a were con-
structed to provide a reporter platform in Streptomyces spp. for an in vivo test
system for translational riboswitches, based on the expression of the reporter
gene xylE. The backbone of all plasmids shown in figure 2.1 was the integrative
vector pSET152 constructed by Bierman et al. (1992). Hence, all the plasmids
feature an oriT region that allows for conjugally transfer from E. coli to Strepto-
myces spp., as well as the int C31 region, that allows site-specific integration of
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the plasmid at the bacteriophage  C31 attachment site in streptomycetes.
Figure 2.1: Integrative plasmids for the xylE reporter system. The pSET152 derived
plasmids pAM01, pAM023, pAM673, pAM893 and pAM893a.
The plasmid pAM01 features the Prib promoter region of S. davawensis up-
stream of the two genes xylT and xylE in their overlapping configuration that
was amplified from the promoter probe plasmid pIPP1. In contrast to pIPP1
the plasmid pAM01 provides two unique restriction sites HindIII and BamHI
upstream of the reporter region, that allows for directional insertion of putative
promoter fragments.
The plasmid pAM023 features the same elements as pAM01 where the cod-
ing sequences for xylT and xylE have been separated and their sequential
arrangement has been inverted so that xylE is placed upstream of xylT.
The plasmid pAM673 features a translational fusion of the he Prib promoter,
the FMN riboswitch and the ribosomal binding site RBSribB, including the GTG
start codon of ribB from S. davawensis replacing the ATG start codon of xylE.
The placement of xylT is identical as on pAM023.
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The plasmid pAM893 includes adjacent to RBSribB the six leading codons of
ribBmerging directly into the coding sequence of xylE.
The plasmid pAM893a features a 34 nt sequence between the six leading
codons of ribB from S. davawensis and the ATG start codon of xylE. This se-
quence contains the original ribosomal binding site RBSxylE. The placement of
xylE, xylT and the respective ribosomal binding sites is identical to the plasmid
pAM023.
2.4.2 Plasmids for the gusA Reporter System
The plsamids pMgus01 and pAMgus04 were constructed based on the work of
Myronovskyi et al. (2011). With the plasmid pGUSHL4aadAMyronovskyi et al.
provided a platform for translational fusions in streptomycetes to the reporter
gene gusA from E. coli. The gene gusA is coding for the enzyme  -glucuronidase
(GusA) that tolerates large C- and N-terminal fusions and hydrolyzes several
 -glucuronides (e.g. p-Nitrophenyl  -D-glucopyranoside (PNPG)).
Figure 2.2: Integrative plasmids for the gusA reporter system. The pSET152 derived
plasmids pAMgus01 for transcriptional fusions and pAMgus04 for transla-
tional fusions with gusA.
The plasmid pAMgus01 features the Prib promoter region of S. davawensis,
the ribososmal binding site RBSribB upstream of gusA. Therefore pAMgus01
functions as a gusA based promoter probe plasmid similar to pSETgus (kindly
provided by Andriy Luzhetskyy, Helmholtz Institute for Pharmaceutical Re-
search, Saarbrücken, Germany).
The plasmid pAMgus04 consists of a 492 nt long sequence from S. davawensis,
including the Prib promoter, the FMN riboswitch, the ribosomal binding site
RBSribB as well as the six leading codons of ribB, that is fused in-frame to the
coding sequence for the helical linker HL4 and the downstream gene gusA.
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2.4.3 Lmo0728 Expression Plasmids
ACTAAT TCGGGATCTGGCAGTGGT TCTGAGAATCT T TAT T T TCAGGGCGCCATGGGTGGCGGTGGCGGTGCCATGGAAGTA
Figure 2.3: Lmo0728 expression plasmids. The plasmids were used for the heterolo-
gous expression of different Lmo0728-fusion proteins. pET-24_lmo0728,
pMAL_0728, pET-MBP-0728 and pET-MBP-pg-0728 with sequence detail.
The plasmid pET-24_lmo0728 features the coding sequence of lmo0728
cloned into pET-24a(+), digested with XbaI/XhoI. The protein Lmo0728-His
expressed from this vector possesses a C-terminal His-tag.
The plasmid pMAL_lmo0728 features a fusion of malE and lm0728, sepa-
rated by a spacer, coding for the FactorXa recognition sequence. The expression
is controlled by the IPTG inducible, synthetic Ptac promoter.
The plasmid pET-MBP-lmo0728 was constructed by replacing egfp in the
plasmid pET-MBP-1a with the coding sequence of lmo0728. The plasmid
provides an expression platform for a N-terminally His-tagged MBP-Lmo0728
fusion protein. The two domains are separated by by a spacer sequence, coding
for the TEV protease recognition sequence.
The plasmid pET-MBP-pg-lmo0728 was derived from pET-MBP-lmo0728
through insertion of a 25 nt long linker into the unique NcoI restriction site
upstream of lmo0728. The linker features the codons GGT and GGC, both
coding for glycine, in an alternating manner. The introduction of the glycine
spacer alleviates the access of the TEV protease to the dedicated cleavage site.
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Table 2.33: Oligonucleotides used in this work. Restriction sites underlined.
Name Sequence (50! 30) Application
F-lmo0728.NheI ATTATTGCTAGCGAAGTATCGCATGTAACG pET-24_lmo0728, pET-28_lmo0728
R-lmo0728.XhoI ATTACTCGAGCTCGGAAAGTTCGTTTTTCA pET-24_lmo0728
F-lmo1329atg.NheI AATAATGCTAGCATGAAGACGATATACTTACA pET-24_lmo1329
R-lmo1329.NotI AATATAGCGGCCGCATCTTCTAATTTAGCAA pET-24_lmo1329
R-lmo0728taa.XhoI TATCCTCGAGTTACTCGGAAAGTTCGTTTTTCA pET-28_lmo0728
F-lmo0728.EcoRV TATAGATATCATGGAAGTATCGCATGTAAC pMAL_lmo0728
R-lmo0728taa.BamHI TATCGGATCCTTACTCGGAAAGTTCGTTT pMAL_lmo0728, pET-MBP-lmo0728
F-lmo0728.NcoI ATAGCCATGGAAGTATCGCATGTAAC pET-MBP-lmo0728
FL-pGly.NcoI CATGGGTGGCGGTGGCGGTGC linker for pET-MBP-pg-lmo0728
RL-pGly.NcoI CATGGCACCGCCACCGCCACC linker for pET-MBP-pg-lmo0728
F-lmo1945.BamHI ATATATGGATCCATGAAGAATTATTCAATGAA pHT01_lmo1945
R-lmo1945.AatII ATTGACGTCTTAATGGCTTATTTCTTGTTGTCTTTT pHT01_lmo1945
F-Rli96.EcoRI CGCGAATTCATAAATAAAACCAGCTAATT pDG268_Rli96
R-Rli96.BamHI CGCGGATCCGAATATTTTCTTACAATTTT pDG268_Rli96
F-Rli96.HindII CGCAAAGCTTATAAATAAAACCAGCTAATT pT7luc_Rli96
R-Rli96.NotI ATATATGCGGCCGCTCATTGAATAATTCTTCATTG pT7luc_Rli96
F-PribSc.BamHI GGGGGATCCA GTCGGTTCCT CTCCACGGA pIPP1_PribSc/(AS)
R-PribSc.BamHI GGGGGATCCCACGGCCAGTGTGCCACGCC pIPP1_PribS/(AS)32
Name Sequence (50! 30) Application
F-PribSd.BamHI GGGGGATCCGTCGGTTCCTCTCCACGGAA pIPP1_PribSd/(AS)
R-PribSd.BamHI GGGGGATCCCAGGGCCAGTGTGCCACGCC pIPP1_PribSd/(AS), pAM01,
pAM023, pAMgus01, pAMgus02,
pAMgus03, pAMgus04
F-PribSc.XbaI ATATATTCTAGAAGTCGGTTCCTCTCCACGGA pAM152ScxE
F-PribSd.XbaI ATATATTCTAGAGTCGGTTCCTCTCCACGGAA pAM152SdxE, pAM01, pAM023,
pAMgus01, pAMgus02, pAMgus03,
pAMgus04
R-ribB.BamHI ATATATGGATCCGACGATTCCGGTGAACACTT pAM152ScxE, pAM152SdxE
F-xylE.BamHI ATATATGGATCCAACAAAGGTGTAATGCG pAM152ScxE, pAM152SdxE
R-xylE.EcoRI ATATATGAATTCTCAGGTCAGCACGGTCATGAAT pAM152ScxE, pAM152SdxE, pAM01
F-xylT.HindIII ATATAAGCTTTCCGTCATGTTTAGTGTATC pAMxT
R-xylT.XbaI ATATATTCTAGATCATGACGTCACCTCTTCAT pAMxT, pAM01
F-xylT.BamHI ATATGGATCCTCCGTCATGTTTAGTGTATC pAM01
F-xylE.BamHI ATATGGATCCAACCTGACAACATGAACTAT pAM023, pAM453a, pAM893a
R-xylE.NotI ATATGCGGCCGCTCAGGTCAGCACGGTCATG pAM023, pAM453/a, pAM673,
pAM893/a
F-xylT.NotI ATATGCGGCCGCTCCGTCATGTTTAGTGTATC pAM023, pAM453/a, pAM673,
pAM893/a
R-xylT.EcoRI ATATATGAATTCTCATGACGTCACCTCTTCAT pAM023, pAM453/a, pAM673,
pAM893/a33
Name Sequence (50! 30) Application
F-xylEatg.BsaI ATATGGTCTCGAAATGAACAAAGGTGTAATGCG pAM453/a
R-RFNatg.BsaI ATATGGTCTCGATTTCCCGGGTCCTCCTGCCTCAT pAM453/a
F-xylEgtg.BsaI ATATGGTCTCGAAGTGAACAAAGGTGTAATGCG pAM673
R-RFNgtg.BsaI ATATGGTCTCGACTTCCCGGGTCCTCCTGCCTCAT pAM673
F-xylE.BsaI ATATGGTCTCATCAACAAAGGTGTAATGCGA pAM893/a
R-ribB.BsaI ATTAGGTCTCATTGACGATTCCGGTGAACACTT pAM893/a
R-RFNSd.BamHI TAGCGGATCCTTCCCGGGTCCTCCTGCCTCAT pAM453a
R-ribB2.BamHI ATTAGGATCCGACGATTCCGGTGAACACTT pAM893a
R-gusA.NotI ATATGCGGCCGCTTATCACTGCTTCCCGC pAMgus01, pAMgus02, pAMgus03,
pAMgus04
F-gusA.BsaI ATATGGTCTCAAGTGCTGCGGCCCGTCGAAACC pAMgus01
F-HL4.BsaI ATATGGTCTCAAGTGCTCGCCGAGGCCGCCGC pAMgus02
F-ribBHL4.BsaI ATATGGTCTCACGTCCTCGCCGAGGCCGCCGC pAMgus03, pAMgus04
R-ribB2.BsaI ATATGGTCTCAGACGATTCCGGTGAACACTT pAMgus04
FL-RBSribB.BamHI GATCCAGGCAGGAGGACCCGGGA linker for pAMgus01, pAMgus02
RL-RBSribB.BamHI CACTTCCCGGGTCCTCCTGCCTG linker for pAMgus01, pAMgus02
FL-ribB.BamHI GATCCAGGCAGGAGGACCCGGGAAGTGTTCACCGGAAT linker for pAMgus03
RL-ribB.BamHI GACGATTCCGGTGAACACTTCCCGGGTCCTCCTGCCTG linker for pAMgus03
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Table 2.34: Plasmids used in this work
Name Relevant Features Resistance Reference
pET-24a(+) PT7, MCS, C-His Kan Novagen (2002)
pET-28a PT7, MCS, N-His / C-His Kan Novagen (2002)
pET-24_lmo0728 modified pET-24a(+), lmo0728-His Kan This work
pET-24_lmo1329 modified pET-24a(+), lmo1329-His Kan This work
pET-28_lmo0728 modified pET-28a, His-lmo0728 Kan This work
pMAL-c5x malE (MBP-), Factor Xa cleavage site, MCS Amp NEB
pMAL_lmo0728 modified pMAL-c5x, MBP-lmo0728 Amp This work
pET-MBP-1a modified pET-24d, PT7, N-His-MBP, TEV cleavage site, eGFP Kan EMBLa
pET-MBP-lmo0728 modified pET-MBP-1a, eGFP replaced by lmo0728 Kan This work
pET-MBP-pg-lmo0728 modified pET-MBP-0728, featuring a spacer, coding for 5
Glycines, between the TEV recognition site and lmo0728
Kan This work
pSET152 IncP↵ oriT, pUC18 oriV, lacZ↵, int C31 Apr Bierman et al. (1992)
pUB307 RP1 derivate, conjugative, broad-host-range helper plasmid Kan Bennett et al. (1977)
pR9406 modified pUB307, cat replaced with bla Amp Jones et al. (2013)
pUWloriTaph pUC18 oriV, pIJ101 oriV, IncP↵ oriT, PermE Kan, Tsr Blaesing et al. (2005)
pIPP1 derived from pXE4 and pSET152, xylE, xylT Apr, Amp Jones (2011)
pIPP1_PribSc Prib of S. coelicolor in BamHI-site of pIPP1 Apr, Amp This work
aEMBL-made plasmid by Gunter Stier
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Name Relevant Features Resistance Source
pIPP1_PribSc(AS) Prib of S. coelicolor in anti sense orientation in BamHI-site of pIPP1 Apr, Amp This work
pIPP1_PribSd Prib of S. davawensis in BamHI-site of pIPP1 Apr, Amp This work
pIPP1_PribSd(AS) Prib of S. davawensis in anti sense orientation in BamHI-site of
pIPP1
Apr, Amp This work
pAM152ScxE pSET152 derived, translational fusion of Prib-RFN-RBS-ribBb
from S. coelicolorwith xylE amplified from pIPP1 (no start codon)
Apr This work
pAM152SdxE pSET152 derived, translational fusion of Prib-RFN-RBS-ribBb
from S. davawensis with xylE amplified from pIPP1 (no start
codon)
Apr This work
pAMxT pUWloriTaph derived, PermE, xylT Kan, Tsr This work
pAM01 pSET152 derived, Prib from S. davawensis, xylT-xylE fragment
from pIPP1
Apr This work
pAM023 pSET152 derived, Prib from S. davawensis, xylE, xylT Apr This work
pAM453c pSET152 derived, translational fusion of Prib-RFN-RBSribB from
S. davawensis and xylE, xylT
Apr This work
pAM453ac pAM453 derivate, where xylE is led by its native RBSxylE Apr This work
pAM673c pSET152 derived, translational fusion of Prib-RFN-RBSribB from
S. davawensis and xylEGTG, xylT
Apr This work
bLeading 6 codons of the ribB-gene incl. GTG start codon
cGolden Gate Cloning
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Name Relevant Features Resistance Source
pAM893c translational fusion of Prib-RFN-RBS-ribBb from S. davawensis
with xylE (w/o start codon), xylT
Apr This work
pAM893ac pAM893 derivate, where xylE is led by its native RBSxylE Apr This work
pSETgus pSET152 derivate, PtipA, gusAd Apr Myronovskyi et al. (2011)
pGUSHL4aadA pTESa derivate, MCS, gusAd fused to helical linker HL4e Apr Myronovskyi et al. (2011)
pAMgus01c pSET152 derived, Prib from S. davawensis, RBSribB, gusAd Apr This work
pAMgus02c pSET152 derived, Prib from S. davawensis, RBSribB, HL4e-gusAd Apr This work
pAMgus03c pSET152 derived, Prib from S. davawensis, RBSribB-ribBb-HL4e-
gusAd
Apr This work
pAMgus04c pSET152 derived, translational fusion of Prib-RFN-RBSribB-ribBb
from S. davawensiswith HL4e-gusAd
Apr This work
pHT01 ColE1 oriV, lacI, Pgrac, MCS Amp, Cm Mobitec (2012)
pHT01_lmo1945 pHT01 derivate, lmo1945 from L. monocytogenes Amp, Cm This work
pDG148 pUB110 oriV, pBR322 oriV, Pspac, MCS, Ppen, lacI Amp, Kan Stragier et al. (1988)
pDG148_ribU pGD148 derived, ribU from B. subtilis Amp, Kan Ott et al. (2009)
pDG268 30–amyE, MCS, lacZ, cat, 50–amyE Amp, Cm Antoniewski et al. (1990)
pDG268_RFNbs modified pDG268, Prib-RFN from B. subtilis upstream of lacZ Amp, Cm Ott et al. (2009)
dCodon optimized for Streptomyces spp.
eRef: Arai et, al. Protein Eng. 14(8) 2001
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Name Relevant Features Resistance Source
pDG268_Rli96 modified pDG268, Rli96 from L. monocytogenes upstream of lacZ Amp, Cm This work
pT7luc PT7, MCS, luc from P. pyralis Amp Promega
pT7luc_RFNbs PT7, RFN from B. subtilis upstream of luc Amp Pedrolli et al. (2012)
pT7luc_Rli96 PT7, Rli96 from L. monocytogenes upstream of luc Amp This work
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2.5 Strains
A comprehensive list of all bacterial strains used in this work, including their
relevant genetic features is given in table 2.35.
2.5.1 B. subtilis Strains for  -galactosidase Activity Assay
The B. subtilis strains Bs::RFNbs and Bs::Rli96 were generated by double
crossover integration of plasmids derived from pDG268 (Cutting, 1990). The
strains feature the putative riboswitch sequence including its upstream pro-
moter controlling the expression of lacZ. The reporter gene lacZ is coding for the
enzyme  -galactosidase (LacZ, EC 3.2.1.23). The basic structure of the plasmids
used for this assay is shown in figure 2.4. The double crossover integration
into the amylase locus amyE of B. subtilis allows for screening with an amylase
production assay (section 3.11.4).
amyE!5‘! amyE!3‘!lacZ( Riboswitch( cat(
amyE!
B.(sub4lis!chromosome(
pDG268!
Promoter!
RB
S!
Figure 2.4: Integrative plasmids for the lacZ reporter system. Double crossover inte-
gration of pDG268 derived riboswitch test plasmids into the amyE locus of
the chromosome of B. subtilis. Figure altered from Ott et al. (2009).
Bs::RFNbs and Bs::Rli96 were used to test the effect of flavins on the in vivo
expression of the reporter gene lacZ. Both strains additionally carry a plasmid
with the riboflavin transporter gene ribU under the control of a constitutive
promoter to ensure the flavin uptake of the cells is not reduced due to regu-
latory effects in the host. The  -galactosidase activity assay is described in
section 3.11.3.
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2.5.2 The L. monocytogenes FMN Riboswitch Mutant Strain M1
!
Figure 2.5: The deregulated FMN riboswitch mutant strain M1. Aptamer portion
of the FMN riboswitch Rli96 from L. monocytogenes (see also figure 1.8 on
page 18). The replacement of nucleotides G37/G38 (grey) by A37/A37 (red
box) in the aptamer generated the FMN riboswitch variant M1, which did
not terminate the transcription when riboflavin or roseoflavin was added
to the medium (Mansjö and Johansson, 2011).
The L. monocytogenesmutant strain M1 was kindly provided by Jörgen Johans-
son (Laboratory forMolecular InfectionMedicine Sweden (MIMS), Department
of Molecular Biology, Umeå University, Umeå, Sweden). It was created by
Mansjö and Johansson (2011) by replacing two nucleotides (GG to AA) in the
aptamer region of the FMN riboswitch Rli96 (figure 2.5). The mutant strain
M1 was able to grow better in the presence of roseoflavin when compared
to the wild type. Mansjö and Johansson demonstrated in a northern blot
experiment that lmo1945 was transcribed in the M1 strain in the presence of
100µM riboflavin and roseoflavin respectively. This was in contrast to the wild
type, where they only observed a terminated fragment (Rli96) under the same
conditions.
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Table 2.35: Bacterial Strains used in this work
Name Relevant Features Reference/Source
E. coli
Top10 host for plasmid propagation
F  mcrA  (mrr-hsdRMS-mcrBC)  80lacZ M15  lacX74 recA1 araD139
 (ara-leu)7697 galU galK rpsL (StrR) endA1 nupG  -
Invitrogen
BL21(DE3) host for recombinant protein production
F  ompT hsdSB (rB  mB ) gal dcm (DE3)
Invitrogen
Rosetta(DE3) host for recombinant protein production
F  ompT hsdSB (rB  mB ) gal dcm lacY1 (DE3), pRARE
Invitrogen
ER2523 host for recombinant protein production
fhuA2 [lon] ompT gal sulA11 R(mcr-73::miniTn10--TetS)2 [dcm] R(zgb-210::Tn10--
TetS) endA1 (mcrC-mrr)114::IS10
NEB
ET12567 dam-13::Tn9, dcm-6, hsdM, pUB307 MacNeil et al. (1992)
GM2163 dam , dcm  NEB
L. monocytogenes
EGDe wild type Johansson
M1 L. monocytogenes EGDe with G37/G38 replaced by A37/A37 in Rli96 Mansjö and Johansson (2011)
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Name Relevant Features Reference/Source
B. subtilis
Marburg 168 wild type DSMZ
Bs ribU  ribU::kanR Hemberger et al. (2011)
Bs ribUB  ribU::kanR  ribB::ermR Hemberger et al. (2011)
Bs::RFNbs amyE::RFNbs-lacZ Ott et al. (2009)
Bs::Rli96 amyE::Rli96-lacZ This work
S. davawensis
JSCC #768 wild type JSCC
S. coelicolor
DSM #40233 wild type DSMZ
Sc::pIPP1 S. coelicolorwith integrated pIPP1 This work
Sc::PribSc S. coelicolorwith integrated pIPP1_PribSc This work
Sc::PribScAS S. coelicolorwith integrated pIPP1_PribSc(AS) This work
Sc::PribSd S. coelicolorwith integrated pIPP1_PribSd This work
Sc::PribSdAS S. coelicolorwith integrated pIPP1_PribSd(AS) This work
Sc::pSET152 S. coelicolorwith integrated pSET152 This work
Sc::ScxE S. coelicolorwith integrated pAM152ScxE This work
Sc::SdxE S. coelicolorwith integrated pAM152SdxE This work42
Name Relevant Features Reference/Source
Sc::pAM01 S. coelicolorwith integrated pAM01 This work
Sc::pAM023 S. coelicolorwith integrated pAM023 This work
Sc::pAM453 S. coelicolorwith integrated pAM453 This work
Sc::pAM453a S. coelicolorwith integrated pAM453a This work
Sc::pAM673 S. coelicolorwith integrated pAM673 This work
Sc::pAM893 S. coelicolorwith integrated pAM893 This work
Sc::pAM893a S. coelicolorwith integrated pAM893a This work
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3
Methods
3.1 Cultivation of Microorganisms
3.1.1 Cultivation of E. coli
E. coliwas cultivated under oxic conditions in baffled glass Erlenmeyer flasks
in Lysogeny Broth (LB) at 37  C on an orbital shaker at 180 rpm. For cultivation
on solid media, E. coli was grown on Lysogeny Agar (LA) at 37  C. Antibiotics
were added to the growth media from sterile filtered stock solutions. Stock and
working concentrations of all used antibiotics are given in table 2.18.
E. coli ER2523 was cultivated for recombinant production of MBP fusion pro-
teins in LB with addition of 0.2% (m/v) glucose to repress the expression of
amylase genes from the host genome.
3.1.2 Preparation of Chemically Competent E. coli
For preparation of chemically competent E. coli 50ml of LB were inoculated
from an overnight culture of the desired strain to an OD600 of 0.03. When
the optical density reached 0.4, the incubation was stopped and the cells
was harvested by centrifugation (10min, 3000 x g, 4  C). The supernatant was
discarded, the cells were resuspended carefully in 20ml pre-chilled, ice cold
CaCl2 (0.1 M) solution and put on ice for 20min and afterwards centrifuged as
before. The cells were resuspended in 2ml of the ice cold CaCl2 solution and
660µl of sterile glycerol (60%v/v) were added. The chemically competent cells
were aliquoted on ice to volumes of 50µl and frozen by immersion in liquid
nitrogen. The frozen aliquots were stored for later use at  80  C (Cohen et al.,
1972; Sambrook and Russell, 2001).
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3.1.3 Preparation of Electrocompetent E. coli
For the preparation of electrocompetent E. coli 1 l (4 x 250ml) LB medium was
inoculated from an overnight culture of the desired strain to an OD600 of 0.03
and incubated at 37  C and 180 rpm. When the OD600 of the cultures reached
0.4, they were put on ice for 30 min and afterwards the cells were harvested
by centrifugation (15min, 5000 x g, 4  C). The cells were carefully resuspended
in 500ml of ice cold, sterile ultra pure water and once again centrifuged as
before. The cells were resuspended in 250ml ice cold glycerol (10%v/v) and
through repeated centrifugation and resuspension in glycerol (10%v/v) the
volume was reduced to 10ml. After a final centrifugation step the cells were
resuspended in 1ml ice cold GYT and aliquoted on ice to volumes of 50µl
and frozen by immersion in liquid nitrogen and stored at  80  C(Elvin and
Bingham, 1991; Sambrook and Russell, 2001; Miller and Nickoloff, 1995).
3.1.4 Transformation of Chemically Competent E. coli
For the transformation of chemically competent E. coli the frozen cells were
thawed on ice for 10min. For each transformation 100 - 500 ng of plasmid
DNA or 5µl of a ligation reaction were added to the vial and mixed gently
by tapping. The mixture was incubated on ice for 30min and subsequently
incubated for 30 s at 42  C by immersion in a water bath. After the heat shock,
the vial was placed on ice for 2min and 250µl pre-warmed (37  C) SOC media
were added. The vial was incubated at 37  C for 1 h with horizontal shaking
at 225 rpm. Following incubation, two volumes per reaction (20µl and 200µl)
were spread onto selective LA plates containing the appropriate antibiotics.
The plates were incubated overnight at 37  C.
The success of the transformation was confirmed by either colony PCR or
purification of plasmid DNA from resistant colony and subsequent restriction
analysis or sequencing of the obtained plasmid DNA.
3.1.5 Transformation of Electrocompetent E. coli
For the transformation of electrocompetent E. coli the frozen cells were thawed
on ice for 10min. For each reaction 10 - 100 ng of plasmid DNA or 2µl of a
ligation reaction were added to the vial and mixed gently by tapping. The
mixture was transferred into a pre chilled electroporation cuvette with 0.1 cm
gap width (Bio-Rad Laboratories). The electroporation was carried out in a
Gene Pulser R  II Electroporation System (Bio-Rad Laboratories) set to a voltage
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of 2.5 kV, capacitance of 25µF and sample resistance of 200⌦. Immediately
after the pulse 250µl of pre-warmed (37  C) SOC media were added into the
cuvette. The mixture was transferred into a 1.5ml testtube and incubated at
37  C for 1 h with horizontal shaking at 225 rpm. Following incubation, two
volumes per reaction (20µl and 200µl) were spread onto LA plates containing
the appropriate antibiotic for plasmid selection. The plates were incubated
overnight at 37  C.
3.1.6 Triparental Mating
Triparental mating was used to move the plasmids pAMxT and pR9406 into
the non-methylating E. coli strain GM2163.
Table 3.1: Strains used for Triparental Mating
Strain Plasmid Resistance
E. coli Top10 pAMxT Kan
E. coli DH5↵ pR9406 Amp
E. coli GM2163 Cm
From each strain given in table 3.1 an overnight culture was diluted 1:100 and
grown into exponential phase. When the OD600 reached 0.4 the respective
culture was harvested by centrifugation (5min, 3500 x g, 4  C) and washed
twice with fresh LB to remove residual antibiotics that might disturb the mating
process, and finally resuspended in 500µl fresh LB. Since the growth rates may
vary for different strains, the resuspended cells were stored on ice until the cells
from all cultures were available. For the mating process 10µl of each strain
were added to the same spot on an LA plate and incubated for 16 h at 37  C. To
select for single colonies of E. coli GM2163 containing pAMxT and the helper
plasmid pR9406, material from each of the spots was streaked onto an LA plate
containing kanamycin, ampicillin and chloramphenicol and incubated over
night at 37  C. Single colonies were picked and tested by colony PCR to verify
the uptake of both plasmids.
The resulting strain E. coli GM2163 (pAMxT, pR9406) was used for the transfor-
mation of S. coelicolor (wt, Sc::pSET152, Sc::ScxE, Sc::SdxE) by conjugation.
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3.1.7 Cultivation of Streptomycetes
Liquid cultures of Streptomyces spp. were grown under oxic conditions in
baffled glass Erlenmeyer flasks on an orbital shaker at 180 rpm. S. coelicolorwas
cultivated in TSB at 30  C while S. davawensis cultures were typically grown
in YS at 37  C. For the production of sporulating cultures, streptomycetes
were grown on MS agar plates at 30  C until the aerial mycelium was clearly
visible.
3.1.8 Preparation of a Spore Suspension from S. coelicolor
For the preparation of a spore suspension, 200µl of a mid-exponential liquid
culture of S. coelicolor were spread on MS agar plates and incubated at 30  C
until the surface was completely covered with sporulating mycelium (up to
96 h). Per milliliter of spore suspension, 3 - 10 of such plates were prepared.
Each plate was covered with 9ml sterile water containing 0.1% (v/v) Tween20
and a sterile cell scraper was used to scrape off spores and mycelia from the
surface of the MS agar. The liquid from all plates was pooled in a sterile
tube and mixed for 1min with a vortex mixer to separate the spores from the
mycelium. The liquid was then passed through sterile cotton, to separate the
mycelium from the spore suspension, and subsequently centrifuged (5min,
3500 x g, 4  C). The spores were resuspended in 1ml sterile glycerol (20% (v/v))
and stored at  80  C. The titer of viable spores in the spore suspension was
determined by spreading 100µl of relevant dilutions (10 6 - 10 9) on MS agar
plates (Kieser et al., 2000).
3.1.9 Transformation of S. coelicolor by Conjugation
A donor strain of E. coli GM2163 with the helper plasmid pUB307 containing
also the oriT-plasmid (e.g. pSET152 or a plasmid derived from it) was prepared
beforehand through electrotransformation of E. coli GM2163 (pUB3017) with
the oriT-plasmid.
A culture with the volume of 50ml of the donor strain was grown in LB, con-
taining chloramphenicol, kanamycin and apramycine to select for the host and
both plasmids, to an OD600 of 0.4. The cells were harvested by centrifugation
(5min, 2500 x g, 4  C) and washed twice with fresh LB without antibiotics and
finally resuspended in 0.5ml of fresh LB.
A volume of 50µl of a S. coelicolor spores suspension (approx. 1010 spores per
ml) were added to 500µl of 2 x YT and incubated for 10min at 50  C to promote
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germination of the spores. After the spore suspension had cooled off to room
temperature, 500µl of the E. coli donor strain suspension were added. The
mixture was inverted several times to ensure proper suspension of donor cells
and recipient spores. The whole volume (1000µl) was spread on one MS agar
plate and incubated at 30  C for 16 - 20 h.
After this first incubation phase, each plate was overlaid with 1ml of water
containing a total amount of 0.5mg nalidixic acid and 1mg of apramycine.
The liquid was spread carefully on the surface of the plates. The plates were
further incubated at 30  C for up to 5 days until exconjugant colonies of S. coeli-
color formed on the plates. The exconjugants were isolated and grown on MS
agar plates containing 25 µg/ml nalidixic acid and 50 µg/ml apramycine. The
correct integration of the oriT-plasmid was verified by colony PCR (Kieser
et al., 2000).
3.1.10 Cultivation of L. monocytogenes
L. monocytogeneswas cultivated under oxic conditions in liquid cultures of brain
heart infusion medium (BHI) at 37  C in baffled glass Erlenmeyer flasks on an
orbital shaker at 180 rpm. For cultivation on solid media, L. monocytogenes was
grown on BHI agar or LA at 37  C.
3.2 Purification of Chromosomal DNA
For the purification of chromosomal DNA the Genomic DNA Purification Kit
(Thermo Scientific) was used according to the included instructions. When the
chromosomal DNA of Gram-positive bacteria (e.g. Streptomyces spp., Bacillus
spp.) was isolated, the cell pellet was treated with lysozyme (5mg/ml) for 30min
at 30  C prior to the addition of the lysis buffer.
3.3 Purification of Plasmid DNA
For the purification of plasmid DNA from an over night culture of E. coli, the
GeneJETTM Plasmid Miniprep Kit (Thermo Fisher Scientific) was used according
to the manufacturers recommendations. The plasmid DNA was eluted from
the column with 30µl elution buffer (supplied with the kit). The concentration
of the plasmid DNAwas determined using a NanoVueTM Plus Spectrophotometer
(GE Healthcare) and was stored at  20  C.
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3.4 Polymerase Chain Reaction
Polymerase chain reaction (PCR) was used for the amplification of DNA frag-
ments from chromosomal or plasmid DNA for subsequent recombination,
sequencing or for confirmation of successful DNA uptake. For subsequent di-
gest and recombination of PCR products modifying oligonucleotides (primers)
including recognition sequences for restriction enzymes adjacent to an approx-
imately 20 – 25 nt long sequence, homolog to the template were used.
Table 3.2: PCR reaction mixture using KAPAHiFiTM DNA polymerase.
Volume Final conc.
Nuclease free water ad 25µl
5 x KAPAHiFiTM Fidelity Buffer 5µl 1 x
dNTP mix (10mM) 0.5µl 200µM each
Forward primer (10µM) 1.25µl 0.5µM
Reverse primer (10µM) 1.25µl 0.5µM
Template DNA 0.5µl as neededa
KAPAHiFiTM DNA Polymerase 0.5µl 0.02 U/µl
a 10 ng plasmid DNA per reaction;  100 ng genomic DNA per reaction
When the amplified DNA fragments were to be used in cloning experiments,
the engineered enzyme KAPAHiFiTM DNA Polymerase (KAPA Biosystems) was
used. The constitution of one 25µl reaction mixture is given in table 3.2. The
amplification was carried out in a C1000TM Thermal Cycler (Bio-Rad) according
to the cycling conditions given in table 3.3.
Table 3.3: Standard cycling conditions for the amplification of DNA fragments using
KAPAHiFiTM DNA polymerase in KAPAHiFiTM Fidelity Buffer.
Temperature Time Cycles
Initial Denaturation 95  C 5:00min 1
Denaturation 98  C 0:20min
9>=>;Annealinga 65  C 0:15min 25Extension 72  C 0:30min/kb
Final Extension 72  C 5:00min 1
aAn annealing temperature of 65  C was chosen by default. If the reaction failed, a gradient
ranging from 60 – 78  C was applied to determine the optimal annealing temperature.
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Prior to subsequent recombination in molecular cloning experiments, the cor-
rect sizes of the respective PCR products were determined through agarose
gel electrophoresis (section 3.5). If necessary the correct nucleotide sequences
were verified through sequencing (Eurofins Genomics GmbH, Ebersberg, Ger-
many).
3.4.1 Colony PCR
Colony PCR was used for the fast verification whether a transformation reac-
tion was successful. Resistant colonies were picked after over night incubation
and suspended in 50µl sterile nuclease free water. This suspension was used as
a template in the colony PCR reaction mixture given in table 3.4. The reaction
conditions are given in table 3.5. The reaction products were analyzed by
agarose gel electrophoresis. The amplification of a DNA fragment with the
expected size was considered to indicate a successful transformation, however,
the verification of the sequence was done by sequencing (Eurofins Genomics
GmbH, Ebersberg, Germany).
Table 3.4: Colony PCR reaction mixture using DreamTaqTM DNA polymerase.
Volume Final conc.
Nuclease free water ad 20µl
10 x DreamTaq Green Buffer 2µl 1 x
dNTP mix (10mM) 0.4µl 200µM each
Forward primer (10µM) 1µl 0.5µM
Reverse primer (10µM) 1µl 0.5µM
Template (colony suspension) 1µl
DreamTaqTM DNA Polymerase 0.1µl 5 U/µl
Table 3.5: Cycling conditions for colony PCR using DreamTaqTM DNA polymerase.
Temperature Time Cycles
Initial Denaturation 95  C 3:00min 1
Denaturation 94  C 0:30min
9>=>;Annealing Tm   5  C 0:30min 30Extension 72  C 1:00min/kb
Final Extension 72  C 5:00min 1
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3.5 Separation of DNA Fragments by Agarose Gel
Electrophoresis
The separation of DNA fragments by agarose gel electrophoresis was carried
out to verify the presence of DNA fragments of a certain size in a solution (e.g.
after plasmid DNA purification, PCR, restriction digest or ligation).
Agarose (1%m/v) was dissolved in TAE buffer by heating the mixture in a
microwave oven until the agarose dissolved completely. The warm solution
was carefully poured into a gel rack, and a comb was placed 5 - 10mm from
one end of the gel to form the loading pockets of the gel. After the gel hardened
completely, the the comb was removed and the gel was transferred into the
buffer tank of a gel electrophoresis cell (Bio-Rad Laboratories). The buffer tank
of the cell was filled with TAE buffer until the gel was covered completely.
The DNA samples were mixedwith 6 fold DNA loading dye (Thermo Scientific)
and loaded into the pockets of the gel. As a reference 3µl GeneRuler 1 kb Plus
DNA Ladder (Thermo Scientific) was loaded in at least one pocket of each
gel. For the separation of the DNA fragments a constant potential of 90V was
applied for 45min.
After the electrophoresis the gel was immersed in a ethidium bromide solution
(1 µg/ml) and stained under constant agitation for at least 20min. The stained
gel was documented using a GelDocTM XR system (Bio-Rad Laboratories).
3.6 Molecular Cloning
For the recombination of DNA molecules FastDigestTM restriction enzymes
(Thermo Scientific) were used to digest PCR products and plasmid DNA (ta-
ble 3.6). To reduce the recircularization rate during the ligation reaction, the
alkaline phosphatase FastAPTM (Thermo Scientific) was added to the digest re-
action of cloning vectors. The digest was typically incubated 20min immersed
into a water bath at 37  C.
After the digest the DNA fragments were, if necessary, separated by agarose
gel electrophoresis (section 3.5) and purified using the GeneJetTM Gel Extraction
kit (Thermo Scientific) or purified directly after the digest with the GeneJetTM
PCR Purification kit (Thermo Scientific).
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Table 3.6: Restriction digest reaction mixture.
Plasmid DNA PCR product
DNA 2µl ( 1µg) 2µl (~0.2µg)
10 x FastDigest R  buffer 2µl 10µl
FastDigestTM enzyme 1µl 1µl
FastAPTM Alkaline Phosphatasea 1µl –
Water ad 20µl ad 30µl
aFastAPTM was used for dephosphorylation of plasmid DNA to prevent recircularization
during ligation.
The purified DNA fragments were then combined in a ligation reaction (ta-
ble 3.7) using T4 DNA Ligase (Thermo Scientific). In one ligation reaction
mixture up to three PCR products were combined with one linearized vector.
The ligation reaction was typically incubated for 1 h at room temperature. For
transformation of chemically competent E. coli cells, 5µl of the ligation reaction
were added directly to one aliquot (50µl) of competent cells (section 3.1.4).
Table 3.7: Reaction mixture for the ligation of purified vector DNA and insert(s).
sticky ends blunt ends
Vector DNA 20 – 100 ng 20 – 100 ng
Insert DNA molar ratio 5:1 molar ratio 5:1
50% PEG 4000 solution – 2µl
10 x T4 DNA Ligase buffer 2µl 2µl
T4 DNA Ligase 0.2µl (1U) 1µl (5U)
Water ad 20µl ad 20µl
3.6.1 Cloning with Linkers
The Linker DNAwas ordered as two separate single stranded oligonucleotides.
Both oligonucleotides were aliquoted with nuclease free water to a concen-
tration of 100µM. Prior to the annealing reaction, the oligonucleotides were
diluted 10-fold in TE buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0). One vol-
ume of each was added to a test tube and heated to 98  C and held at that
temperature for 10min. The mixture was allowed to cool off slowly (~2 h)
while remaining in the heating block. The annealed linker DNA was added to
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the ligation reaction in a molar ratio of 100:1 over the vector DNA. If the vector
DNA was treated with FastAPTM during the digest reaction, the linker DNA
had to be phosphorylated prior to the ligation reaction. Phosphorylation of the
linker DNA was carried out using T4 Polynucleotide Kinase (T4 PNK, Thermo
Scientific). The phosphorylation reaction (table 3.8) was incubated at 37  C for
20min and subsequently inactivated at 75  C (10min) before it was added to a
ligation reaction.
Table 3.8: Reaction mixture for linker dephosphorylation.
Volume
Linker DNA (5µM) 10µl (~50 pmol)
10 x reaction buffer A 2µl
ATP (10mM) 2µl
T4 Polynucleotide Kinase 1µl (10U)
Water ad 20µl
3.6.2 Golden Gate Cloning
The cloning strategy described as Golden Gate Cloningwas based on the work of
Engler et al. (2008). In this method, type IIs restriction enzymes were employed
to digest the PCR products prior to ligation. Since type IIs restriction enzymes
feature non-palindromic, asymmetric recognition sites and cleave DNA at a
defined distance from them, their use facilitates the seamless assembly of two
or more PCR products in a ligation reaction. This was of great use for the
creation of translational fusions, as the ligation product did not contain the
recognition sequence and thus did not introduce additional codons into the
translated sequence.
GGTCT CNNNNNNNN
CCAGAGNNNNNNNN
……. — 3'
……. — 5'
5' —
3' —3' 
' 
Figure 3.1: The type IIs restriction enzyme BsaI. Recognition sequence (black) and
cleavage site (arrows) of the type IIs restriction enzyme BsaI. Bases denoted
as ’N’ can be chosen arbitrarily to form user designed overhangs.
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Throughout this work the enzyme BsaI (Thermo Scientific) was used. Figure 3.1
shows the recognition sequence and the cleavage site of BsaI. The bases denoted
as ’N’ can be chosen freely to design user defined overhangs, which then
recombine seamless with homolog overhangs of other assembly parts.
3.7 Separation of Proteins by Polyacrylamide Gel
Electrophoresis
Purified proteins and cell free extracts were separated according to their elec-
trophoretic mobility, i.e. a function of the molecular weight, using denaturing
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Typ-
ically 15µl of each sample were mixed 1+1 with 2 x denaturing SDS sample
buffer and incubated at 95  C for 5min using a C1000TM Thermal Cycler (Bio-
Rad Laboratories). After cooling off to room temperature the samples were
centrifuged briefly.
Up to 20µl per sample were applied to an Any kDTM Mini-PROTEAN R  TGXTM
Precast Protein Gel (Bio-Rad Laboratories). On each gel at least one lane was
loaded with 10µl PageRulerTM Plus Prestained Protein Ladder (Thermo Scientific)
to serve as a reference for protein size. For the separation the gel was mounted
in aMini-PROTEAN R  Tetra Cell System (Bio-Rad Laboratories) filled with Tris-
Glycin buffer and a direct current with constant voltage was applied (100V
for 10min, then 150V for 45min). After the electrophoresis, the gel was either
stained with PageBlueTM Protein Staining Solution (Thermo Scientific) and
documented by scanning or further processed as described in section 3.8.
3.8 Western-Blot
For the western-blot analysis, the polyacrylamide gel was not stained after
the SDS-PAGE, but the proteins were transferred electrophoretically from the
gel onto a nitrocellulose membrane in a semi-dry transfer procedure using a
Trans-Blot R  SD Cell (Bio-Rad Laboratories) with a constant current of 0.04A for
1 h. For the detection of His-tagged proteins, the His·Tag R  AP Western Reagents
kit (Merck Milipore) was used as described in the included user’s manual
(Novagen, 2011).
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3.9 Recombinant Protein Production
The production of recombinant proteins was carried out in E. coli BL21(DE3) or
E. coli Rosetta(DE3) with pRAREa. The plasmids with the genetic information
coding for the proteins of interest were pET derivates where the expression of
the gene of interest is controlled by the IPTG inducible promoter PT7.
For the protein production 50 – 200ml of LB, supplemented with all necessary
antibiotics, were inoculated with material from a 10ml overnight culture to an
initial OD600 of 0.03. When the OD600 reached 0.4, the protein production was
induced by addition of IPTG to a final concentration of 1mM. The production
phase lasted usually 3 – 5 h and was carried out at 37  C.
Alternatively, the induction could be delayed until OD600 reached 0.8 and
IPTG concentration could be lowered down to 0.1mM. Also the temperature
during the production phase could be lowered to 20, 25 or 30  Cwith prolonged
production times of 16 – 24 h. The cells were harvested by centrifugation (8000 x
g, 10min, 4  C) and stored at  20  C upon lysis and subsequent purification of
the recombinantly produced proteins.
aencodes tRNAs for the in E. coli rarely used codons AGA and AGG (arginine), GGA (glycine),
AUA (isoleucine), CUA (leucine), CCC (proline)
3.10 Protein Purification (FPLC)
For the purification of recombinantly produced proteins, the Fast Protein
Liquid Chromatography (FPLC) system ÄKTApurifier UPC-900 (GE Healthcare)
with an additional sample collector (FRAC-920) was applied. The system
was controlled manually via the UNICORN software package. Additionaly to
the user-set parameters, such as flow rate and buffer constitution, the system
pressure, the conductivity and the UV absorption at 280 nm (relative protein
concentration) were monitored and recorded continuously throughout the
purification process.
3.10.1 Immobilized Metal Ion Aﬃnity Chromatography (IMAC)
For the purification of HIs-tagged proteins, prepacked nickel-sepharose
columns HisTrapTM HP (GE Healthcare) with a column volume (CV) of 5ml
were used. Up to 50ml of cell free extract were applied to the column with a
50ml superloop, which allowed the introduction of larger samples into the pres-
surized fluid system. The flow rate during sample application was typically
5ml/min and was adjusted when necessary, to not exceed the recommended
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maximal system pressure of 0.3MPa given in the column’s specifications.
After sample application, the column was washed with at least 10 CV Buffer A
for IMAC (20mM Imidazole) until the UV signal at 280 nm returned to a stable
baseline. The elution of proteins bound to the column was performed through
a linear gradient of Buffer B for IMAC (200 mM Imidazole) over 10 CV. The
fractionation of the eluate was controlled manually to separate the occurring
peaks into independent samples.
Prior to freezing of protein samples, the imidazole was removed by gel filtration
(see section 3.10.4) to avoid protein precipitation.
3.10.2 Aﬃnity Purification of MBP-tagged Fusion Proteins
For the purification of MBP fusion proteins expressed from pMAL-c5X
derivates in E. coli ER2524, prepacked dextrin sepharose columnsMBPTrapTM
HP (GE Helthcare) with column volumes of 1 and 5ml were used. The sam-
ples were loaded in binding buffer (Buffer A for MBPTrap) as described in
section 3.10.1 and eluted from the column with a linear gradient or in a step
elution profile with Buffer B for MBPTrap (10mMmaltose).
Buffer exchange after the purification was necessary if subsequent protease
treatment, AEX or IMAC purification were carried out.
3.10.3 Anion Exchange Chromatography (AEX)
For the separation of proteins based on their net surface charge the anion
exchange column HiTrapTM Q FF (GE Healthcare) prepacked with Q sepharose,
a strong anion exchange matrix, featuring quaternary amine ligands with a
column volume of 1ml were used. The samples were loaded to the column
in Buffer A for AEX (20mM Tris-HCl, 25mM NaCl, pH 8.0) and eluted with
a linear gradient over 20CV to Buffer B for AEX with higher ionic strength
(20mM Tris-HCl, 500mM NaCl, pH 8.0). Alternatively, a linear gradient over
10CV to 50% (v/v) Buffer B for AEX and a subsequent step elution profile with
an immediate increase to 100% (v/v) Buffer B for AEX was applied, to gain a
better focus on the proteins eluting at higher concentrations.
3.10.4 Gel Filtration Size Exclusion Chromatography (SEC)
For desalting and buffer exchange of previously purified protein samples
a HiPrep 26/10 Desalting (GE Healthcare) column, prepacked with the cross-
linked dextran matrix Sephadex G-25 Fine and a column volume of 53ml, was
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applied. The samples were injected via a 10ml sample loop. The successful
buffer exchange was monitored by observation of two separated peaks for the
absorption and conductivity signal respectively.
3.11 Enzyme Activity Assays
3.11.1 Catechol 2,3–dioxygenase (XylE) Activity Assay
The catechol 2,3–dioxygenase activity (EC 1.13.11.2) of the reporter en-
zyme XylE was assayed by measuring the increasing absorption of the
sample at 375 nm due to the conversion of pyrocatechol and oxygen into
2–hydroxymuconate semialdehyde (2–HMS) (see figure 3.2).Catechol 2,3-dioxygenase Assay 
Andreas Matern – TAC I – Dezember  2011 
Catechol 2,3-dioxygenase 
 
Catechol 2-HMS 
• 50 mL Flüssigkultur, 40 h bei 30°C und 200 rpm 
• Mechanischer Zellaufschluss (French Press) 
• 100 µL Rohextrakt (evtl. verdünnt) zu 2,9 mL 0,2 mM Catechol 
• Absorptionsverlauf bei 375 nm über 6 min messen 
• Steigung der Absorption bezogen auf die Proteinkonzentration 
 –> spez. Aktivität  
 
Zukowski et al., PNAS 80 (1983)  
 
Figure 3.2: The conversion of catechol into 2–HMS. The conversion of catechol (col-
orless) and oxygen into 2–HMS (yellow) is catalyzed by the catechol 2,3–
dioxygenase XylE. Specific XylE activity is used to measure expression of
the reporter gene xylE. Figure adapted from Zukowski et al. (1983).
To assay the catechol 2,3–dioxygenase activity in the cell free extract of Strepto-
myces spp., the mycelia were harvested by centrifugation (3,000 x g for 10min
at 4  C) and washed twice with 20mM potassium phosphate buffer pH 7.2. The
cells were r suspended in an appropriate volume of sample buffer (100mM
potassium phosphate, 20mM EDTA, pH 7.5) and lysed twice with a TS Se-
ries Benchtop Cell Disruptor System (Constant Systems Ltd.) and put on ice for
15min prior to centrifugation (8,000 x g for 10min at 4  C) and subsequent
ultracentrifugation (108,000 x g for 30min at 4  C). The protein concentration
of the samples was determined with the method described by Bradford (1976).
For each sample 2.9ml assay buffer (100mM potassium phosphate, 0.2mM
pyrocatechol, pH 7.5) were prewarmed to 30  C in a cuvette. To start the re-
action 100µl of the respective sample (i.e. cell free extract) were added to
the substrate and mixed by stirring. The abance at 375 nm was recorded for
6min in intervals of 20 s in a spectrophotometer. If the absorption exceeded
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the measurable range or the change in absorption did not increase in a linear
fashion, the sample had to be diluted and the measurement was repeated.
AXylE =
dE375 nm
dt
· 1
✏2–HMS · d ·
Vtotal
Vsample
· 1
cProtein
·DF (3.1)
AXylE specific XylE activity in the sample [mmol/min·mg]
dE375 nm
dt change of the extinction at 375 nm over the recorded time [1/min]
✏2–HMS molar attenuation coefficient of 2–HMS; ✏2–HMS = 4.4 · 104 l/mol·cm
d pathlength of the cuvette; d = 1 cm
Vtotal total volume of the assay; Vtotal = 3ml
Vsample volume of the sample in the assay; Vsample = 0.1ml
cProtein Protein concentration of the sample determined after Bradford mg/ml
DF dilution factor; DF = 100 for 1:100 dilution of the sample
The specific catechol 2,3–dioxygenase activity AXylE calculated according to
equation 3.1 results the amount of 2–HMS in mmol that was formed in the
reaction per minute relative to the total protein concentration of the sample.
Since enzymatic activity is commonly denoted in enzyme units (U) where 1U
is defined as the amount of enzyme necessary for the conversion of 1µmol
substrate per minute, the results of equation 3.1 have to be multiplied with
a factor of 1000 in order to obtain a result for the specific activity with the
dimension U/mg.
Qualitative Colorimetric XylE Plate Assay A qualitative XylE assay can be
performed by spraying approximately 1ml of a 0.5M aqueous pyrocatechol
solution onto an agar plate with grown colonies. Colonies producing XylE
exhibit a yellow stained halo around the colony. This assay has to be performed
on duplicate plates, since the colonies can not be picked for recultivation after
the assay (Ingram et al., 1989; Jones, 2011).
3.11.2  -glucuronidase (GusA) Activity Assay
To assay the GusA activity of a cell free extract from a liquid culture in a
spectrophotometer, the cells were harvested by centrifugation (10min, 3500 xg,
4  C) and resuspended in 20mL of extraction buffer (50mM NaPB pH 7, 5mM
DTT, 0.1% (v/v) Triton-X 100) and lysed with a TS Series Benchtop Cell Disruptor
System and stored on ice until centrifugation (8,000 x g for 10min at 4  C) and
subsequent ultracentrifugation (108,000 x g for 30min at 4  C). The protein
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concentrations of the samples were determined after Bradford (1976).
A volume of 750µl (1 - 5 µg total protein) of the cell free extract was pre-
incubated in a cuvette for 15min at 28  C. To start the reaction, 80µl of the
substrate (0.2 M PNPG) were added to the cuvette. The absorption at 415 nm
was recorded over 30min in intervals of 20 s. The specific GusA activity of the
sample was calculated similar to the XylE activity (equation 3.1).
Since the accurate measurement of enzyme activity requires the 4-nitrophenol
product of the reaction to be fully deprotonated, i.e. pH > 9.2, the absorbance
values of the real time measurements of the reaction in phosphate buffer at
pH 7 were used to calculate the specific activity GusA activity in GUS Units
(GU) where the molar attenuation coefficient of the product was not taken into
account. So that 1GU def= 1A415nm·min 1·mg 1 (Myronovskyi et al., 2011).
3.11.3  -galactosidase (LacZ) Activity Assay
The  -galactosidase (LacZ) activity assay was performed as described by Ott
et al. (2009). B. subtilis strains with integrated pDG268 derivates were cultivated
in SMM at 37  C until the optical density reached 0.4. Flavins (riboflavin,
roseoflavin or 8-amino riboflavin) were added to a final concentration of 50
and 100µM, respectively. Cultivation was continued for 4.5 h at 37  C. The cells
were harvested by centrifugation (10min, 4000 x g, 4  C) and washed 3 times
with PM buffer (100mM sodium phosphate, 1mM magnesium sulfate, pH
7.8) and finally resuspended in 0.05 volumes of PM. To disrupt the cells, 1ml
of the resuspended cells was mixed with 1.2 g glass beads (0.3mm diameter)
in a 1.5ml test tube and treated 5min at maximum speed in a vibratory tube
mill. The lysate was cleared by centrifugation (10min, 13000 x g, 4  C) and the
specific LacZ activity of the supernatant was determined.
To assay the specific LacZ activity of a sample, 800µl ortho-Nitrophenyl- -
galactoside (ONPG) substrate (2 mg/ml) were prewarmed to 37  C. To start
the reaction, 50µl of the sample were added to the substrate. The change in
absorbance at 415 nm was recorded with a spectrophotometer over 5min.
3.11.4 Amylase Production Assay
The successful integration of pDG268 derived plasmids into the chromosome of
B. subtilis resulted in disruption of the gene amyE. The loss of amylase activity
after transformation with pDG268 derivates indicated the double crossover
integration into the locus amyE had been successful. To test the generated
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strains for amylase activity, single colonies were picked and cultivated on
LA supplemented with 1% (m/v) potato starch. After approximately 24 h the
plates were flooded with 1ml Lugol’s iodine solution. Colonies with intact
amyE gene exhibited an unstained halo around them, due to the absence of
stainable amylose in the growth medium, while colonies with disrupted amyE
were fully stained and no halo was visible (O’Kane et al., 1986; Cutting, 1990).
3.11.5 Coupled In Vitro Transcription/Translation Luciferase
Activity Assay
The coupled in vitro transcription/translation (TK/TL) luciferase activity assay
was performed as described by Pedrolli et al. (2012). The assay mixture (TK/TL
mix) was prepared by combining the T7 extract solution, the S30 premix and
the amino acid mix from the E. coli T7 S30 Extract System for Circular DNA Kit
(Promega) in the proportion 3:4:1 (v/v/v). To 8µl TK/TL mix, 1µl from a 10 x
flavin stock solution (nuclease free water as control) and 1µl plasmid solution
(0.2 – 10 ng/µl) were added and incubated by immersion into a water bath at
30  C for 5min. To stop the reaction, the vial was placed on ice and 90µl stop
solution (1 mg/ml BSA, 2mM DTT, 25mM Tris-phosphate, pH 7.8) were added
to the reaction mixture.
To assay luciferase activity, 50µl Luciferase Assay Reagent (provided with the kit)
were mixed with 10µl of the sample. Luminescence was determined from the
resulting mixture in a Tecan Genios Pro microplate reader (Tecan) at 26  C. If the
luminescence level reached saturation, the sample was diluted appropriately
with an aqueous BSA (1mg/ml) solution.
3.11.6 Flavokinase/FAD synthetase Activity Assay
Flavokinase and FAD synthetase activity was determined with an enzyme ac-
tivity assay based on the work of Pedrolli et al. (2011). The reaction mixture was
set up as given in table 3.9. The enzyme was added after 5min of preincubation
of the mixture at 37  C to start the reaction. The first sample, corresponding
to t = 0min, was removed immediately afterwards. The reaction was kept in
the dark at 37  C. Subsequent samples were removed after appropriate time
intervals. To stop the reaction the sample, aliquots were added to a prepared
volume of trichloroacetic acid (TCA) to a final concentration of 2% TCA.
The samples were centrifuged (13,000 x g for 2min) and filtered with 0.2µm
regenerated cellulose syringe filters prior to to HPLC-MS analysis.
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Table 3.9: Reaction mixture for the flavokinase/FAD synthetase activity assay.
Stock Conc. (mM) Volume for 2ml (µl) Final Conc. (mM)
Buffer 100 1000 50.0
Flavina 20 1 – 25 0.01 – 0.25
ATP 10 200 1.0
MgCl2 60 200 6.0
NaF 120 200 12.0
Na2S2O4b 240 200 24.0
Enzymec 200 – 300 10 1.0 – 1.5
H2O ad 2000
aFlavin for FK-activity assay, flavin mononucleotide for FADS-activity assay
bprepared fresh before use
cEnzyme concentrations given in µg/ml
3.12 Determination of Intracellular Flavin
Concentrations
For the determination of the intracellular flavin concentration in L. monocy-
togenes, cells from 10ml of a liquid culture were harvested by centrifugation
(8000 x g, 10min, 4  C). The cells were washed three times with 1ml washing
buffer (50mM NaCl, 50mM Tris-HCl, pH 7.5) to remove all residual flavins
contained in the media.
The cells were resuspended in 50µl ultrapure water, OD600 of an appropriate
dilution was determined and correlated to a cell count. 100µl GES buffer (5M
guanidinium thiocyanate, 0.1M EDTA, 0.5% (m/v) laurylsarkosin, pH 8) were
prewarmed to 70  C using a heatblock (Thermomixer Comfort, Eppendorf).
To the preheated GES buffer, 40µl of the sample were added and mixed im-
mediately for 5 s. The mixture was then incubated for 1min at 70  C. The
reaction was stopped by addition of 860µl ice-cold water. The mixture was
then centrifuged and the supernatant was subject to flavin quantification via
HPLC-MS (von Canstein et al., 2007; Takemoto et al., 2014).
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3.13 High-Performance Liquid Chromatography-Mass
Spectrometry (HPLC-MS)
For the identification and quantification of flavins in cell free extracts and
assay preparations an Agilent 1220 Infinity LC system (Agilent Technologies,
Waldbronn, Germany) using reverse-phase columns was applied. Detection of
flavins and cofactors was carried out with a diode array detector (1260 DAD)
and a quadrupole mass spectrometer (6130 Quadrupole MS).
Throughout this work two columns with different methods were applied:
HPLC-MS Method1 was used for analysis of riboflavin and the cofactors
FAD and FMN. The absorption at 445 nm was recorded for detection.
Column: ReproSil-Pur C18-AQ column (5µm; 250mm x 2.0mm; Dr. Maisch
GmbH, Ammerbich-Entringen, Germany)
Liquid phase: methanol (40%v/v) / 20mM formic acid and 20mM ammo-
nium formate (pH 3.7; 60%v/v). Flow rate: 0.6 ml/min.
Retention times: FAD (4.45min), FMN (5.64min), riboflavin (7.19min)
HPLC-MS Method2 was applied for separation of riboflavin, roseoflavin,
8-amino riboflavin and their respective cofactors and cofactor analogs. The
development of this method was based on the work of Aliverti et al. (1999).
Since each group of analytes exhibits a unique absorption spectrum, the detec-
tion was carried out at three wavelengths in parallel to utilize the respective
absorption maximum. Riboflavin, FAD and FMN were detected at 445 nm,
8-amino riboflavin, AFAD and AFMNwere detected at 480 nm and roseoflavin,
RoFAD and RoFMN were detected at 503 nm.
Column: ReproSil-Pur C18-AQ column (5µm; 250mm x 4.6mm; Dr. Maisch
GmbH, Ammerbuch-Entringen, Germany).
Liquid phase: A solvent ratio of 15%v/v methanol / 20mM formic acid and
20mM ammonium formate (pH 3.7; 85%v/v) was used for equilibration of
the column. After 2.5min the methanol concentration was increased in a lin-
ear gradient over 8min to 42%v/v. This concentration was maintained for
2min. That was followed by an increase of the methanol concentration up to
100%v/v and re-equilibration to the conditions in the beginning, in order to
remove excess flavins when samples with high concentrations were analyzed.
A diagram of the solvent ratios throughout the method is depicted in figure 3.3.
Flow rate: 1.0 ml/min.
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Retention times: AFAD (9.26min); AFMN (10.33min); AF (11.51min);
FAD (11.45min); FMN (12.77min); RF (14.31min); RoFAD (12.15min);
RoFMN (13.63min); RoF (15.14min).
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Figure 3.3: Solvent profile of HPLC-MSMethod2. The diagram shows the methanol
concentration throughout the HPLC-MS Method2. Column: ReproSil-Pur
C18-AQ column (5µm; 250mm x 4.6mm). Flow rate: 1 ml/min.
3.14 Determination of the pH Optimum
For the determination of the optimal pH of enzymatic reactions, a buffer system
with a broad range spanning the relevant interval from pH 6 to 10 was desired.
The BIS-Tris propane (BTP) buffer system with its two pKa values being 6.8
and 9.0 at 25  C fulfilled this requirement. The necessary ratios of BTP and
hydrochloric acid for certain buffer pH values were determined by titration of
a 50mM BTP solution with 1M HCl (see figure 3.4).
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Figure 3.4: pH range of the BIS-Tris propane buffer system. Titration of 50mM BIS-
Tris propane with 1M HCl. Measured pH values plotted against the molar
ratio of HCl:BTP. The relevant pH range for the buffer system is marked
with dashed lines.
By reading off the molar ratio at the desired pH values from the diagram in
figure 3.4 the volumes given in table 3.10 were determined. Each combination
was tested to verify its final pH in a 50mM BTP solution.
Table 3.10: Volumes used for 1ml 100mM BIS-Tris propane buffer with various pH.
pH VBTP 1M [µl] VHCl 1M [µl] VH2O [µl] molar ratio
7.0 100 161 739 1.61
7.5 100 137 763 1.37
8.0 100 114 786 1.14
8.5 100 91 809 0.91
9.0 100 67 833 0.67
9.5 100 44 856 0.44
The 100mM BTP solutions were used as 2 x buffer to perform the flavoki-
nase/FAD synthetase activity assay as described in section 3.11.6 at different
pH values. For each pH value, 50µM FMN were used as substrate in triplicate
assays. The FAD concentration was determined at 0, 3 and 6min to calculate
the initial reaction velocity which corresponds to the enzyme activity. The
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resulting FAD synthetase activities for Lmo0728 and Lmo1329 plotted against
the respective pH values are shown in figure 4.24.
3.15 Determination of the Kinetic Parameters for
Flavokinase and FAD synthetase Activity
The numeric values of the the Michaelis constant Km and the maximal reac-
tion rate vmax are constant for an enzymatic reaction that follows the kinetic
equation formulated originally by Michaelis and Menten (equation 3.2) with
the molar substrate concentration [S] (Michaelis and Menten, 1913; Kenneth
and Goody, 2011).
v0 = vmax · [S]
[S] +Km
(3.2)
The initial reaction rate v0 for each substrate concentration was determined by
linear regression of the product formation at the start of the reaction, while
the relationship [S]   [P ] holds true. Since the product formation of the
flavokinase and FAD synthetase reactions had to be measured by HPLC, only
a limited amount data points per reaction could be acquired. Several aspects
regarding the sampling times as well as substrate and enzyme concentrations
had to be considered. The time difference between samples had to be the
same for all measurements of a kinetic plot to minimize the influence of the
sampling process itself. The time points had to be chosen so that the product
concentrations in the samples were above the detection limit for the product but
the requirement of [S]  [P ] still held true. This requirements also determined
the minimal substrate concentration that could be tested. The sampling times
were determined to be 0, 3 and 6min, while the enzyme concentration in the
assay reaction was chosen to meet all the requirements mentioned above.
For each substrate concentration the reaction mixture according to table 3.9,
excluding the enzyme, was set up and separated into three reaction volumes
of 2ml each. The parallel reactions were started by addition of the enzyme
and the first sample for t = 0min was removed immediately. The assay was
performed as described in section 3.11.6. From the nine collected samples
per substrate concentration a mean initial reaction rate v0,[S] for the respective
substrate concentration was calculated by linear regression of the product
formation over time. By relating v0,[S] to the enzyme concentration in the
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reaction the specific activity of the enzyme at the given substrate concentration
was calculated.
kcat =
vmax
[E]
(3.3)
The specific activities were plotted against the substrate concentration and the
apparent values for the Michaelis constantKm and the maximal reaction rate
vmax were determined through the best fit of the kinetic function given in equa-
tion 3.2 to the results of the experiment. Non-linear regression was performed
with OriginPro R  9 (OriginLab, Wellesley Hills). From these two constants the
turnover number kcat and the kinetic efficiency kcatKm were calculated according
to equation 3.3 with [E] being the molar enzyme concentration.
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4
Results
4.1 Growth of L. monocytogenes is Aﬀected by
Flavin Analogs
L. monocytogenes wild type and the mutant strain M1 (see section 2.5.2), fea-
turing a deregulated FMN riboswitch upstream of the riboflavin transporter
gene lmo1945, were grown in BHI liquid media supplemented with 100µM ri-
boflavin, roseoflavin or 8-amino riboflavin (DMSO as control).
To survey if the altered riboswitch sequence of L. monocytogenes M1 confers
roseoflavin resistance, the mutant strain and the wild type of L. monocytogenes
were grown under identical conditions (37  C, 180 rpm, 100µM flavin) in BHI.
The optical density of the cultures was recorded over 7 h, until they reached
the stationary growth phase (figure 4.1).
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Figure 4.1: Deregulation of lmo1945 confers increased roseoflavin tolerance.
Growth curves of L. monocytogenes wild type (left panel) and mutant strain
M1 (right panel) in BHI supplemented with 100µM riboflavin (RF), rose-
oflavin (RoF) and 8-amino riboflavin (AF). DMSO was used as a control.
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The growth data shown in figure 4.1 confirmed the finding of Mansjö and
Johansson (2011), who reported the M1 strain to grow significantly better in
the presence of 100µM roseoflavin, when compared to the wild type. How-
ever, the performance of the M1 strain, grown in media supplemented with
roseoflavin, was not restored to the level of the controls treated with riboflavin
and DMSO. The growth of cultures treated with 8-amino riboflavin was only
slightly reduced for the wild type, while growth of the M1 strain was not
affected under the tested conditions. It was, however, reported that 8-amino
riboflavin concentrations as high as 267µM did significantly impair the growth
of L. monocytogenes (unpublished data, personal communication with Jörgen
Johansson, Laboratory for Molecular Infection Medicine Sweden, Department
of Molecular Biology, Umeå University, Umeå, Sweden).
4.2 Intracellular Concentration of Flavins and
Cofactors in L. monocytogenes
The following experiments were done to evaluate if the flavin analogs rose-
oflavin and 8-amino riboflavin are taken up into the cell and whether they are
present as flavin or if they are converted to the respective cofactor analogs.
Also, a comparison of the intracellular flavin and cofactor concentrations found
in the wild type with those found in the mutant strain M1 were of interest, as
they might reflect the effect of deregulated expression of the riboflavin trans-
porter gene lmo1945. The qualitative HPLC analysis of cell free extracts from
L. monocytogenes wild type and M1 is shown in figure 4.2. The cultures were
grown in BHI supplemented with 100µM riboflavin, roseoflavin and 8-amino
riboflavin respectively (DMSO was added as a control). The HPLC analy-
sis showed that both strains converted all three flavins into their respective
mononucleotides and adenine dinucleotides.
The peak sizes in figure 4.2 do not directly correlate with intracellular con-
centrations, as the samples were taken at the end of the growth experiment
described in section 4.1. Due to the treatment with roseoflavin and 8-amino
riboflavin, the cultures did grow to the different final cell densities, however,
the sample preparation for the HPLC measurement was done identically for
all samples. The differences in cell counts of the respective cultures were taken
into account when the intracellular concentrations given in table 4.1 were
calculated from the chromatograms shown in figure 4.2.
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Figure 4.2: Flavin analogs are converted into cofactor analogs in L. monocytogenes.
HPLC analysis of cell free extracts from cultures of L. monocytogeneswild
type (left) and the deregulated FMN riboswitch mutant strain M1 (right),
grown to the stationary phase in brain heart infusion media (BHI) with
flavin supplementation (100µM). DMSO was used as a solvent for flavin
stocks and was added to the untreated culture as a control. RF: riboflavin;
RoF: roseoflavin; AF: 8-amino riboflavin.
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Table 4.1: Intracellular flavin and cofactor concentrations calculated from the HPLC-
data shown in Figure 4.2.
RFa FADa FMNa RoFa RoFADa RoFMNa AFa AFADa AFMNa
wt (DMSO) 0 60 7 0 0 0 0 0 0
wt (RF) 0 84 17 0 0 0 0 0 0
wt (RoF) 0 11 0b 4 63 7 0 0 0
wt (AF) 0 18 0b 0 0 0 35 64 26
M1 (DMSO) 0 74 11 0 0 0 0 0 0
M1 (RF) 14 140 24 0 0 0 0 0 0
M1 (RoF) 0 24 0b 20 113 16 0 0 0
M1 (AF) 0 29 0b 0 0 0 65 88 28
aµM cofactor for an assumed cell volume of 1µm3
bbelow detection limit
Regarding the calculated intracellular flavin and cofactor concentrations, given
in table 4.1, the mutant strain M1 appears to contain generally higher levels of
the measured cofactors. This observation supports the hypothesis of increased
flavin import due to constitutive and unregulated expression of lmo1945. No-
tably, the FAD and FMN concentrations found in the cells that were treatedwith
roseoflavin and 8-amino riboflavin were decreased compared to the controls,
treated with DMSO exclusively. This finding suggested a possible competition
of riboflavin and its analogs as substrates for the generation of the cofactors.
Since the applied concentration of 100µMwas already in a range where pas-
sive uptake of riboflavin and roseoflavin through diffusion effects had to be
considered over the transporter mediated active uptake (section 4.7.1), L. mono-
cytogenes ild type and M1 cultures were treated with roseoflavin concentrations
as low as 10µM prior to determination of intracellular cofactor concentra-
tions.
Figure 4.3 shows the intracellular concentrations after the cultures were treated
with flavins and grown to the stationary phase. Panels A-D give a direct
comparison of L. monocytogeneswild type and M1 cells. The previous finding
of elevated cofactor levels in the cells of the M1 strains was confirmed. The
difference is supposed to be a result of the mutation in Rli96.
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Figure 4.3: Intracellular cofactor concentrations of L. monocytogeneswild type and
mutant strain M1. The cultures were grown to the stationary phase in
BHI medium supplemented with various flavin concentrations. A: DMSO
control; B: 10µM roseoflavin; C: 50µM roseoflavin; D: 50µM riboflavin and
50µM roseoflavin; E: FAD and FMN concentrations in wild type cells; F:
FAD and FMN concentrations in M1 cells. Level of significance: * p  0.05;
** p  0.01.
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Notably the FAD and FMN concentrations were reduced when only roseoflavin
was added to the medium. When, in addition to 50µM roseoflavin, also
riboflavin in a concentration of 50µMwas added to the medium, the FAD and
FMN concentrations were brought back the levels of the untreated cultures
(figure 4.3-D). For a better comparison the FAD and FMN concentrations
are displayed side by side for either strain in panels E and F of figure 4.3
respectively. The fact that this effect could be observed not only in the wild
type but in the mutant strain as well, indicated that it was not a result of the
mutation in the FMN riboswitch Rli96.
4.3 Identification of Flavokinase/FAD synthetase
Genes in L. monocytogenes
As a riboflavin auxotrophic bacterium, L. monocytogenes does not posses genes
coding for enzymes involved in riboflavin biosynthesis and relies solely on
transporter mediated uptake of the vitamin. However, the metabolic active,
phosphorylated forms of riboflavin are the cofactors FMN and FAD. In bacte-
ria, these cofactors are typically synthesized by bifunctional enzymes, which
exhibit flavokinase activity (EC 2.7.1.26.) as well as FAD synthetase activity
(EC 2.7.7.2.).
A BLAST search at http://blast.ncbi.nlm.nih.gov/ based on the amino
acid sequence of the bifunctional flavokinase/FAD synthetase RibC from
B. subtilis (UniProtKB accession number: P54575) in a database containing
translated nucleotide sequences from L. monocytogenes EGD-e (Taxonomy ID:
169963) resulted in two sequences producing significant alignments. Those
two sequences corresponded to the two loci annotated as lmo1329 (nucleotides
1357753 to 1358697, GenBank accession number: WP_009925599 ) and lmo0728
(nucleotides 758656 to 759396, GenBank accession number: WP_003721848) in
the genome of L. monocytogenes EGD-e.
Since the genesis of cofactors appeared to play an important role in the toxic
effect of flavin analogs on L. monocytogenes, both proteins (Lmo1329 and
Lmo0728) were produced in recombinant E. coli strains and purified by affinity
chromatography to study their catalytic flavokinase/FAD synthetase activities
in vitro.
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4.4 Recombinant Production and Purification of
Lmo1329
The gene lmo1329was amplified from genomic DNA of L. monocytogenes, using
the modyfying oligonucleotides F-lmo1329atg.NheI and R-lmo1329.NotI. The
product of the PCR was inserted into the plasmid pET-24a(+) after digest with
NheI and NotI. The gene was placed under the control of the IPTG inducible
PT7 promoter, in frame with the sequence coding for a C-terminal His-Tag.
The plasmid pET-24_lmo1329 was used to transform the expression strain
E. coli BL21(DE3). Expression of lmo1329-his was induced with 1mM IPTG in a
culture volume of 250ml and protein production was carried out for 5 h at 37  C.
The cells were harvested by centrifugation and lysed with a high pressure cell
disruptor. The crude extract was applied to a HisTrapTM HP column, packed
with nickel-sepharose (see section 3.10.1). The column bound proteins were
eluted from the column with a gradient of imidazole and collected in fractions
of 5ml each.
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Figure 4.4: Purification of Lmo1329-His. FPLC chromatogram of the elution of recom-
binantly produced Lmo1329-His from aHisTrapTM HP column with a linear
gradient of imidazole. Blue: absorption at 280 nm; green: ratio (v/v) of
elution buffer (Buffer B for IMAC, 200mM imidazole) and loading buffer
(Buffer A for IMAC, 20mM imidazole). Collected fractions are numbered
and indicated by vertical lines.
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The chromatogram of the purification (figure 4.4) shows a single peak during
the elution, led by a shoulder. The collected samples were applied to an SDS
gel and separated electrophoretically, to verify the purity of the eluates. The
resulting gel is displayed in figure 4.5. The gel shows a dominant band of
with the expected size of Lmo1329-His. For the use in subsequent activity
assays, Sample#6 was desalted via gel filtration and stored at -20  C in 50mM
potassium phosphate buffer (pH 7.5). All other samples were discarded as they
appeared to contain less Lmo1329-His and more contaminating proteins.
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Figure 4.5: Purified Lmo1329-His. SDS-PAGE after HisTrap purification of Lmo1329-
His. Sizes in kDa corresponding to the bands of the marker are given on
the left. The arrow on the right marks the expected position of Lmo1329-
His (36.8 kDa). Sample numbers according to figure 4.4. M: Marker
(PageRulerTM Plus); A: Sample#4; B: Sample#5; C: Sample#6; D: Sample#7;
E: Sample#8.
4.5 Recombinant Production and Purification of
Lmo0728
The initial approach of expression of lmo0728 from pET-24a(+) and pET28
derivates in E. coli BL21(DE3) as C- and N-termnially His-tagged versions of
Lmo0728, resulted in an accumulation of insoluble recombinant protein in the
debris fraction after disruption of the cells. The absence of His-tagged Lmo0728
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in the cell free extract, as well as its accumulation in the insoluble debris was
confirmed through western blot analysis with an anti-His primary antibody.
To modulate the speed of protein production during induction, in order
to ease correct folding of the produced protein and prevent aggregation,
E. coli Rosetta(DE3) was used as host strain for protein production. E. coli
Rosetta(DE3) allowed for adjustable levels of expression throughout all cells in
a culture. By adjusting the concentration of the inducer IPTG, gene expression
could be modulated from very low expression levels up to the fully induced
expression levels of E. coli BL21(DE3). According to the manufacturer’s recom-
mendations, low-level expression may enhance the solubility and activity of
difficult target proteins (Novagen, 2002). In addition to reduced IPTG concen-
trations the incubation temperature during protein production was reduced to
20  C and the production phase was extended to 24 h.
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Figure 4.6: Expression and purification of inactive Lm0728-His. left: SDS-PAGE of
cell free extracts from E. coli Rosetta(DE3) containing the expression plas-
mid pET-24_lmo0728 induced with varying IPTG concentrations at 20  C
for 24 h. M: Marker (PageRulerTM Plus); A: 0µM IPTG; B: 25µM IPTG; C:
100µM IPTG; D: 250µM IPTG; E: 1mM IPTG.
right: SDS-PAGE of the elution fraction after FPLC purification with a
HisTrapTM HP column. M: Marker (PageRulerTM Plus); F: Elution fraction
containing purified Lmo0728 from a culture induced with 100µM IPTG at
20  C for 24 h.
Sizes in kDa corresponding to the bands of the marker. The red arrow
marks the band that is assumed to be soluble Lmo0728. Expected position
of Lmo0728-His (black arrow, 27.8 kDa).
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To test whether reduced IPTG concentrations in combination with lower tem-
peratures during the protein production phase were beneficial for the solubility
of Lmo0728-His, expressed from pET-24_lmo0728, three intermediate IPTG
concentrations, i.e. 25µM, 100µM and 250µM were applied to induce gene
expression. The cell free extracts of these cultures were analyzed by SDS-PAGE
and compared to an uninduced (no IPTG) and a fully induced (1mM IPTG)
culture. The result of the electrophoresis is shown in the left panel of figure 4.6.
From the tested IPTG concentrations 100µM appeared to yield the maximal
amount of soluble Lmo0728-His (red arrow). The cell free extract of the culture
was applied to a HisTrapTM HP column packed with nickel-sepharose to purify
the protein. The SDS-PAGE analysis displayed in the right panel of figure 4.6,
shows the fraction that was eluted from the column with imidazole concen-
trations above 128mM (60% Buffer B for IMAC). In addition to the dominant
band with the approximate size of Lmo0728-His, at least four contaminating
proteins were present in the eluate. The eluate was desalted and subject of
a flavokinase/FAD synthetase activity assay. Since neither flavokinase nor
FAD synthetase activity of the eluate could be detected, further purification of
Lmo0728-His from the mixture was not pursued.
4.5.1 Maltose Binding Protein Fusions with Enhanced Solubility
A new approach to produce a soluble and active form of Lmo0728 was to pro-
duce a fusion protein with the highly soluble maltose binding protein (MBP)
from E. coli, encoded by the gene malE, N-terminally fused to Lmo0728. For
this approach the commercially available pMALTM Protein Fusion and Purifi-
cation System (New England BioLabs) was applied. The coding sequence of
lmo0728 was introduced into the expression plasmid pMAL-c5x that provides
the genetic information, necessary to produce a fusion of MBP connected to the
protein of interest via a linker, that contains a protease recognition sequence,
which facilitates the separation of the two parts of the fusion protein with the
protease FactorXa subsequent to the purification of the fusion protein. Since the
fusion protein MBP-Lmo0728 did not feature a His-tag, aMBPTrapTM column
(GE Healthcare), packed with amylose resin that binds the MBP portion of
the fusion protein was used for affinity purification. Column bound proteins
were eluted from the column with a buffer containing 10mM maltose. The
purification of MBP-fusion proteins with the FPLC system is described in more
detail in section 3.10.2.
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Figure 4.7: Purification of active MBP-Lmo0728 fusion protein. FPLC chro-
matogram of the elution of recombinantly produced MBP-Lmo0728 from a
MBPTrapTM HP column with a one step elution profile. Blue: absorption at
280 nm; green: ratio (v/v) of elution buffer (Buffer B for MBPTrap, 10mM
maltose) and loading buffer (Buffer A for MBPTrap). Collected fractions
are numbered and indicated by vertical lines.
The production of MBP-Lmo0728 from pMAL_lmo0728 was carried out in
E. coli ER2523. Gene expression was induced at OD600 = 0.4 with 0.3mM IPTG
and the culture was incubated for protein production for 3 h at 37  C. After
lysis of the cells, the cell free extract was clarified by centrifugation and was
subsequently applied to a MBPTrapTM HP column (GE Healthcare) with a
column volume of 5ml. The FPLC chromatogram of the elution of the column
bound proteins is shown in figure 4.7. A single peak eluted from the column
after the a maltose concentration was raised in a step profile to 2mM (20% (v/v)
Buffer B for MBPTrap). The cell free extract, a sample collected from the flow
through of the column and the elution peak were subject to SDS-PAGE analysis.
The gel is depicted in figure 4.8.
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Figure 4.8: Purified MBP-Lmo0728 fusion protein. SDS-PAGE after MBPTrap pu-
rification of MBP-Lmo0728. Sizes in kDa corresponding to the bands of
the marker are given on the left. The arrows on the right indicate the
expected positions of a) the MBP-Lmo0728 fusion protein (71.5 kDa) and
b) MBP (42.5 kDa). M: Marker (PageRulerTM Plus); A: cell free extract that
was loaded to the column; B: flow through; C: elution peak (sample #4,
figure 4.7).
The SDS-PAGE analysis of the peak, eluted from the MBPTrap column (fig-
ure 4.8 lane C) showed that in addition to the two expected bands of MBP (a)
and MBP-Lmo0728 fusion protein (b), several other proteins co-purify on the
MBPTrap column. The eluate was tested for flavokinase and FAD synthetase
activity. When riboflavin was used as substrate in the assay, no flavokinase
activity could be detected. However, when FMN was used as a substrate in the
activity assay, FAD was produced (figure 4.9) proving that the MBP-Lmo0728
fusion protein is an active FAD synthetase.
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Figure 4.9: FAD synthetase activity of MBP-Lmo0728. HPLC chromatograms of an
FAD synthetase activity assay, performed with 10µM FMN as substrate
and 170 µg/ml of the desalted elution fraction (sample #4, figure 4.7) from
the MBPTrap column. The reaction was stopped immediately after enzyme
addition (left) and after 7 h incubation at 37  C (right).
For further characterization, especially for the determination of kinetic pa-
rameters, it was desired to cleave the fusion protein and purify the protein of
interest (i.e. Lmo0728) to apparent homogeneity. The user’s instructions for the
pMALTM Protein Fusion and Purification System suggested to use the protease
FactorXa that was supplied with the kit, followed by a separation of the target
protein from the cleaved off MBP through anion exchange chromatography
(AEX). The proteolytic digest was performed within the specifications of the
manufacturer’s recommendations (NEB, 8200).
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Figure 4.10: Incomplete digest and AEX purification of MBP-Lmo0728. SDS-PAGE
after FactorXa digest of the MBPTrap eluate (left) and after AEX chro-
matography of the digested sample (right). Sizes in kDa corresponding to
the bands of the markers. The arrows indicate the expected position of a)
MBP-Lmo0728 fusion protein (71.5 kDa); b) MBP (42.5 kDa); c) Lmo0728
(27.8 kDa).
M: Marker (PageRulerTM Plus); A: Undigested eluate from MBPTrap col-
umn (sample #4, figure 4.7); B: Mock digest (8 h at room temperature
without protease) of the MBPTrap eluate; C: FactorXa digest (8 h at room
temperature) of the MBPTrap eluate; D: AEX flow through (sample #1,
figure 4.11); E: AEX elution peak1 (sample #3, figure 4.11); F: AEX elution
peak2 (sample #4, figure 4.11).
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The SDS-PAGE analysis of the digested eluate (figure 4.10 lane C) revealed that
the digestion of the fusion protein was incomplete after 8 h at room tempera-
ture. An extended incubation time of 18 h at 4  C did not result in a complete
digestion of the fusion protein (gel not shown). The reaction, although incom-
plete, resulted in the formation of cleaved Lmo0728. The separation of Lmo0728
from MBP and the remaining fusion protein was approached by loading the
digest reaction to a HiTrapTM Q FF (GE Life Sciences) anion exchange column.
The bound protein was eluted with a gradient of sodium chloride in the buffer
(detailed information on AEX chromatography see section 3.10.3).
0 5 10 15 20 25 30 35 40
Volume (ml)
0
50
100
150
200
250
A
bs
. 2
80
 n
m
 (m
A
U
)
0
10
20
30
40
50
60
70
80
90
100
B
uf
fe
r B
 (%
)
Abs. 280 nm
Buffer B
#1                                    #2        #3                                           #4
                                        
Figure 4.11: AEX chromatography after Factor Xa digest of MBP-Lmo0728. FPLC
chromatogram of the separation of the FactorXa digest (8 h at room tem-
perature) of the eluate fraction (sample #4, figure 4.11) of the MBPTrap
purification with a HiTrapTM Q FF (CV = 1ml) AEX column. Blue: ab-
sorption at 280 nm; green: ratio (v/v) of elution buffer (Buffer B for AEX,
500mM NaCl) and loading buffer (Buffer A for AEX), 25mM NaCl). Col-
lected fractions are numbered and indicated by vertical lines.
The chromatogram of the anion exchange chromatography of the digested
MBPTrap eluate with a HiTrapTM Q FF (figure 4.11) shows the separation of the
sample into three fractions: the flow through, a main peak eluting from the
column as the salt concentration rises and a smaller peak eluted with a step
profile from 50% to 100% Buffer B for AEX, to focus the peak and counteract
further dilution. The fractions collected during the AEX chromatography were
analyzed by SDS-PAGE. The resulting gel (figure 4.10 right gel) shows that the
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main elution peak contained purified MBP but it was, however, not possible to
separate Lmo0728 from the uncleaved fusion protein, as both are present in
the flow through as well as in the secondary elution peak (samples #1 and #4
in figure 4.11).
4.5.2 His-MBP-Lmo0728 Fusion Proteins Digested with
His-tagged TEV Protease
Since the strategy of producing aMBP-Lmo0728 fusion proteinwith subsequent
proteolytic digest seemed to be the most promising approach, considering the
previous issues of solubility and activity of Lmo0728. Instead of optimizing the
separation of cleaved Lmo0728 via AEX, a His-tagged MBP-Lmo0728 fusion
was produced. On the pET-24d derived expression plasmid pET-MBP-1a the
genetic information for egfp was replaced with the coding sequence lmo0728 to
form the plasmid pET-MBP-lmo0728.
90 100 110 120 130 140 150
Volume [ml]
0
20
40
60
80
100
120
140
160
180
A
bs
. 2
80
 n
m
 (m
A
U
)
0
10
20
30
40
50
60
70
80
90
100
B
uf
fe
r B
 (%
)
Abs. 280 nm
Buffer B
#4              #5               #6             #7
Figure 4.12: Purification of His-MBP-Lmo0728 fusion protein. FPLC chromatogram
of the elution of recombinantly produced His-MBP-Lmo0728 from a
HisTrapTM HP column with a linear gradient of imidazole. Blue: ab-
sorption at 280 nm; green: ratio (v/v) of elution buffer (Buffer B for IMAC,
200mM imidazole) and loading buffer (Buffer A for IMAC, 20mM imi-
dazole). Collected fractions are numbered and indicated by vertical lines.
The fusion protein His-MBP-Lmo0728 could be purified on a HisTrapTM HP
column while the MBP portion of the fusion still provides enhanced solubil-
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ity. Additionally the fusion protein featured a recognition sequence for the
highly specific tobacco etch virus (TEV) protease between MBP and Lmo0728.
After the proteolytic digest was performed with a His-tagged TEV protease
(expressed from the plasmid pTH24 and purified via IMAC) the His tagged
MBP, potentially uncleaved fusion protein and the Protease could be captured
on a HisTrapTM HP column while the, now untagged, Lmo0728 remains in the
flow through.
The His-MBP-Lmo0728 fusion protein was produced in BL21(DE3) from the
expression plasmid pET-MBP-lmo0728. The expression was induced with
1mM IPTG and carried out for 3 h at 37  C. The cleared cell free extract was
applied to a HisTrapTM HP column and proteins bound to the column were
elutedwith a linear gradient of imidazole. The elution profile of the purification
is shown in figure 4.12.
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Figure 4.13: Purified His-MBP-Lmo0728 fusion protein. SDS-PAGE analysis of the
HisTrap purification of the His-MBP-Lmo0728 fusion protein. Sizes in
kDa corresponding to the bands of the marker are given on the left. The
arrows on the right mark the expected position of a) His-MBP-Lmo0728
(70.8 kDa); b) His-MBP (42 kDa). Sample numbers corresponding to the
chromatogram in figure 4.12. M: Marker (PageRulerTM Plus); A: sample
#4; B: sample #5; C: sample #6; D: sample #7.
The SDS-PAGE analysis of the collected samples (figure 4.13) showed that
the main peak of the elution profile (sample #5) did contain a major band
which corresponded in size to His-tagged MBP (42 kDa), however, a band
with the expected size of the His-MBP-Lmo0728 fusion (70.8 kDa) eluted in the
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collected samples #5 – #7. These three samples were pooled and concentrated
using a Vivaspin R  20 centrifugal concentrator (MWCO 10kDA, Satorius) for
subsequent incubation with His-tagged TEV protease. The introduction of
His-MBP into the sample was accepted, since it was formed as a side product
during the digest and had to be removed together with TEV-His and possibly
remaining, uncleaved fusion protein subsequently to the digest reaction.
The pooled elution fractions (samples #5 – #7) were incubated with TEV-His
over night at room temperature. A preparation of purified His-MBP-EGFP,
purified after expressed from pET-MBP-1a was digested as a control to verify
the proteolytic activity of the used TEV-His protease. A mock setup, that was
incubated side by side with the digest but without addition of TEV-His, was
also included in the subsequent SDS-PAGE analysis. The mock was done to
check the stability of the fusion proteins under the chosen conditions. From
the gel, that is shown in figure 4.14, the general proteolytic activity of TEV-His
can be recognized, as the His-MBP-GFP fusion protein was clearly digested
(figure 4.14 lane C). The His-MBP-Lmo0728 fusion protein, however, was not
affected by the protease present in the mixture (figure 4.14 lane A).
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Figure 4.14: Incomplete digest of His-MBP-Lmo0728 with TEV-His. SDS-PAGE
analysis after TEV-His digest of His-MBP-Lmo0728 and His-MBP-
EGFP. A: TEV-His digest of His-MBP-Lmo0728; B: Mock digest of
His-MBP-Lmo0728; M: Marker (PageRulerTM Plus); C: TEV-His di-
gest of His-MBP-EGFP; D: Mock digest of His-MBP-EGFP. The arrows
indicate the expected position of a)His-MBP-Lmo0728/-EGFP fusion
protein (71.5/70.6 kDa); b) MBP (42.5 kDa); c) TEV-His (33.5 kDa);
d) Lmo0728/EGFP (27.7/26.9 kDa).
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To improve the accessibility of the protease recognition site between the N-
terminal MBP portion and the C-terminal Lmo0728 domain of the fusion
protein, a linker sequence was introduced. The linker consisting of five glycine
residues was chosen to improve the structural flexibility of the fusion protein
with minimal influence on the activity of Lmo0728 as it remained on the N-
terminus of Lmo0728 after successful cleavage.
ACTAAT TCGGGATCTGGCAGTGGT TCTGAGAATCT T TAT T T TCAGGGCGCCATGGGTGGCGGTGGCGGTGCCATGGAAGTA
Figure 4.15: Glycine linker improves proteolytic accessibility of His-MBP-
Lmo0728. Detail of the DNA sequence of the plasmid pET-MBP-pG-
lmo0728. The plasmid was derived from pET-MBP-lmo0728 by introduc-
tion of a 25 nt long linker into the unique NcoI restriction site, directly
upstream of lmo0728 (see section 2.4.3). The translated amino acid se-
quence is shown below.
A 25nt long linker sequence featuring the the codons GGT and GGC, both
coding for glycine, in an alternating manner was introduced into the unique
NcoI restriction site present of pET-MBP-lmo0728 between the TEV recogni-
tion sequence and the Lmo0728 domain of the fusion protein. The resulting
plasmid, pET-MBP-pg-lmo0728, was used to produce the fusion protein MBP-
pg-Lmo0728 in E. coli BL21(DE3). The expression was carried out for 16 h after
it was induced with 1mM IPTG at OD600 = 0.8. The incubation temperature
for the protein production phase was reduced to 25  C. This optimization was
necessary since the introduction of the pGly-linker appeared to increase the
amount of the by-product His-MBP. Especially if the expression was induced
at lower OD600 (0.4) and carried out at higher temperatures (37  C). The cell
free extract was applied to a HisTrapTM HP column and an imidazole gradient
was used for the elution of column bound proteins. The chromatogram in
figure 4.16 shows one major elution peak that was collected in several fractions.
The subsequent SDS-PAGE analysis of the fractions collected during the elution
process is shown in figure 4.17.
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Figure 4.16: Purification of the His-MBP-pg-Lmo0728 fusion protein. FPLC chro-
matogram of the elution peak His-MBP-pg-Lmo0728 from aHisTrapTM HP
column with a linear gradient of imidazole. Blue: absorption at 280 nm;
green: ratio (v/v) of elution buffer (Buffer B for IMAC, 200mM imidazole)
and loading buffer (Buffer A for IMAC, 20mM imidazole). Collected
fractions are numbered and indicated by vertical lines.
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Figure 4.17: Purified His-MBP-pg-Lmo0728 fusion protein. SDS-PAGE analysis of
the samples collected during the HisTrap purification of His-MBP-pg-
Lmo0728. The arrows on the right mark the expected positions of a) His-
MBP-pg-Lmo0728 (71.5 kDa); b) His-MBP (42.5 kDa). Sample numbers
corresponding to figure 4.16. M: Marker (PageRulerTM Plus); A: sample #3;
B: sample #4; C: sample #5; D: sample #6; E: sample #7; F: sample #8.
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The gel revealed that different fractions contained varying amounts of the ex-
pected proteins as well as contaminating proteins, which elute mainly at lower
imidazole concentrations (figure 4.17 lane A-C). Since fraction #6 (figure 4.17
lane D) appeared to have the best ratio of His-MBP-pg-Lmo0728 fusion protein
to His-MBP and other contaminations, this fraction was used for the proteolytic
digest with TEV-His.
The digest reaction was incubated at 4  C for 16 h. The whole reaction mixture
was then applied to a HisTrapTM HP column (CV = 1ml). The flow through
was collected and all column bound protein was was eluted with a single step
elution profile to 100% Buffer B for IMAC. The FPLC chromatogram is shown
in figure 4.18.
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Figure 4.18: Separation of His-MBP and pg-Lmo0728 after TEV-His digest. FPLC
chromatogram after the TEV-His digest reaction of sample #6 from the
HisTrap purification of His-MBP-pg-Lmo0728 (figure 4.16). The Digest
mixture was applied to a HisTrapTM HP column (CV = 1ml). Inset graph
shows the flow through peak with amplified scale for the absorption. Blue:
absorption at 280 nm; green: ratio (v/v) of elution buffer (Buffer B for
IMAC, 200mM imidazole) and loading buffer (Buffer A for IMAC, 20mM
imidazole). Collected fractions are numbered and indicated by vertical
lines.
In the FPLC chromatogram in figure 4.18 an approximately 50-fold lower UV
absorption of the flow through compared to the elution peak was observed.
This was consistent with a very low protein concentration in the flow through
fraction, when compared to the elution fraction. Prior to the subsequent
SDS-PAGE analysis (figure 4.19), the flow through fraction was concentrated
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approximately 6-fold to a volume of about 1ml with a Vivaspin R  6 centrifugal
concentrator (MWCO 10kDa, Satorius). The final protein concentration in the
concentrate was determined to be 0.3 mg/ml.
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Figure 4.19: Purified pg-Lmo0728. SDS-PAGE analysis of the TEV-His digest reaction
of His-MBP-pg-Lmo0728. The arrows on the left mark the expected po-
sitions of a) His-MBP-pg-Lmo0728 (71.5 kDa); b) His-MBP (42.5 kDa); c)
pg-Lmo0728 (27.7 kDa); d) TEV-His (33.5 kDa) Sample numbers corre-
sponding to figure 4.18. A: Digest reaction mixture, that was loaded to
the column; B: concentrated flow through (sample #1); C: elution peak
(sample #2); M: Marker (PageRulerTM Plus).
A sample of the digest reaction, the concentrated flow through fraction and
the eluate fraction were analyzed by SDS-PAGE (figure 4.19). Notably, the
dominant protein band of the concentrated flow through fraction was found
on the same height as the 35 kDa band of the marker. Western blot analysis
confirmed that the dominant band on lane B in figure 4.19 did not react with the
anti-His primary antibody and thus was considered to be the C-terminal part
(pg-Lmo0728) of the cleaved fusion protein. The concentrated flow through
fraction was tested for flavokinase/FAD synthetase activity (section 4.6.2) and
found to contain an active FAD synthetase.
4.6 Flavokinase/FAD synthetase Activity of Lmo1329
and Lmo0728
To test the recombinantly produced proteins Lmo1329 and Lmo0728 for flavoki-
nase (EC 2.7.1.26) and FAD synthetase (EC 2.7.7.2) activity, the purified proteins
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were subject to the flavokinase/FAD synthetase activity assay described in
section 3.11.6. For qualitative evaluation of the enzymes’ flavokinase activity,
the assay was supplied with riboflavin as a substrate. Samples were taken
immediately after addition of the respective enzyme and after 10min an 60min
of incubation at 37  C from the same reaction mixture. The FAD synthetase
activity was tested alike with FMN added as the substrate in the assay reaction
instead of riboflavin. The assays were repeated to test for enzyme activity
with the riboflavin analogs 8-amino riboflavin and roseoflavin as well as the
cofactor analogs AFMN and RoFMN. All samples were analyzed by HPLC-
MS (Method2) to monitor the the potential reduction of the substrate and the
formation of the reaction products over time.
4.6.1 Lmo1329 is a Bifunctional Flavokinase/FAD synthetase
AF 
Lmo1329 
RF RoF 
0 min 
10 min 
60 min 
8 10 12 14 16
0
25
50
75
100
125
A
bs
. 4
80
 n
m
 (m
A
U
)
AF 
8 10 12 14 16
0
25
50
75
100
125
A
bs
. 4
80
 n
m
 (m
A
U
)
AFMN 
AFAD AF 
retention time (min) 
8 10 12 14 16
0
25
50
75
100
125
A
bs
. 4
80
 n
m
 (m
A
U
)
AFAD 
AFMN 
8 10 12 14 16
0
10
20
30
40
50
A
bs
. 4
45
 n
m
 (m
A
U
)
RF 
8 10 12 14 16
0
10
20
30
40
50
A
bs
. 4
45
 n
m
 (m
A
U
)
FMN 
FAD 
RF 
retention time (min) 
8 10 12 14 16
0
10
20
30
40
50
A
bs
. 4
45
 n
m
 (m
A
U
)
FAD 
8 10 12 14 16
0
50
100
150
A
bs
. 5
03
 n
m
 (m
A
U
) RoF 
8 10 12 14 16
0
50
100
150
A
bs
. 5
03
 n
m
 (m
A
U
)
RoF 
RoFMN 
retention time (min) 
8 10 12 14 16
0
50
100
150
A
bs
. 5
03
 n
m
 (m
A
U
)
RoFMN 
Figure 4.20: Flavokinase activity assay of Lmo1329. HPLC Chromatograms of flavok-
inase/FAD synthetase activity assays performed with Lmo1329. 8-amino
riboflavin (AF, left), riboflavin (RF, middle) and roseoflavin (RoF, right) as
substrates. The reactions were stopped after 0 min (top), 10 min (middle)
and 60 min (bottom) of incubation.
The results of the HPLC-MS analysis in the middle column of Figure 4.20
confirmed that Lmo1329 is a bifunctional enzyme, that has flavokinase and
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FAD synthetase activity. If riboflavin was provided as substrate, FMN was
formed as an intermediate reaction product which was further converted
into FAD. If 8-amino riboflavin was used as substrate, the two corresponding
reaction products AFMN and AFAD could be detected (Figure 4.20 left column).
In contrast to these findings, when roseoflavin was used as substrate for the
reaction, only the formation of RoFMN could be observed. After 60 min the
roseoflavin present in the reaction mixture has been completely converted
into RoFMN but no RoFAD formation could be detected (Figure 4.20 right
column).
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Figure 4.21: FAD synthetase activity assay of Lmo1329. HPLC Chromatograms of
flavokinase/FAD synthetase activity assays performed with Lmo1329.
AFMN (left), FMN (middle) and RoFMN (right) as substrates. The reac-
tions were stopped after 0 min (top), 10 min (middle) and 60 min (bottom)
of incubation.
When the respective flavin mononucleotides (AFMN, FMN and RoFMN) were
used as substrates in the flavokinase/FAD synthetase activity assay, no FAD
synthetase activity of Lmo1929 could be detected with RoFMN in contrast to
the other two substrates (figure 4.21).
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4.6.2 Lmo0728 is a Monofunctional FAD synthetase
The recombinantly produced enzyme Lmo0728, did not convert any of the
substrate within 60min, when it was tested in the flavokinase/FAD synthetase
activity assay with 8-amino riboflavin, riboflavin and roseoflavin as substrates
(figure 4.22). Also extended incubation times up to 18 h did not lead to any
substrate consumption or cofactor formation (data not shown).
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Figure 4.22: Flavokinase activity assay of Lmo0728. HPLC Chromatograms of flavok-
inase/FAD synthetase activity assays performed with Lmo0728. 8-amino
riboflavin (AF, left), riboflavin (RF, middle) and roseoflavin (RoF, right) as
substrates. The reactions were stopped after 0 min (top) 10 min (middle)
and 60 min (bottom) of incubation.
When the respective flavin mononucleotides (AFMN, FMN and RoFMN) were
applied as substrates in the flavokinase/FAD synthetase activity assay with
Lmo0728, FAD synthetase activity was observed for all three substrates (Fig-
ure 4.23). Notably, in contrast to Lmo1329, Lmo0728 showed FAD synthetase
activity also when RoFMN was used as substrate. RoFAD was formed in this
reaction (figure 4.23 right column).
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Figure 4.23: FAD synthetase activity assay of Lmo0728. HPLC Chromatograms of
flavokinase/FAD synthetase activity assays performed with Lmo0728.
AFMN (left), FMN (middle) and RoFMN (right) as substrates. The reac-
tions were stopped after 0 min (top) 10 min (middle) and 60 min (bottom)
of incubation.
The results of the flavokinase/FAD synthetase activity assays presented in
figures 4.22 and 4.23 show that Lmo0728 is a monofunctional FAD synthetase
without detectable flavokinase activity. Further the presence of RoFAD in the
cell free extract of L. monocytogenes grown in the presence of roseoflavin can be
attributed to the cooperation of Lmo1329, producing RoFMN from roseoflavin
and ATP, and Lmo0728, converting it into RoFAD.
4.6.3 Optimal pH for FAD synthetase Activity of Lmo0728 and
Lmo1329
Throughout the qualitative experiments presented in section 4.6.2 a high depen-
dence of the FADS activity, particularly of Lmo0728, to the pH of the reaction
buffer was noticed. Several BIS-Tris propane (BTP) buffer compositions (given
in Table 3.10) with a pH range from 7.0 to 9.5 were used in the flavokinase/FAD
synthetase activity assays to identify the pH with maximal enzyme activity.
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Figure 4.24: Determination of the optimal pH for FAD synthetase activity. Normal-
ized FAD synthetase activities of Lmo0728 (n) and Lmo1329 (l) in 50 mM
BIS-TRIS propane buffer with varying pH.
The specific FAD synthetase activities plotted in figure 4.24 were normalized to
the maximal activity obtained for the respective enzyme to ease the comparison
between both enzymes. The optimal pH for the FAD synthetase reaction of
each enzyme was determined by reading off the pH corresponding to the
enzyme’s maximal activity. Thus pH 8.5 was determined to be the optimum for
Lmo1329 while pH 9.0 was found to be the optimum for Lmo0728. All further
characterizations of the enzymes were carried out in BTP buffer at the optimal
pH for the respective enzyme.
4.6.4 Kinetic Characterization of the Flavokinase and
FAD synthetase Activity of Lmo0728 and Lmo1329
To determine the apparent kinetic parameters for the enzyme-substrate com-
bination, the Michaelis constantKm and the maximal reaction rate vmax were
calculated from the best fit of the Michaelis-Menten kinetic (equation 3.2 on
page 65) to the experimental data. From these two constants, the turnover num-
ber kcat and the kinetic efficiency kcatKm for each enzyme-substrate combination
were calculated.
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Figure 4.25: FAD synthetase kinetic of Lmo0728. Specific FAD synthetase activities
of Lmo0728 plotted against the corresponding substrate (FMN) concen-
tration. Solid line gives the non-linear regression according to the kinetic
model of Michaelis-Menten. Km = 12.9µM; vmax = 1093 nmol/min·mg.
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Figure 4.26: FAD synthetase kinetic of Lmo1329. Specific FAD synthetase activities
of Lmo1329 plotted against the corresponding substrate (FMN) concen-
tration. Solid line gives the non-linear regression according to the kinetic
model of Michaelis-Menten. Km = 29.2µM; vmax = 3706 nmol/min·mg.
For the determination of the kinetic parameters of the enzymes, their specific
activity for various substrate concentrations was measured and plotted against
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the corresponding substrate concentration. From these data pairs the kinetic
function described by theMichaelis-Menten equation could be derived through
non-linear regression. The method is described in more detail in section 3.15.
Figures 4.25 and 4.26 show the specific FAD synthetase activities of Lmo0728
and Lmo1329, respectively. The specific activities were plotted against the
corresponding FMN concentrations. Figure 4.27 shows the specific flavokinase
activities of Lmo1329 plotted against the corresponding riboflavin concentra-
tions. The apparent kinetic parameters for each enzyme-substrate pair were
derived from the best fit according to the kinetic model of Michaelis-Menten
and are summarized in table 4.2.
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Figure 4.27: Flavokinase kinetic of Lmo1329. Specific flavokinase activities of
Lmo1329 plotted against the corresponding substrate (RF) concentration.
Solid line gives the non-linear regression according to the kinetic model
of Michaelis-Menten. Km = 6.9µM; vmax = 668 nmol/min·mg.
Table 4.2: Apparent kinetic parameters of Lmo0728 and Lmo1329, calculated from the
results of flavokinase/FAD synthetase assays.
Enzyme Substrate Km (µM) vmax( nmolmin·mg ) kcat (s
-1) kcatKm (
1
s·µM)
Lmo0728 FMN 12.9 1093 0.51 0.040
Lmo1329 FMN 29.2 3706 4.39 0.150
Lmo1329 RF 6.9 668 0.40 0.057
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4.7 Characterization of the Gene Product of lmo1945
from L. monocytogenes and its 50–UTR Rli96
Mansjö and Johansson were able to show that, if riboflavin or roseoflavin was
added to the growth medium, transcription was terminated between Rli96 and
lmo1945 in a L. monocytogenes wild type strain indicating that the expression of
lmo1945 is regulated by the transcriptional FMN riboswitch Rli96. The nothern-
blot data presented by Mansjö and Johansson are merely qualitative and give
no information about the level of regulation regarding the expression level of
the gene downstream of Rli96 (Mansjö and Johansson, 2011).
The crystal structure of Lmo1945 has been solved recently by Karpowich et al..
They show that Lmo1945 is a a membrane-embedded substrate-binding sub-
unit (EcfS) of an energy-coupling factor (ECF) riboflavin transporter. However,
physiological experiments showing that Lmo1945 indeed is involved in ri-
boflavin uptake were not carried out (Karpowich et al., 2015). In the context of
this work, the question whether Lmo1945 is involved in the uptake of the flavin
analogs roseoflavin was of great interest. Although the findings of Mansjö and
Johansson (2011) suggest that roseoflavin is incorporated by L. monocytogenes,
it remained unclear if the uptake is facilitated by Lmo1945.
4.7.1 The Gene Product of lmo1945 from L. monocytogenes is
Responsible for Riboflavin and Roseoflavin Uptake
To show that the FMN riboswitch controlled gene lmo1945 from L. monocy-
togenes indeed codes for the substrate binding domain Lmo1945 of an ECF
riboflavin importer, similar to RibU from B. subtilis, the expressed in the spe-
cialized B. subtilis test strain Bs ribUB (Hemberger et al., 2011). The coding
sequence of lmo1945 was introduced into the riboflavin auxotrophic double
mutant ( ribB::Ermr  ribU::Kanr) B. subtilis strain Bs ribUB, deficient in ri-
boflavin synthesis ( ribB) and also deficient with respect to riboflavin uptake
( ribU) on the IPTG inducible plasmid pHT01_lmo1945.
The strain Bs ribUB (pHT01_lmo1945) was streaked next to the control strain
Bs ribUB (pHT01), carrying the empty plasmid, on LA plates, containing
0.1mM IPTG to induce expression. The agar plates were supplemented with
increasing amounts of riboflavin and incubated over night at 37  C. The pho-
tographs in figure 4.28 show that the expression of lmo1945 restored the ability
of Bs ribUB to grow on unsupplemented LA, which contains approximately
95
4µM riboflavin (figure 4.28-A). The control strain was able to grow on LA sup-
plemented with 100µM riboflavin, since the flavin can enter the cells passively
as a result of the high riboflavin concentration in the growth medium.
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Figure 4.28: Lmo1945 is a functional riboflavin transporter - plate assay. Streaks
(top) and 10 µl drop of an overnight culture OD600 = 2.0 (bottom) of
Bs ribUB expressing lmo1945 from pHT01_lmo1945 (left) and empty
vector control (right) were applied to LA plates supplemented with addi-
tional amounts of riboflavin (A: no supplementation, B: 1 µM, C: 10 µM,
D: 100 µM) and 0.1 mM IPTG to induce gene expression.
A growth experiment on agar plates gives only a qualitative result whether or
not a strain is able to grow on certain media but it does not yield information
about parameters like growth rate, biomass concentration or overall perfor-
mance of the culture. To gain a better understanding, the same Bs ribUB
strains that were used in the experiment above, were grown in liquid cultures
of Spizizen-Minimal-Medium (SMM). The medium was prepared without any
riboflavin and was later supplemented with two defined concentrations of
riboflavin (10µM and 100µM) and an equivalent volume of the solvent DMSO
as a control. The recorded growth curves are depicted in figure 4.29.
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Figure 4.29: Lmo1945 is a functional riboflavin transporter - liquid culture growth
assay. Growth curves of Bs ribUB expressing lmo1945 of L. monocytogenes
from pHT01_lmo1945 (right panel) and empty vector control (left panel).
Cultures were grown in SMM supplemented with different amounts of
riboflavin (©: no supplementation, s: 10 µM, l: 100 µM) and 0.1 mM
IPTG.
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In those cultures where no riboflavin was added to the medium, no growth was
observed for both strains, since both are ribB deficient and thus are depending
solely on riboflavin provided with the growth medium. In those cultures,
grown with a riboflavin concentration of 10µM, the control strain with the
empty plasmid was still not able to grow, while the strain carrying the plasmid
pHT01_lmo1945 could grow to a final OD600 > 5.0 within 8 h. If the medium
was supplemented with riboflavin concentrations as high as 100µM both
strains were able grow with no significant difference in growth rate or final cell
density.
To find out if Lmo1945 also functions as a transporter for the toxic riboflavin
analog roseoflavin, a similar experiment was performed. Instead of the ri-
boflavin auxotrophic strain Bs ribUB, the B. subtilis strain Bs ribU was em-
ployed and the cultures were treated with roseoflavin instead. This strain
features an undisrupted ribB gene and, hence, is riboflavin heterotrophic and
does not rely exclusively on riboflavin import to survive, while it still does not
express the native ribU gene coding for the substrate binding domain RibU,
responsible for riboflavin import in B. subtilis.
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Figure 4.30: Lmo1945 is a functional roseoflavin transporter - plate assay. Streaks
(top) and 10 µl drop of an overnight culture OD600 = 2.0 (bottom) of
BS ribU expressing lmo1945 of L. monocytogenes from pHT01_lmo1945
(left) and empty vector control (right) were applied to LA plates supple-
mented with different amounts of roseoflavin (A: no supplementation,
B: 50 µM, C: 100 µM, D: 250 µM) and 0.1 mM IPTG.
The strain Bs ribU (pHT01_lmo1945) was streaked side by side with the
control strain Bs ribU (pHT01), carrying the empty plasmid, on LA plates
supplemented with 0.1mM IPTG to induce expression and various amounts of
roseoflavin. The plates were incubated over night at 37  C. The photographs in
figure 4.30 show that the expression of lmo1945made Bs ribU more suscepti-
ble to the adverse effect of roseoflavin (figrue 4.30-B & 4.30-C). The difference in
performance was not visible as clearly, since the empty plasmid control strain
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also showed signs of diminished growth, if the media was supplemented with
100µM roseoflavin (figure 4.30-C). On the other hand, both strains yielded re-
sistant colonies, that were able to grow on LA with a roseoflavin concentration
as high as 250µM (figure 4.30-D).
To get a better understanding of the effect roseoflavin has on the growth rates
of the two Bs ribU strains and in particular to show if the heterologous expres-
sion of lmo1945 influences this effect, liquid cultures of Bs ribU (pHT01) and
Bs ribU (pHT01_lmo1945) were grown in SMM supplementedwith 50µMand
100µM roseoflavin. The recorded growth curves are depicted in figure 4.31.
The growth behavior of the empty plasmid control Bs ribU (pHT01) was
not influenced by the addition of 50µM roseoflavin to the medium when
compared to the culture treated with DMSO only, while 100µM roseoflavin
clearly reduced the growth rate of the culture as well as the final cell density to
which the culture grew within 10 h. The growth rate of the Lmo1945 producing
strain Bs ribU (pHT01_lmo1945) was reduced already by 50µM roseoflavin
when compared to the DMSO treated culture and showed stagnation of growth
for approximately 8 h if the growth medium was supplemented with 100µM
roseoflavin. Also, when compared to the empty vector control strain, Bs ribU
(pHT01_lmo1945) exhibited slower growth and lower OD600 in the presence of
roseoflavin.
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Figure 4.31: Lmo1945 is a functional roseoflavin transporter - liquid culture growth
assay. Growth curves of Bs ribU expressing lmo1945 of L. monocytogenes
from pHT01_lmo1945 (right panel) and empty vector control (left panel)
in SMM supplemented with different amounts of roseoflavin (©: no sup-
plementation,s: 50 µM, l: 100 µM) and 0.1 mM IPTG.
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4.7.2 Characterization of the FMN Riboswitch Rli96
To functionally characterize the FMN riboswitch Rli96 from L. monocytogenes, it
was evaluated with an in vivo  -galactosidase (LacZ) activity assay. The applied
test system was already used by Ott et al. (2009) for the characterization of the
FMN riboswitch of B. subtilis in the 50–UTR of the rib-operon. The sequence
of Rli96was placed upstream of the  -galactosidase gene lacZ from E. coli on
the integrative plasmid pDG268. The strain Bs::Rli96 was created through
integration of pDG268_Rli96 into the locus amyE of B. subtilis wild type. To
prevent downregulation of the riboflavin transporter RibU in the host during
the treatment, the B. subtilis gene ribU was expressed additionally from the
IPTG inducible, non integrative plasmid pDG148_ribU. The Strain Bs::RFNbs
featuring the FMN riboswitch from B. subtiliswas used as a reference.
Both strains were grown with additional 50µM and 100µM riboflavin, as
well as without supplementation as control. The expression of ribU from
pDG148_ribU was induced in all cultures with 1mM IPTG. LacZ activity
assays were performed as described in section 3.11.3. The LacZ activities were
normalized to the untreated control, to account for the different strengths of
the promoters (figure 4.32).
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Figure 4.32: Rli96 reduces reporter expression by 25% in vivo. Relative  -
galactosidase (LacZ) activity of transcriptional riboswitch-lacZ fusions
integrated into the amyE-locus of B. subtilis (pDG148_ribU). Cultures were
treated with 50µM and 100µM riboflavin.
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The relative LacZ activity of Bs::Rli96 (pDG148_ribU) cultures, treated with
50µM and 100µM riboflavin, was reduced to about 75% of the activity of the
untreated control, while the reference strain Bs::RFNbs (pDG148_ribU) showed
reduction to 35% and 40% of the untreated control, respectively.
To survey whether the flavin analogs roseoflavin and 8-amino riboflavin also
effect the lacZ expression in Bs::Rli96 (pDG148_ribU) the above experiment
was repeated with roseoflavin and 8-amino riboflavin treatments. The LacZ
activity data collected in this experiment (figure 4.33) suggested that roseoflavin
reduced LacZ activity in a similar manner as riboflavin, while cultures treated
with 8-amino riboflavin, however, exhibited a slight increase of LacZ activity
rather than the expected reduction.
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Figure 4.33: Rli96 reduces reporter expression in vivo in the presence of riboflavin
and roseoflavin. Relative LacZ activities of Bs::Rli96 (pDG148_ribU) after
treatment with 50µM and 100µM of riboflavin (RF), roseoflavin (RoF)
and 8-amino riboflavin (AF).
The unreduced LacZ activity in the cultures treated with 8-amino riboflavin
could possibly be attributed to the lack of the FMN analog AFMN inside the
cell, since there was no evidence whether RibU of B. subtilis did transport
8-amino riboflavin into the cell. Also, the further metabolization of 8-amino
riboflavin to AFMN and possibly AFAD in B. subtilis remained unclear.
To address these drawbacks in the experimental design of an in vivo assay,
Rli96was placed on the plasmid pT7luc_Rli96 between the PT7 promoter and
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the reporter gene luc coding for firefly luciferase. The plasmid was used in a
coupled in vitro transcription/translation assay. The effect of FMN, RoFMN and
AFMN on the luciferase activity was assayed as described in section 3.11.5. The
results shown in figure 4.34 support the hypothesis, of AFMN not hindering
the expression of the gene downstream of Rli96 and thus confirmed the results
collected from the in vivo experiments.
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Figure 4.34: Rli96 reduces reporter expression in vitro in the presence of FMN and
RoFMN. Relative luciferase activities obtained in the presence of phos-
phorylated flavins FMN, RoFMN and AFMN in a coupled in vitro tran-
scription/translation assays from the plasmid pT7luc_Rli96.
4.8 In Vivo Reporter System for the Characterization
of Translational Riboswitches
FMN riboswitches are promising targets for antimicrobial compounds. In
contrast to the transcriptional FMN riboswitch of B. subtilis that has been
characterized in vivo earlier by Ott et al. (2009), the FMN riboswitches of many
streptomycetes regulate gene expression of downstream genes by sequestration
of the ribosomal binding site. In these translationally controlled riboswitches,
the ribosomal binding site is part of the secondary structure and is obstructed
in the “off”-state of the riboswitch (see figure 1.2 on page 8). Streptomyces
coelicolor and S. davawensiswere chosen as models, since they are closely related
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while S. davawensis is resistant to the antibiotic roseoflavin but S. coelicolor is
sensitive to the compound. The FMN riboswitches of these two species have
been studied earlier in vitro, as described by Pedrolli et al. (2012). However, a
functional characterization in vivo has, for the lack of a suitable reporter system,
not been described.
The translational control of gene regulation required a highly specialized re-
porter system, where the open reading frame of the reporter gene is fused
directly to a short leader (six codons) of the controlled gene downstream of
the riboswitch. Furthermore the previously used reporter gene lacZ, coding
for the enzyme  -galactosidase of E. coli, cannot be used as a reporter gene
in Streptomyces spp. since these bacteria exhibit a high level of endogenous
 -galactosidase activity (Ingram et al., 1989). For the in vivo characterization
of the FMN riboswitches of S. davawensis and S. coelicolor the establishment of
new reporter systems based on a translational fusion with the reporter genes
xylE, coding for the catechol 2,3–dioxygenase from Pseudomonas putida, and
gusA, coding for the  -glucuronidase from E. coli, were designed.
4.8.1 The XylE Reporter System is Not Suitable for the In Vivo
Characterization of FMN Riboswitches
To compare the rib-promoters (Prib) from S. coelicolor and S. davawensis,
derivates of the xylE based promoter probe plasmid pIPP1, constructed by
Jones (2011), were used to generate S. coelicolor strains with an integrated copy
of xylE downstream of the respective Prib promoter sequences. A schematic rep-
resentation of the integrative promoter probe plasmid is given in figure 4.35.
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Figure 4.35: Integrative promoter probe plasmids. Schematic representation of the
pIPP1 derived promoter probe plasmids. Putative promoter sequence
cloned into unique BamHI restriction site upstream of the reporter gene
xylE. Apramycine resistance gene aprR and  C31 integration site.
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Cell free extracts from liquid cultures of the test strains Sc::PribSd and Sc::PribSc
showed XylE activity. The control strains Sc::PribSdAS and Sc::PribScAS with
the same Prib sequences inserted in anti sense (AS) orientation, however, did
not exhibit specific XylE activities different to the background activity of the
control strain Sc:pIPP1, with integrated empty plasmid pIPP1. Crude extract of
S. coelicolorwild type did not show any XylE activity when tested in the same
assay. The specific XylE activities are displayed in figure 4.36.
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Figure 4.36: Prib is an active promoter in S. coelicolor. Specific catechol 2,3–dioxy-
genase (XylE) activity measured for the cell free extract of S. coelicolor (Sc)
wt and strains with integrated pIPP1 derivates. Strains with putative Prib
promoter sequences cloned in the correct orientation upstream of xylE
show catechol 2,3–dioxygenase activity while anti-sense (AS) controls
exhibit only background levels of activity.
To provide an in vivo reporter system that allows the characterization of ri-
boswitches with translational attenuation, the original ribosomal binding site
(RBS) has to remain unchanged and cannot be spaced out differently relative to
the riboswitch sequence, since it is part of the sequester loop (see figure 1.6 on
page 14). The strain Sc::SdxE features the reporter gene xylE in frame connected
to the leading six codons of ribB forming a translational fusion of the promoter
and riboswitch sequence from S. davawensis including the RBS and the reporter
gene xylE.
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TATGAGGCAGGAGGACCCGGGAAGTGT T CACCGGAAT CGT CGGAT CCAACAAA
Figure 4.37: Translational fusion of the ribB-leader and xylE. Schematic representa-
tion of the translational fusion of the Prib promoter, the FMN riboswitch
and the ribB-leader with the reporter gene xylE in the strain Sc::SdxE (top).
Sequence detail of the translational fusion (bottom).
As the specific XylE activity in cell free extracts of Sc:SdxE was only at about
10% of the activity level of the pIPP1 derived promoter test strain Sc::PribSd
(see figure 4.38), the gene xylT was introduced into Sc::SdxE with the non inte-
grative plasmid pAMxT. The gene xylT is coding for the soluble ferredoxin XylT
which is reactivating inactive XylE by reducing an oxidized iron atom at the
active center of XylE (Gonzalez-Ceron et al., 2001). The data obtained from ac-
tivity measurements of cell free extracts from Sc::SdxE (pAMxT), constitutively
expressing xylT, did not show the expected increase in XylE activity but rather
a further decrease to one third of the specific activity observed for Sc::SdxE.
This reduced level of XylE activity is not different to the background activities
measured for the promoterless XylE construct Sc::pIPP1 (figure 4.36).
A [U/mg] Stdev Date of 
measurement
Sc::PribSd) 0.215 0.0064 15.09.11
Sc::SdxE 0.024 0.002497724 02.05.12
Sc::SdxE)(pAMxT) 0.007 0.001495235 19.02.13
Sc::pAM01 0.236 0.001261493 09.05.13
Sc::pAM023 0.1698 0.014138927 29.05.13
Sc::pAM673 <0.002 0.000900946 09.05.13
Sc::pAM893 0.001 0.002092986 09.05.13
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Figure 4.38: Coexpression of xylT does not restore activity of translational xylE-
fusions. Specific catechol 2,3–dioxygenase (XylE) activity measured for
the cell free extracts of S. coelicolor strains with integrated plasmids fea-
turing different fusions of promoter and FMN riboswitch elements from
S. davawensis controlling the expression of the reporter gene xylE.
The coding sequences of xylT and xylE on the original sequence derived from
Pseudomonas putida overlap and they are transcribed in a shared message,
driven by a single promoter. To ensure that the separation of xylT and xylE into
two independent transcription units, where xylT is constitutively expressed
from a non-integrative plasmid, and the riboswitch controlled expression of
xylE occrus from a single integrated copy, is not the reason for the observed
decrease in activity, the two genes were regrouped into a single transcription
unit.
Figure 4.39: The pSET152 derived plasmids pAM01 and pAM023. The plasmids
pAM01 and pAM023 were used to verify the rearrangement of the coding
sequences does not impair XylE activity (see section 2.4.1).
Sc::pAM01 featuring the Prib promoter upstream of the original overlapping
xylT-xylE constellation, similar to Sc::PribSd, was used as a reference with
a specific XylE activity comparable to the activity obtained from Sc:PribSd.
To allow the translational fusion of xylE to the riboswitch sequence it was
necessary to interchange the order of the two genes in the transcription unit
and place xylT downstream of xylE. The XylE activity, measured from crude
extracts of the strain Sc::pAM023, featuring xylE and xylT separately and in
reversed order in one transcription unit downstream of the Prib promoter,
proved that the permutation of the two genes lead to specific XylE activities in
the range of 75% compared to the reference strain Sc::pAM0 (figure 4.38).
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Figure 4.40: The pSET152 derived plasmids pAM673 and pAM893. The plasmids
pAM673 and pAM893 were used to test translational fusions of the
S. davawensis ribB FMN riboswitch and xylE (see section 2.4.1).
The two strains Sc::pAM673 and Sc::pAM893 with translational fusions of xylE
to the riboswitch element directly after the RBS and to the ribB-leader sequence
respectively, however, did not exhibit any XylE activity in their cell free extracts
(figure 4.38).
A qualitative XylE plate assay revealed that the expression of functional XylE
in S. coelicolor was restored by translational uncoupling of xylE from the RFN-
RBSribB domain in Sc::pAM893.
Figure 4.41: The pSET152 derived plasmid pAM893a. The plasmid pAM893a fea-
tures the S. davawensis ribB FMN riboswitch, similar to pAM893, but
translationally uncoupled from xylE (see section 2.4.1).
Spores of Sc::pAM01 (positive control), S. coelicolor wt (negative control),
Sc::pAM893 (translational fusion of Prib promoter, riboswitch, RBSribB and
ribB-leader from S. davawensis with xylE) and Sc::pAM893a (translationally
uncoupled xylE by insertion of RBSxylE between ribB-leader and xylE) were
streaked on a MS agar plate and incubated at 30  C for 72 h. The plate was
flooded with 1ml freshly prepared 0.5M pyrocatechol solution and incubated
at room temperature for approx. 5min. In contrast to S. coelicolorwt and
Sc::pAM893, the positive control Sc::pAM01 and Sc::pAM893a exhibit a clearly
visible, bright yellow halo around the edge of the colonies (see figure 4.42).
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Figure 4.42: Translational uncoupling of xylE restores reporter activity. Qualitative
XylE plate assay of Sc::pAM01 (top left), S. coelicolor wild type (top right),
Sc::pAM893a (bottom left) and Sc::pAM893 (bottom right).
The restoration of XylE activity after uncoupling of xylE from the ribB-leader
and its RBS through the introduction of RBSxylE suggested that expression of
functional XylE in Sc::pAM893 was hindered by the N-terminal fusion of of
XylE to the RibB-leader and its upstream RBS. Since these sequences are part
of the secondary structure that forms the sequester loop of the riboswitch, they
could not be replaced or omitted without corrupting the test system.
4.8.2 The GusA Reporter System
Due to the fact that the XylE based test system described above was not suitable
to characterize the in vivo behavior of FMN riboswitches under investigation, a
GusA based reporter system, based on the work of Myronovskyi et al. (2011),
was approached.
A transcriptional fusion placing the codon optimized reporter gene gusA under
the control of the promoter Prib (pAMgus01) and a translational fusion of gusA
with the riboswitch domain of S. davawensis including the ribB-leader sequence
(pAMgus04), similar to pAM893 were constructed and integrated into the
chromosome of S. coelicolor.
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Figure 4.43: The pSET152 derived plasmids pAMgus01 and pAMgus04. Plasmids
for transcriptional (pAMgus01) and translational (pAMgus04) fusions
with gusA.
GusA activity was assayed as described in section 3.11.2. The strain
Sc::pSETgus where gusA expression is controlled by the thiostrepton inducible
promoter PtipA was used as a positive control and reference of GusA activity.
The results of the GusA activity assays are displayed in figure 4.44.
A [A.U./min*mg] Stdev
Sc::pSET152 0.0024 0.001525044
Sc::pAMgus01 0.0026 0.000577446
Sc::pAMgus04 0.0049 0.000983645
Sc::pSETgus 0.1075 0.018975872
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Figure 4.44: Prib and Prib-RFN fusions with gusA show no reporter activity. Specific
GusA activity measured for the cell free extracts of S. coelicolor strains with
integrated plasmids featuring a transcriptional fusion of the Prib promoter
(pAMgus01) and the ribB FMN riboswitch (pAMgus04) from S. davawensis
controlling the expression of the reporter gene gusA.
While the positive control Sc::pSETgus reached GusA activity levels of ap-
proximately 0.1 GU, the strains carrying the transcriptional fusion of Prib and
gusA (Sc::pAMgus01) as well as the strain featuring the translational fusion
of Prib, FMN riboswitch, RBS and ribB-leader with gusA (Sc::pAMgus04) did
not exhibit GusA activities significantly different from the negative control
Sc::pSET152.
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Discussion
The potential of flavin analogs as antimicrobial compounds, affecting the
growth of bacteria which take up flavins from their environment, has been
evaluated for several years (Mack and Grill, 2006). In particular, the antibi-
otic roseoflavin was reported to impair the growth of the human pathogen
L. monocytogenes (Mansjö and Johansson, 2011). Since themetabolism of L. mono-
cytogenes does not include a pathway for the biosynthesis of riboflavin, it relies
entirely on the uptake of riboflavin from its environment. The lack of a ri-
boflavin biosynthesis pathway in L. monocytogenes leaves a reduced number of
enzymes involved in flavin metabolism, comprising only the functions of ri-
boflavin uptake and cofactor synthesis. Thus L. monocytogenesis an ideal system
to study the uptake and metabolism of flavin analogs. FMN riboswitches have
been identified as target molecules for roseoflavin and other flavin analogs
(Blount and Breaker, 2006; Lee et al., 2009; Ott et al., 2009; Howe et al., 2015).
5.1 Flavin Analogs Aﬀect the Growth of
L. monocytogenes
As previously reported by Mansjö and Johansson (2011), roseoflavin and 8-
amino riboflavin inhibit the growth of L. monocytogenes. Growth experiments
of L. monocytogenes in BHI liquid cultures supplemented with riboflavin and
roseoflavin, respectively, confirmed this adverse effect of roseoflavin on the
growth of L. monocytogenes. The deregulated mutant strain M1, featuring
a mutation in the FMN riboswitch Rli96, was tolerant to roseoflavin in the
medium to some extend. The growth inhibiting effect of roseoflavin on the
deregulated mutant strain M1, was not as strong as on the L. monocytogenes
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wild type. The fact that the mutant strain M1 still shows reduced growth, when
compared to untreated controls or cultures treated with riboflavin, signifies
that the FMN riboswitch Rli96 is not the only target in L. monocytogenes that is
affected by roseoflavin or one of its metabolites.
When L. monocytogeneswild type was grown in the presence of the riboflavin
analog 8-amino riboflavin, a key intermediate of the roseoflavin biosynthesis,
growth was reduced only slightly, while the mutant strain M1 did not show any
signs of impaired growth. However, a stronger effect of 8-amino riboflavin on
the growth of L. monocytogenes was reported by Jörgen Johansson (Laboratory
for Molecular Infection Medicine Sweden, Department of Molecular Biology,
Umeå University, Umeå, Sweden) in a personal communication, for 8-amino
riboflavin concentrations as high as 267µM. While these results could either
be explained by reduced 8-amino riboflavin uptake into the cell, or 8-amino
riboflavin not being metabolized to the riboswitch targeting cofactor analog
AFMN inside the cell. Another possible explanation of the less pronounced
effect of 8-amino riboflavin was that AFMN does not interact with the FMN
riboswitch Rli96, which was confirmed to be the case through in vivo and in
vitro assays throughout this work.
The analysis of the cell free extracts of L. monocytogenes wild type and M1
cultures, treated with riboflavin and the flavin analogs roseoflavin and 8-amino
riboflavin revealed, that the two flavin analogs were present inside the cells
and that they were converted to their respective cofactor analogs. The presence
of 8-amino riboflavin inside the cells, as well as the cofactor analogs AFMN
and AFAD, in similar concentrations as RoFMN and RoFAD, excluded possible
explanations for the less distinct effect of 8-amino riboflavin on the growth of
L. monocytogenes.
Higher concentrations of flavins and cofactors were found in cell free extracts
of the mutant strain M1. This difference was attributed to the deregulated
expression of lmo1945 in the mutant strain. In cells, treated with the flavin
analogs roseoflavin or 8-amino riboflavin, the concentrations of riboflavin de-
rived cofactors was found to be reduced drastically when compared to the
untreated controls. This observation, however, could not be attributed to a
restrained riboflavin uptake due to insufficient amounts of the riboflavin trans-
port protein Lmo1945, since the effect was observed in the wild type and the
mutant strain M1 in a similar manner. A more likely explanation for this effect
would be the competition of the substrates (i.e. riboflavin and the respective
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flavin analog) for the cofactor producing flavokinase/FAD synthetase enzymes
inside the cell. This hypothesis was further supported by the finding that a
combined treatment of L. monocytogeneswild type and M1 cultures with both,
riboflavin and roseoflavin, reduced the concentrations of roseoflavin derived
cofactors found in the cell free extract, while it restored the concentrations
of riboflavin derived cofactors to a level, that was not different from that in
untreated cells. Since this effect was observed in a similar manner in wild type
and M1 cells (see figure 4.3 D-F on page 71), it could not be attributed to the
deregulation of lmo1945.
5.2 Metabolization of Flavins and Flavin Analogs
5.2.1 Identification of Two Enzymes with Flavokinase/FAD
synthetase Activity in L. monocytogenes
Two genes, coding for enzymes with putative flavokinase/FAD synthetase
activity, have been identified in L. monocytogenes through comparison of trans-
lated nucleotide sequences with the bifunctional flavokinase/FAD synthetase
RibC from B. subtilis, a close relative of L. monocytogenes.
An alignment of the amino acid sequences of the two hypothetical proteins
Lmo0728 and Lmo1329 (Lmo_RibC) with known bifunctional enzymes with fla-
vokinase/FAD synthetase activity from other bacterial species (Cornyebacterium
ammoniagenes, E. coli, B. subtilis, S. coelicolor and S. davawensis) was performed
(figure 5.1). The alignment revealed that both amino acid sequences of the two
hypothetical proteins feature all motifs that were reported by Serrano et al.
(2012) to be involved in FAD synthetase activity (red boxes in figure 5.1), while
only Lmo0728 lacks three out of five motifs (blue boxes in figure 5.1) that were
reported by Serrano et al. (2013) to be responsible for the flavokinase activity
of bifunctional enzymes. Especially the absence of the highly conserved “GxP-
TAN” motif (amino acids 213 - 219 of the alignment) has been attributed to the
lack of flavokinase activity in monofunctional FAD synthetases in plants, and
is also present in flavokinase enzymes found in fungi and humans (Sandoval
et al., 2008; Yruela et al., 2010; Herguedas et al., 2015).
111
- - - MD I WYGT AAV PKD LDN S AVT I GV FDGV HRGHQKL I NA T V EKAREVGA KA I MVT FD PH PV SV F L PRRA PL - G I T T LAE RFALAESFG I
MKL I RG I HN L SQAPQE- - GC V LT I GN FDGV HRGHRAL LQG LQEEGRKRN L PVMVML F EPQ PL EL FATDKA PAR- LT RLRE KLRY LAECGV
MKT I H I TH PH H L I KEEQAKS VMALGY FDGV H LGHQKV I GT AKQ I AEEKGL T LAVMT FHPH PSHV LGRDKE PKD L I T P L ED K I NQ I EQLGT
- - - VQRWRGL ED I PEDWGRS VVT I GSYDGV HRGHQL I I RH AVDRARELGV PAVVVT FD PH PSEVVRPGSH PP - L LAPHHR RAELMAD LGV
- - - VQRWRGL ED I PQDWGRS VVT I GSYDGV HRGHQL I I QH T VDRARELGL PAVVVT FD PH PKEV LRPGTH PP - L LAPHHR RAELMAD LGV
MKT I Y LHHP I T TD EWTD I NK VMALGF FDGV H LGHQAV I KQ AKQ I AGQKGL QTAV LT FD PH PSVV L SN I RK QVKY LT PL ED KAEKMAKLGV
- - - MEV SHVT LAPNKD SRAA V LT I GKFDGV H I GHQT I LNT AL S I KKENE I LT A I - SF SPH PLWALKQ I E I YREMLT PRME KERWLAYYGV
DGV LV I D FT R EL SGT SPEKY V EF L L EDT LH ASHVVVGAN F T FGENAAGTA D SLRQ I CQSR - LT VDV I D L L - - - - DD EGVR I SST T VREF L
DYV LCVRFDR RFAALTAQN F I SD L LVKH LR VKF LAVGDD F RFGAGREGD F L L LQKAGMEY GFD I T STQT F - - - - CEGGVR I SSTAVRQAL
EV LYVVKFNE V FASL SPKQF I DQY I I - GLN VQHAVAGFD F T YGKYGKGTM KTMPDD LDGK - AGCTMV EKL - - - - T EQDKK I SSSY I RT AL
DAV L I L P FT K EF SKL SAAD F VVKV LVDRLR AKAVV EGPN F RFGHKAAGNV D F L I EQGKVY D F EV EVVD LY VTGDAGGGEP F SST LT RRLV
DAV LV L PFT T EF SN L SPAD F I VKV L I DKLR AKAVV EGPN F RFGHRAAGDV MY LAELGKT Y D FDV EVVD L F V SGEAGGGQP F SST LT RRLV
D I MYVVRFT T QF SEL SPQAF VDNY LV - A LH V EHVVAGFDY SYGKKGEGKM TD LAKYADGR - F EVT I VDKQ - - - - T AASDK I SSTN I RRA I
NH L I ET EFT S RYAET T PEEF VTDH LT - N LN L SH I VVGSEF N FGKGRD SDV D L LRD LCKPY D I GVT SV PV I ETNQT - - - - K I SSTN I RA F I
SEGDVARANW ALGRH FYVTG PVVRGAGRGG KELGF PTANQ Y FHDT VAL PA DGVYAGWLT I L PT EAPV SGN MEPEVAYAAA I SVGTNPT F -
ADDN LALAES L LGHPFA I SG RVVHGDELG- RT I GF PTANV PLRRQV S- PV KGVYA - - - - - - - V EV LGLGE K- - - - P L PGV AN I GT RPT V -
QNGDV ELANV L LGQPY F I KG I V I HGDKRG- RT I GF PTANV GLNN SY I V PP TGVYA - - - - - - - VKAEVNGE V - - - - - YNGV CN I GYKPT FY
AEGDVAGAAE I LGRPHRV EG VVVRGAQRG- REMGFPTANV ET L PHTA I PA DGVYAGWLH - - - - - - - AQGE AMP- - - - - AA I SVGTNPQF -
GEGDV EGAME I LGRPHRV EG VVVRGAQRG- RELGV PTANV ET L PHTA I PA DGVYAGWLH - - - - - - - AQGE AMP- - - - - AA I SVGTNPT F -
T EGEL EEANQ L LGYPYT T KG T V I HGDKRG- RT I GF PTAN I RVNEDY L I PK LGVYA - - - - - - - VKFRVNGE T - - - - - H LGM AS I GYN I T F -
RRGH FQEAEE L LGHPWY I TG I V ENGEMTG- - - - - - - - - - - - - LDDYV L PA TGT YQ- - - - - - - - - - - - - - - - - - - - TD SG I VNVTNN - - - -
- - GD EQRSV E SFV LDR- DAD LYGHDVKV EF VDHVRAMEKF D SV EQL L EVM AKDVQKT RT L LAQDVQAHKM APET Y F LQAE S
- - AG I RQQL E VH L LD - VAMD LYGRH I QVV L RKK I RNEQRF ASLD ELKAQ I ARD ELTAREF FGLT KPA - - - - - - - - - - - - - -
EKRPEQPS I E VN L FD - FNQE VYGAA I K I EW YKR I RSERKF NG I KELT EQ I EKDKQEA I RY F SN LRK- - - - - - - - - - - - - - -
- - EGT ERT V E AYA I DRVGL E LYGLHVAVD F VAFVRGQAKF ET LDAL L EQM AVDVDRCRE I T ATDAPRP * - - - - - - - - - - - -
- - DGT ERT V E AHV I DRVGLD LYGLHVAVD F LAYVRGQVKF D SLDAL I ERM GED I KV SREL TAAAEAGDR * - - - - - - - - - - -
- KDDQAL S I E VY I LD - FHRE I YGEEAE I KW YQF FRPELKF NGV EGL I AQL EKD EQDT RAF FAKL ED * - - - - - - - - - - - - - -
- - - - - - RT I E VGL SD - - - - G LQQLHMKNEL SE * - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
1
FAD synthetase flavokinase 
weblogo.berkeley.edu
N 2
4
L
I
2
5
G
2
6
2
7
Y
F
2
8
D
2
9
G
3
0
V
3
1
H
3
2
I
L
R
3
3
G
3
4
H
3
5
R
Q
C
weblogo.berkeley.edu
G
P
F
E
N
D
Y
F
S
N
T
R
Y
FG
E
A
H
K
K
GR
G
A
K
D
E
A
S
G
weblogo.berkeley.edu
F
I SSSTNLVTIRRLFAVIL
weblogo.berkeley.edu
V
C
A
I N
S
I
V
T
G
N
Y
T
R
K
N
I
P
Q
T
V
F
weblogo.berkeley.edu
GVFPTANQIV
weblogo.berkeley.edu
V
L
IPVPKALKTDGTVYQA
weblogo.berkeley.edu
ESAVYH IAVLSFILD
weblogo.berkeley.edu
R MQE RKFNDTGS IVLKEDEALLI AEVRQLIMGEAVREKD
Figure 5.1: Multiple sequence alignment of representative primary structures of
bacterial flavokinases/FAD synthetases (FK/FADS). Conserved residues
are highlighted in red. UniProtKB accession numbers for proteins are as
follows: Cam_RibF, bifunctional FK/FADS from Cornyebacterium ammo-
niagenes, Q59263; Eco_RibF, bifunctional FK/FADS from E. coli, P0AG40;
Bsu_RibC, bifunctional FK/FADS from B. subtilis, P54575; Sco_RibC, bi-
functional FK/FADS from S. coelicolor, Q9Z530; Sdav_RibC1, bifunctional
FK/FADS from S. davawensis, K4R340; Lmo_RibC, bifunctional FK/FADS
from L. monocytogenes, Q8Y7F2; Lmo_0728, monofunctional FAD synthetase
from L. monocytogenes, Q8Y914. The amino acid motifs enclosed by blue
and green boxes were reported to be relevant for the flavokinase function,
whereas amino acid motifs in red boxes were reported to be relevant for
the FAD synthetase function (Serrano et al., 2012, 2013; Frago et al., 2008).
The presence of two motifs associated with flavokinase activity (green boxes)
in Lmo0728, however, indicates an evolutionary origin of the enzyme from
a former bifunctional enzyme. Interestingly a phylogenetic representation
(figure 5.2) of the N-terminal portion (amino acids 1 - 195) of the alignment sug-
gests that Lmo0728 is more closely related to the bifunctional flavokinase/FAD
synthetase RibF from E. coli than to Lmo1329. This leads to the assumption that
the presence of two genes coding for an enzyme with FAD synthetase activity
in the genome of L. monocytogenes is a result of horizontal gene transfer in the
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gastrointestinal tract, rather than duplication and subsequent truncation of
lmo1329.
Figure 5.2: FAD synthetase domains of Lmo0728 and RibF from E. coli share a
branch in the phylogenetic tree. Phylogenetic representation of the N-
terminal portion (amino acids 1 - 195) of the multiple sequence alignment
(see figure 5.1). The tree was created using the Unweighted Pair Group
Method using Arithmetic averages (UPGMA) described by Sneath and Sokal
(1973).
5.2.2 Production and Purification of Two Flavokinase/FAD
synthetase Enzymes from L. monocytogenes
For the functional and kinetic characterization of the two enzymes Lmo0728
and Lmo1329, recombinant production and subsequent purification was neces-
sary. An active, C-terminally His-tagged, version of Lmo1329 (Lmo1329-His)
was recombinantly produced in E. coli BL21(DE3) and could be purified to
apparent homogeneity in an affinity purification process, using a standard
nickel-sepharose column.
The same approach of directly adding a His-tag, C- or N-terminal, to Lmo0728,
resulted in the accumulation of insoluble recombinant protein in the production
cells. Expression of soluble C-terminally His-tagged Lmo0728 (Lmo0728-His)
was achieved by reducing the speed of protein production employing the
specialized production strain E. coli Rosetta(DE3). An enriched fraction of
Lmo0728-His, however, did not exhibit any activity when tested in a flavoki-
nase/FAD synthetase activity assay.
The N-terminal fusion of the maltose binding protein MalE from E. coli (MBP)
to Lmo0728 (MBP-Lmo0728) yielded a fusion protein that was soluble and
could be enriched from the cell free extract with an amylose column in an FPLC
system. The MBP-Lmo0728 fusion protein was found to be an active FAD
synthetase when tested in a flavokinase/FAD synthetase activity assay. The
proteolytic removal of the MBP-tag and subsequent purification of untagged
Lmo0728 was challenging and required several iterations in the design of
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the fusion protein as well as in the purification strategy, until a homogenous
preparation of active, untagged Lmo0728 was obtained. This was possible by
the cleavage of the fusion protein His-MBP-pg-Lmo0728 with a C-terminally
His-tagged TEV protease (TEV-His) so that the cleaved off His-MBP part of
the fusion protein and the TEV-His protease could be removed after a digest
reaction by a single affinity chromatography step.
5.2.3 Functional and Kinetic Characterization of Two
Flavokinase/FAD synthetase Enzymes from
L. monocytogenes
To assay their flavokinase activity (EC 2.7.1.26) the two recombinantly pro-
duced proteins Lmo1329-His and Lmo0728 were tested with different flavin
substrates, such as riboflavin, roseoflavin and 8-amino riboflavin in a flavoki-
nase/FAD synthetase activity assay. The FAD synthetase activity (EC 2.7.7.2)
of the two enzymes was tested with phosphorylated flavin substrates, such as
FMN, RoFMN and AFMN.
HPLC analysis of the collected samples revealed, that Lmo1329 indeed is a
bifunctional flavokinase/FAD synthetase, producing the cofactors FMN and
FAD from riboflavin. A similar behavior was found when 8-amino riboflavin
was used as substrate, the formation of AFMN and subsequently AFAD could
be observed. Notably, the reaction of roseoflavin with Lmo1329 led to an
accumulation of RoFMN whereas no RoFAD could be detected. These results
were confirmedwhen the phosphorylated cofactor FMN and its analogs AFMN
and RoFMN were used as substrates for Lmo1329 in the assay. No RoFAD
was produced by Lmo1329 from roseoflavin or RoFMN respectively, under
the tested conditions, which is different to what was reported for all other
bifunctional flavokinases/FAD synthetases tested with this substrates so far
(Grill et al., 2008; Pedrolli et al., 2011; Langer et al., 2013a).
When the flavokinase/FAD synthetase assays were performed with Lmo0728
instead of Lmo1329, the flavin substrates riboflavin, 8-amino riboflavin and
roseoflavin remained unchanged in the reaction mixture. The phosphorylated
forms FMN, AFMN and also also RoFMN were metabolized by Lmo0728 to
the respective adenylated forms FAD, AFAD and RoFAD. The predicted lack
of flavokinase activity of Lmo0728 was confirmed, while it was found to act as
a monofunctional FAD synthetase that also accepts the FMN analogs AFMN
and RoFMN as alternative substrates.
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Prior to the kinetic characterization of the two enzymes, their optimal pH for
the FAD synthetase reaction was determined experimentally. The pH optimum
for both enzymes was found to be pH 8.5 for Lmo1329-His and pH 9.0 for
Lmo0728. While Lmo1329-His was found to exhibit approximately 90% of
its maximal FAD synthetase activity at pH 7.0, the FAD synthetase activity
of Lmo0728 was reduced to only 50% of the maximum at pH 7.0. Hence,
the activity assays for the kinetic characterization of the two enzymes were
performed at the respective pH of maximal activity.
The kinetic model of first-order kinetics by Michaelis and Menten (1913) was
fitted to the data obtained for the flavokinase and FAD synthetase reactions
of Lmo1329-His and FAD synthetase reaction of Lmo0728, respectively. The
Michaelis constant Km and the maximal reaction rate vmax were derived di-
rectly from the fitted Michaelis-Menten equation, while the turnover number
kcat and the kinetic efficiency kcatKm were calculated according to equation 3.3
on page 66. The apparent kinetic parameters obtained for the tested enzyme-
substrate pairs are summarized in tables 5.1 and 5.2, together with values
published for other flavokinase/FAD synthetase enzymes for comparison.
Table 5.1: Apparent kinetic parameters for the FAD synthetase activity of Lmo0728
and Lmo1329 compared to values published for other enzymes.
Enzyme Substrate Km vmax kcat kcatKm Reference
(µM) ( nmolmin·mg ) (s
-1) (s-1·µM-1)
L. monocytogenes
Lmo0728 FMN 12.9 1093 0.51 0.040 This work
Lmo1329 FMN 29.2 3706 4.39 0.150 This work
E. coli
RibCF FMN 3.6 110 0.06 0.017 Langer et al. (2013a)
C. ammoniagenes
CaFADS FMN 1.2 –a 0.28 0.238 Serrano et al. (2013)
Homo sapiens
hFADS2 FMN 68 88 0.08 0.0012 Pedrolli et al. (2011)
anot available
115
In direct comparison of the apparentKm values for FMN, the value determined
for Lmo0728 is lower when compared to Lmo1329-His, indicating a higher
affinity of Lmo0728 to the substrate and the ability of Lmo0728 to produce FAD
at lower FMN concentrations. Both Km values lie within the range reported
for other FAD synthetase enzymes. The maximal reaction rate vmax of the FAD
synthetase reaction, however, is considerably higher for Lmo1329-His than for
Lmo0728. This leads to the assumption that Lmo1329 is the dominant enzyme
for FAD production in L. monocytogenes. This is also supported by the report of
Wurtzel et al. who found Lmo1329 being expressed at a level more than 5-fold
higher than Lmo0728 (Wurtzel et al., 2012). Notably, the turnover number kcat
for the FAD synthetase reaction of Lmo1329-His was determined to be 4.39 s-1,
which is about 15-fold higher than the turnover number reported by Serrano
et al. for the bifunctional enzyme CaFADS from C. ammoniagenes, the highest
reported turnover number so far (Chang et al., 2009).
Table 5.2: Apparent kinetic parameters for the flavokinase activity of Lmo1329 com-
pared to values published for other enzymes.
Enzyme Substrate Km vmax kcat kcatKm Reference
(µM) ( nmolmin·mg ) (s
-1) (s-1·µM-1)
L. monocytogenes
Lmo1329 RF 6.9 668 0.40 0.057 This work
E. coli
RibCF RF 1.7 660 0.38 0.22 Langer et al. (2013a)
S. davawensis
RibC RF 40 500 0.3 0.0075 Grill et al. (2008)
B. subtilis
RibC RF 55 1200 0.7 0.013 Grill et al. (2008)
Homo sapiens
Fmn1p RF 36 1667 0.5 0.014 Pedrolli et al. (2011)
The kinetic parameters determined for the flavokinase activity of Lmo1329-
His lie within the range of what was reported for other bacterial bifunctional
flavokinase/FAD synthetase enzymes (table 5.2).
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5.3 Transporter Mediated and Riboswitch Controlled
Flavin Uptake in L. monocytogenes
Based on sequence analysis that identified an FMN riboswitch in the upstream
region of Lmo1945, together with the high level of sequence similarity to the
ECF riboflavin transport protein RibU from B. subtilis, Lmo1945 was consid-
ered being responsible for riboflavin import as well (Vitreschak et al., 2002;
Mansjö and Johansson, 2011). The crystal structure of Lmo1945 was resolved
recently by Karpowich et al. giving insight into the mechanism of ECF trans-
porters. They also demonstrated binding of riboflavin to purified recombi-
nantly produced Lmo1945 (Karpowich et al., 2015). Its physiological function
as a riboflavin import protein, however, has not been demonstrated in vivo so
far.
Proof of Lmo1945’s functional role in riboflavin import could now be provided
through this work. The recombinant expression of lmo1945 in a riboflavin
auxotrophic double mutant strain of B. subtilis, also lacking the gene coding for
the substrate binding subunit RibU of the ECF riboflavin transporter, restored
the ability of that strain to grow on LA without riboflavin addition, and in
minimal medium with only 10µM riboflavin supplementation. These results
also suggest that the protein Lmo1945 is able to function as substrate binding
subunit (EcfS) with the remaining, substrate independent, ECF transporter
system of B. subtilis.
Since the FMN riboswitch Rli96, controlling expression of lmo1945, was sug-
gested by Mansjö and Johansson (2011) as a target for the antibiotic flavin
analog roseoflavin, it was of great interest to investigate whether Lmo1945 is
also involved in the uptake of roseoflavin. The susceptibility to roseoflavin
of the ribU deletion mutant B. subtilis strain, BS ribU, was increased by het-
erologous expression of lmo1945, which indicated that Lmo1945 also facilitates
roseoflavin uptake into the cell.
For the characterization of the FMN riboswitch Rli96 an in vivo reporter system
in B. subtilis, based on the work of Ott et al. (2009), was applied. The FMN
riboswitch, together with its native promoter sequence was placed upstream of
the reporter gene lacZ and integrated into the amyE locus into the chromosome
of B. subtilis, forming the strain Bs::Rli96. Treatment of this modified strain with
various concentrations of riboflavin, showed that Rli96 reduced the reporter
activity in the cell free extract only by 20%, which appears to be low when
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compared to 60% reduction by the FMN ribG riboswitch of B. subtilis, which
served as a reference.
The conclusion that the repression of the downstream gene of the FMN ri-
boswitch Rli96 in L. monocytogenes is regulated not as strictly as it is by other
FMN riboswitches, agrees with its function of modulation of the expression
of a transporter protein, providing the only source of riboflavin, an essential
vitamin, to an auxotrophic organism. Indeed, tight regulation or even complete
cessation of the expression of lmo1945 could potentially cause a riboflavin
deficiency for the cell. This assumption is further supported by the recent tran-
scriptome analysis of L. monocytogenes that revealed that full-length transcripts
of lmo1945, including Rli96, are present in all growth phases during growth of
L. monocytogenes in BHI (Wurtzel et al., 2012).
When Bs::Rli96 was treated with the flavin analogs roseoflavin and 8-amino
riboflavin, roseoflavin caused a reduction of reporter activity in a range similar
to that caused by riboflavin. While, notably, treatment with 8-amino riboflavin
even caused a slight increase of the reporter activity in the cell free extract.
Whether this effect was the result of the FMN analog AFM not affecting the
FMN riboswitch Rli96 or if it was the result of 8-amino riboflavin not being
taken up into the cells by the riboflavin transporter RibU, was investigated
with a coupled in vitro transcription/translation assay. In this assay the plasmid
pT7luc_Rli96 was used as a template in the presence of various concentrations
of FMN and its analogs RoFMN and AFMN. The results of the in vitro assay
confirmed the previous finding of a slight increase of expression of the gene
downstream of Rli96 in the presence of AFMN. The reduction due to the
presence of RoFMN was even more pronounced in vitro, when compared to
FMN.
While the FMN riboswitch Rli96 was confirmed as a target molecule for the
roseoflavin derived FMN analog RoFMN, it was shown that Rli96 was not
affected by the 8-amino riboflavin derived cofactor analog AFMN. Therefore
the antimicrobial effect of roseoflavin on L. monocytogenes can partially be
attributed to RoFMN affecting the FMN riboswitch Rli96, while the adverse
effect of 8-amino riboflavin very likely results from other targets, such as
flavoenzymes, being affected by it or its metabolites.
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5.4 Evaluation of Reporter Systems for the In Vivo
Characterization of Translational Riboswitches in
Streptomycetes
Expression of the riboflavin synthase RibB in S. coelicolor and S. davawen-
sis is controlled by translationally acting FMN riboswitches. These two
FMN riboswitches have been characterized in vitro using a coupled transcrip-
tion/translation assay by Pedrolli et al. (2012). An in vivo characterization of
these regulatory elements, however, was not performed since an appropriate
reporter system was not available for streptomycetes. Establishment of such
a system would provide a useful tool to study not only the regulatory mech-
anism underlying the roseoflavin resistance of S. davawensis, but also for the
better comparison of translationally acting riboswitches from streptomycetes
and other bacterial species with G+C rich genomes.
For the in vivo characterization of transcriptionally controlled FMN ri-
boswitches the  -galactosidase based reporter system in B. subtilis, described
by Ott et al. (2009) is available. The system was successfully applied for
the in vivo characterization of the FMN riboswitch Rli96 of L. monocytogenes
throughout this work. The available system, however, was not suitable for
the in vivo characterization of the translationally controlled FMN riboswitches
of S. coelicolor, S. davawensis and other Streptomyces species. For the charac-
terization of FMN riboswitches from streptomycetes, B. subtilis would not
be an adequate host, due to the great difference in G+C content of the DNA.
Especially the promoter sequences, found in streptomycetes are not recognized
by the transcription machinery of B. subtilis. Also the available system only
provides a test platform for transcriptionally controlled riboswitches that do
not include the RBS of the regulated gene in their secondary structure (i.e.
RBS sequestor). The adaption of the available  -galactosidase based reporter
system to streptomycetes was not favorable, since the use of lacZ as a reporter
gene in streptomycetes was reported to be impaired by their endogenous
 -galactosidase activity, disqualifying it as a suitable reporter in Streptomyces
species (King and Chater, 1986).
The catechol 2,3-dioxygenase XylE, encoded by the gene xylE from Pseudomonas
putidawas described as a suitable reporter enzyme in streptomycetes by Ingram
et al. and was employed successfully in S. coelicolor, e.g. in promoter probe
119
plasmids created by Jones (Ingram et al., 1989; Jones, 2011). XylE was evaluated
as a possible reporter in a reporter system suitable for the characterization of
translationally regulating riboswitches in streptomycetes. For a translational
fusion of the FMN riboswitch and the reporter gene xylE, rearrangement of the
genetic elements on pIPP1 was necessary. The complete 50–UTR, comprising
the promoter region, the aptamer of the FMN riboswitch and the sequestor
sequence, including the ribosomal binding site down to the actual start codon
of the regulated gene had to be placed directly upstream of the reporter gene.
Since the secondary structure of the RBS sequestor hairpin of the ribB FMN
riboswitches of S. coelicolor and S. davawensis reaches up directly to the GTG
start codon of ribB a short leader (18 nt) of the coding sequence of ribB was
also included. This was necessary to prevent possible interference of the 50 end
of the xylE coding sequence with the stability of the RBS sequestor secondary
structure.
5.4.1 The XylE Reporter System
The putative promoter regions upstream of the FMN riboswitch aptamer se-
quences from S. davawensis (PribSd, 188 nt) and S. coelicolor (PribSC, 194 nt), were
tested with the promoter probe plasmid pIPP1 with regard to their promoter
activity in S. coelicolor. The assay of the specific XylE activity showed that both
sequences contain promoters that are active in S. coelicolor. Due to the very
high diversity in Streptomyces promoter sequences, which are recognized by
various   factors, there is no strong consensus in the -35 and -10 regions and the
location of the transcription start simply by sequence analysis is not possible
without additional experimental data (Strohl, 1992; Seghezzi et al., 2011; Luo
et al., 2015).
For maximal activity, the enzyme XylE requires the soluble ferredoxin XylT,
which reactivates inactive XylE by reduction of an oxidized iron atom at the
active center of XylE (Gonzalez-Ceron et al., 2001). Since xylT is part of the
transcription unit placed under the control of the putative promoter sequence
on the plasmid pIPP1, both genes are transcribed if the promoter is active. For
the use of xylE as reporter in a translational fusion, however, the coexpression
of xylT requires attention, since the coding sequence of xylT lies upstream of
xylE in the original configuration, derived from P. putida, and thus is not auto-
matically included in a translational xylE fusion. The constitutive coexpression
of xylT from a non integrative plasmid was approached, but did not result
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in increased XylE activity from a strain carrying a translational fusion of the
ribB-leader and xylE (Sc::SdxE (pAMxT)). Alternatively a coexpression of the
two genes was attempted by changing their order in the transcription unit,
placing xylT downstream of xylE. In this configuration a translational fusion of
xylEwas possible, while the two genes would still share the same transcription
unit.
The strain Sc::pAM023, featuring the two genes in reversed order downstream
of the Prib promoter of S. davawensis yielded approximately 75% of specific XylE
activity when compared to the strain Sc::pAM01, carrying the same promoter
upstream the two coding sequences in their original configuration.
When the FMN riboswitch, including the ribosomal binding site RBSribB and
the GTG start codon (Sc::pAM673) were introduced between the Prib promoter
and xylE, no XylE activity could be found in the cell free extract. The same
effect was observed for the strain Sc::pAM893, including the six leading codons
of ribB in the translational xylE fusion.
A reintroduction of the original ribosomal binding site RBSxylE between the ribB-
leader and xylE (Sc::pAM893a), translationally uncoupling xylE from the FMN
riboswitch, led to a reconstitution of XylE activity in this strain, suggesting that
the diminished XylE activity is a result of the translational fusion of xylE to
the expression platform of the FMN riboswitch. Even small alternations of the
N-terminus of XylE might prevent proper folding or could possibly interfere
with the tetramerization of the enzyme, although N-terminally His-tagged
XylE has been reported to be active after heterologous expression in E. coli
(Winkler et al., 1995; Dong et al., 2009).
5.4.2 The GusA Reporter System
Since the ribosomal binding site RBSribB and the ribB-leader sequence are
part of the expression platform of the FMN riboswitch they have to remain
unaltered. To fulfill this requirement of the reporter system an alternative
reporter was needed, that would tolerate N-terminal fusions. The gene gusA,
coding for the  -glucuronidase enzyme GusA, which was used as a reporter
in plants successfully over more than two decades, has been demonstrated by
Myronovskyi et al. to be functional in N-terminal fusions. They constructed
the plasmid pGUSHL4aadA containing gusA without a start codon and a short
sequence coding for a helical linker intended to separate the N-terminally fused
protein and GusA (Myronovskyi et al., 2011).
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Based on the wok of Myronovskyi et al. a transcriptional fusion of the
Prib promoter, the ribosomal binding site RBSribB of S. davawensis and gusA
(Sc::pAMgus01) and a translational fusion featuring the complete 50–UTR, in-
cluding the Prib promoter, the FMN riboswitch, RBSribB, and the six codons of
the ribB-leader of S. davawensis connected to gusA through the helical linker
as it is present on the plasmid pGUSHL4aadA. Both constructs, however, did
not yield GusA activity that was significantly higher than background levels
found in a control strain.
With respect to the work of Rudolph et al., who successfully used a gusA based
reporter system for the characterization of transcriptinally and translationally
controlled artificial riboswitches in S. coelicolor, the further development of the
reporter system throughout this work was suspended (Rudolph et al., 2013).
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6
Conclusion
The riboflavin human pathogen Listeria monocytogenes relies exclusively on the
uptake of riboflavin, since this bacterium is riboflavin auxotrophic. The produc-
tion of the protein, facilitating the uptake of riboflavin from the environment
is regulated by an FMN riboswitch. This FMN riboswitch represents a poten-
tial drug target, since a reduced expression of the riboflavin transporter gene
lmo1945 would consequently reduce the intracellular flavin level. Novel antibi-
otics based on flavin analogs have the potential to negatively interfere with
FMN riboswitch function. The uptake and subsequent conversion of riboflavin
analogs into cofactor analogs is supposedly a key part in the mechanism of
how antimicrobial flavin analogs affect the metabolism of L. monocytogenes.
The riboflavin transporter Lmo1945 was confirmed to be responsible for the
uptake, not only of riboflavin, but also of the toxic flavin analog roseoflavin.
The FMN riboswitch Rli96, modulating expression of lmo1945, is negatively
affected by FMN and RoFMN. However, it is not affected by the 8-amino ri-
boflavin derived cofactor analog AFMN.
Two enzymes, involved in the conversion of riboflavin into the cofactors FMN
and FAD in L. monocytogenes could be identified and were purified after het-
erologous expression in E. coli. The functional and kinetic characterization of
these two enzymes showed that the bifunctional flavokinase/FAD synthetase
Lmo1329 appears to be the dominant enzyme for FMN and FAD production in
L. monocytogenes. Notably, it did not catalyze the synthesis of RoFAD. A second
enzyme with FAD synthetase activity, Lmo0728 was identified in L. monocyto-
genes. This enzyme, however, was producing the cofactor analog RoFAD in
vitro from RoFMN and ATP. Interestingly, Lmo0728 did not have any flavok-
inase activity and thus, is the first monofunctional FAD synthetase found in
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bacteria to be functionally characterized.
The FMN riboswitch Rli96 in L. monocytogenes was confirmed as a target for
the roseoflavin derived cofactor analog RoFMN, which is synthesized by the
bifunctional flavokinase/FAD synthetase Lmo1329. Growth experiments with
a deregulated L. monocytogenes strain indicated that additional targets for cofac-
tor analogs exist in this bacteria, since the deregulation of Rli96 did not confer
full roseoflavin resistance to L. monocytogenes.
Further insight into the metabolization of flavin analogs in L. monocytogenes
could be gained through a more detailed characterization of the two flavoki-
nase/FAD synthetases Lmo1329 and Lmo0728 with special attention to their
activity in assays with riboflavin and flavin analogs as competing substrates.
Also, the heterologous expression of flavoenzymes from L. monocytogenes, fol-
lowed by activity assays in the presence of cofactor analogs could help to
identify additional targets for flavin analogs in L. monocytogenes.
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